<?xml version='1.0' encoding='UTF-8' ?><Trials_downloaded_from_ICTRP>
  <Trial>
    <Internal_Number>2452965</Internal_Number>
    <TrialID>EUCTR2004-001298-24-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>An open-label, randomized, multicenter, parallel group study to demonstrate correction of anemia using intravenous injections of RO0503821 in patients with chronic kidney disease who are on dialysis</Public_title>
    <Scientific_title>An open-label, randomized, multicenter, parallel group study to demonstrate correction of anemia using intravenous injections of RO0503821 in patients with chronic kidney disease who are on dialysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>F. Hoffmann-La Roche Ltd</Primary_sponsor>
    <Date_registration3>20040628</Date_registration3>
    <Date_registration>28/06/2004</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-001298-24                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>01/07/2004</Date_enrollement>
    <Target_size>168</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Baseline predialysis (for HD patients) Hb concentration 8-11 g/dL determined from the mean of 2 screening values with at least one day between measurements&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Previous therapy with recombinant human erythropoetin or any other erythropoeitc substance within 12 weeks prior to screening. If epoetin treatment has been interrupted for at least 12 weeks, the patient may be enrolled in the study. Ongoing epoetin treatment should not be discontinued to allow participation in the trial.&lt;br&gt;</Exclusion_Criteria>
    <Condition>anemia in chronic kidney patients who are in dialysis</Condition>
    <Intervention>&lt;br&gt;Product Name: cera&lt;br&gt;Product Code: RO 0503821&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: not yet available&lt;br&gt;Other descriptive name: Methoxy polyethilene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;INN or Proposed INN: not yet available&lt;br&gt;Other descriptive name: Methoxy polyethilene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;INN or Proposed INN: not yet available&lt;br&gt;Other descriptive name: Methoxy polyethilene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;INN or Proposed INN: not yet available&lt;br&gt;Other descriptive name: Methoxy polyethilene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 400-&lt;br&gt;INN or Proposed INN: not yet available&lt;br&gt;Other descriptive name: Methoxy polyethilene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1000-&lt;br&gt;&lt;br&gt;Trade Name: Neorecormon&lt;br&gt;Product Name: Neorecormon&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Epoetin beta&lt;br&gt;Other descriptive name: Methoxy polyethilene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50000-&lt;br&gt;INN or Proposed INN: epoetin beta&lt;br&gt;Other descriptive name: Methoxy polyethilene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100000-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To demonstrate the efficay of IV RO 0503821;Secondary Objective: - To asses time to response&lt;br&gt;- To asses the safety and tolerability of multiple doses of RO 0503821 during the correction and extension periods in this patient population&lt;br&gt;- To asses long term safety with RO 0503821 in this patient population&lt;br&gt;- To investigate the farmachokinetics and the concentration-effect relationships after IV administration of RO 0503821 in this patient population;Primary end point(s): To demonstrate the efficay of IV RO 0503821 treatment for correction of anemia in patients with kidney chronic disease who are on dialysis</Primary_outcome>
    <Secondary_ID>BA16736</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2453174</Internal_Number>
    <TrialID>EUCTR2004-002160-22-HU</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety of MK-0431
Monotherapy in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency Who Have Inadequate Glycemic Control - MK-0431 Monotherapy Study in Patients With Type 2 DM and Chronic Renal Insufficiency</Public_title>
    <Scientific_title>A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety of MK-0431
Monotherapy in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency Who Have Inadequate Glycemic Control - MK-0431 Monotherapy Study in Patients With Type 2 DM and Chronic Renal Insufficiency                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Merck &amp; Co., Inc.</Primary_sponsor>
    <Date_registration3>20041012</Date_registration3>
    <Date_registration>12/10/2004</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002160-22                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>17/11/2004</Date_enrollement>
    <Target_size>90</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;a.	Patient has type 2 diabetes mellitus (T2DM). &lt;br&gt;b.	Patient has moderate, severe, or end-stage renal insufficiency as indicated by a ‘yes’ answer to one or more of the following :&lt;br&gt;1)	Creatinine clearance =30 to &lt; 50 mL/min&lt;br&gt;2)	Creatinine clearance &lt; 30 mL/min&lt;br&gt;3)	Patient receiving dialysis&lt;br&gt;c.	Patient is =18 years of age.&lt;br&gt;d.	Patient has an understanding of the study procedures and agrees to participate in the study by giving written informed consent.&lt;br&gt;e.	Patient is not pregnant or breast-feeding and does not plan to become pregnant for the duration of the study and poststudy follow-up period.&lt;br&gt;f.	Patient is a male, or a female who is highly unlikely to conceive.&lt;br&gt;g.	HbA1c =6.5% and =10% measured at, or within 2 weeks prior to, Visit 3.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;a.	Patient has a history of type 1 diabetes mellitus or a history of ketoacidosis&lt;br&gt;b.	Patient has an ALT or AST &gt;2.0-fold the Upper Limit of Normal (ULN)&lt;br&gt;c.	Patient has acute or rapidly progressive renal disease, or a history of renal transplant.&lt;br&gt;d.	Patient has any of the following disorders within the past 6 months: &lt;br&gt;•	Acute coronary syndrome (e.g., MI or unstable angina).&lt;br&gt;•	Coronary artery intervention (e.g., CABG or PTCA).&lt;br&gt;•	Worsening congestive heart failure (e.g., worsening symptoms or increase in pharmacologic therapy).&lt;br&gt;•	Stroke or transient ischemic neurological disorder.&lt;br&gt;e.	Patient has new or worsening signs or symptoms of coronary heart disease within the past 3 months.&lt;br&gt;f.	Patient has a BMI &lt;20 kg/m2 or &gt;43 kg/m2&lt;br&gt;g.	Patient has a positive urine pregnancy test&lt;br&gt;h.	Patient has any other condition or therapy which, in the opinion of the investigator or Merck medical monitor, might pose a risk to the patient or make participation not in the patient’s best interest.&lt;br&gt;i.	Patient has poor mental function or any other reason to expect that the patient may have difficulty in complying with the requirements of the study.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Type 2 Diabetes Mellitus

Chronic Renal Insufficiency [MedDRA classification code:  10050441] &lt;br&gt;MedDRA version: 7.0
Level: LLT
Classification code 10045242
</Condition>
    <Intervention>&lt;br&gt;Product Name: MK-0431   25-mg Tablet&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Current Sponsor code: MK-0431&lt;br&gt;Other descriptive name: L-000224715&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: Glibinese [Glipizide 5-mg scored tablets]&lt;br&gt;Product Name: Glibinese 5-mg scored tablets&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: glipizide&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: In patients with type 2 diabetes mellitus and chronic renal insufficiency with inadequate glycemic control&lt;br&gt;&lt;br&gt;Primary:  To assess the safety and tolerability of MK-0431 after 12 weeks.&lt;br&gt;;Secondary Objective: In patients with type 2 diabetes mellitus and chronic renal insufficiency with inadequate glycemic control&lt;br&gt;&lt;br&gt;To assess the safety and tolerability of MK-0431 over 54 weeks.;Primary end point(s): N/A</Primary_outcome>
    <Secondary_ID>0431-028</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2453243</Internal_Number>
    <TrialID>EUCTR2004-000587-26-HU</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A 24-month Extension to a one-year, multicentre, double-blinded, double-dummy, randomized study to evaluate the safety and efficacy of two doses of FTY720 combined with full-dose Neoral and steroids versus Cellcept combined with full-dose Neoral and steroids, in de novo adult renal transplant recipients.</Public_title>
    <Scientific_title>A 24-month Extension to a one-year, multicentre, double-blinded, double-dummy, randomized study to evaluate the safety and efficacy of two doses of FTY720 combined with full-dose Neoral and steroids versus Cellcept combined with full-dose Neoral and steroids, in de novo adult renal transplant recipients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Novartis Pharma Services AG</Primary_sponsor>
    <Date_registration3>20041110</Date_registration3>
    <Date_registration>10/11/2004</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000587-26                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>01/02/2005</Date_enrollement>
    <Target_size>690</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: yes&lt;br&gt;Other trial design description: Partially double blinded, partially open&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;a)	The patient has given written informed consent to participate in the extension study.&lt;br&gt;b)	The patient has completed the core study (through 12 months post-transplantation, either being maintained on study medication or having attended the Follow-up visits up to Month 12 after being discontinued from study medication).  &lt;br&gt;c)	Females capable of becoming pregnant are required to practice a medically approved method of birth control as long as they are on study medication and for a period of 3 months following discontinuation of study medication.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients with any medical or psychosocial condition which the investigator believes would hinder compliance with the study requirements.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Prophylaxis of kidney allograft rejection in de novo adult renal transplant recipients &lt;br&gt;MedDRA version: 7.0
Level: LLT
Classification code 10023439
</Condition>
    <Intervention>&lt;br&gt;Product Name: FTY720&lt;br&gt;Product Code: FTY720&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: CellCept&lt;br&gt;Product Name: Mycophenolate Mofetil&lt;br&gt;Product Code: RS-61443&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: Sandimmun Neoral&lt;br&gt;Product Name: Ciclosporin for microemulsion&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The objective of this extension is to assess long-term safety and efficacy data of two doses of FTY720 (2.5 or 5.0 mg) combined with full dose Neoral and steroids versus MMF combined with full dose Neoral and steroids in de novo adult renal transplant recipients beyond 12 months post-transplantation.;Secondary Objective: To provide continued treatment for patients who have completed the 12-month core study on study medication.;Primary end point(s): Biopsy-proven acute rejection, graft loss, death or discontinuation from study</Primary_outcome>
    <Secondary_ID>CFTY720A2218E1</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2453302</Internal_Number>
    <TrialID>EUCTR2004-004416-22-SE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Platelet function in diabetic patients without and with renal impairment, and the effects of lipid-lowering treatment</Public_title>
    <Scientific_title>Platelet function in diabetic patients without and with renal impairment, and the effects of lipid-lowering treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Karolinska Institutet, Dept of Medicine, Clinical Pharmacology Unit</Primary_sponsor>
    <Date_registration3>20041206</Date_registration3>
    <Date_registration>06/12/2004</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-004416-22                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>05/01/2005</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: yes&lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: yes&lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Diabetes mellitus type 2&lt;br&gt;&lt;br&gt;With or without established microalbuminuria (urinary albumin excretion of 30-299 µg/mg creatinine in a spot sample) Two out of three specimens collected within a 3-6 month period should be abnormal before the diagnosis can be settled. &lt;br&gt;&lt;br&gt;Glomerular filtration rate (GFR) between 15-50 ml/min (measured the last 6 months) or GFR &gt;75ml/min. GFR will be established by 24-hour Iohexolclearence.&lt;br&gt;&lt;br&gt;Age 18-80 years&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Definite history of myocardial infarction, coronary revascularisation procedure or stroke. (i.e, a strong clinical indication for statin treatment) &lt;br&gt;&lt;br&gt;Functioning renal transplant, or living donor-related transplant planned.&lt;br&gt;&lt;br&gt;Patients on dialysis.&lt;br&gt;&lt;br&gt;Poor metabolic control, i.e HbA1c &gt; 9%&lt;br&gt;&lt;br&gt;Definite history of chronic liver disease, or abnormal liver function (i.e ALT &gt;1,5 x ULN or, if ALT not available, AST &gt; 1,5 x ULN). &lt;br&gt;&lt;br&gt;Evidence of active inflammatory muscle disease (e.g dermatomyositis, polymyositis), or CK&gt;3 x ULN&lt;br&gt;&lt;br&gt;Definite previous adverse reaction to a statin or to ezetimibe&lt;br&gt;&lt;br&gt;Definite previous adverse reaction to acetylsalicylic acid.&lt;br&gt;&lt;br&gt;Definite previous adverse reaction to an ACE-inhibitor.&lt;br&gt;&lt;br&gt;Need for concomitant treatment with a strong inhibitor of CYP3A4, such as itrokonazole, ketokonazole, erythromycin, clarithromycin, HIV-protease inhibitors or nefazodone (i.e. agents that may markedly elevate simvastatin levels).&lt;br&gt;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Diabetes mellitus type 2, without or with renal impairment
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Zocord  R&lt;br&gt;Product Name: Zocord  R&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Simvastatin&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration number: 40-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: Ezetrol&lt;br&gt;Product Name: Ezetrol  R&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: ezetimibe&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration number: 10-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To compare the effects of simvastatin + ezetimibe with those of simvastatin alone, on thrombogenic mechanisms, in patients with diabetes mellitus type 2.;Secondary Objective: a) Compare the effects of simvastatin alone with those of placebo (baseline data) on thrombogenic mechanisms&lt;br&gt;b) Compare the effects of simvastatin + ezetimibe with those of simvastatin alone, and simvastatin alone with placebo on inflammatory variables.&lt;br&gt;c) Assess how the treatment effects relate to renal function.  &lt;br&gt;;Primary end point(s): ADP stimulated platelet P-selectin expression (flow cytometry in whole blood).&lt;br&gt;Other flow cytometric platelet variables related to the primary end point are (a) circulating platelet-platelet aggregates, (b) circulating platelet-leukocyte aggregates, (c) single platelet counts.&lt;br&gt;</Primary_outcome>
    <Secondary_ID>DMK001</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2453351</Internal_Number>
    <TrialID>EUCTR2004-002032-26-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>An open-label, multi-center study to document the efficacy, safety and tolerability of long-term administration of RO0503821 in patients with chronic renal anemia</Public_title>
    <Scientific_title>An open-label, multi-center study to document the efficacy, safety and tolerability of long-term administration of RO0503821 in patients with chronic renal anemia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>F. Hoffmann-La Roche Ltd.</Primary_sponsor>
    <Date_registration3>20041112</Date_registration3>
    <Date_registration>12/11/2004</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002032-26                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>23/12/2004</Date_enrollement>
    <Target_size>1000</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Aranesp, NeoRecormon&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	1.	Written informed consent&lt;br&gt;2.	Adult patients (equal or more than 18 years old) with chronic renal anemia&lt;br&gt;3.	Continuous maintenance erythropoietic therapy with RO0503821 or a protocol-specified reference medication (epoetin alfa formulated with human albumin,  epoetin beta or darbepoetin alfa) in one of the following studies: BA16528, BA16285, BA16286, BA16736, BA16738, BA16739, BA16740, BA17283 and BA17284&lt;br&gt;4.	Hemoglobin concentration between 10.5 and 13.0 g/dL &lt;br&gt;5.	Adequate iron status defined as serum ferritin equal or more than 100 ng/mL or TSAT equal or more than 20% (or percentage of hypochromic RBCs &lt; 10%)&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;6.	Poorly controlled hypertension necessitating interruption of erythropoietin treatment in the 6 months before screening&lt;br&gt;7.	Epileptic seizure in the  6 months before screening&lt;br&gt;8.	Platelets  &gt; 500 x 10 9/L&lt;br&gt;9.	Pure red cell aplasia &lt;br&gt;10.	Chronic congestive heart failure (New York Heart Association Class IV)&lt;br&gt;11.	High likelihood of early withdrawal or interruption of the study (e.g., myocardial infarction, severe or unstable coronary artery disease, stroke, severe liver disease within the 12 weeks before screening)&lt;br&gt;12.	Active malignant disease (except non-melanoma skin cancer)&lt;br&gt;13.	Life expectancy less than 12 months&lt;br&gt;14.	Pregnancy or breast-feeding&lt;br&gt;15.	Women of childbearing potential without effective contraception&lt;br&gt;16.	Administration of another investigational drug planned during the study period&lt;br&gt;17.	Known hypersensitivity to recombinant human erythropoietin, polyethylene glycol or to any constituent of the study or reference drug  formulations&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patient with chronic renal anaemia</Condition>
    <Intervention>&lt;br&gt;Product Name: N/A&lt;br&gt;Product Code: RO0503821&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: not available yet&lt;br&gt;Other descriptive name: Methoxy polyethylene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;INN or Proposed INN: not available yet&lt;br&gt;Other descriptive name: Methoxy polyethylene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;INN or Proposed INN: not available yet&lt;br&gt;Other descriptive name: Methoxy polyethylene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;INN or Proposed INN: not available yet&lt;br&gt;Other descriptive name: Methoxy polyethylene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 400-&lt;br&gt;INN or Proposed INN: not available yet&lt;br&gt;Other descriptive name: Methoxy polyethylene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1000-&lt;br&gt;&lt;br&gt;Trade Name: NeoRecormon&lt;br&gt;Product Name: NeoRecormon &lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection&lt;br&gt;INN or Proposed INN: Epoetin beta&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50.000-&lt;br&gt;INN or Proposed INN: Epoetin beta&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100.000-&lt;br&gt;&lt;br&gt;Trade Name: Aranesp&lt;br&gt;Product Name: Aranesp&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Darbepoetin alfa&lt;br&gt;Concentration unit: µg microgram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 15-&lt;br&gt;INN or Proposed INN: Darbepoetin alfa&lt;br&gt;Concentration unit: µg microgram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;INN or Proposed INN: Darbepoetin alfa&lt;br&gt;Concentration unit: µg microgram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 30-&lt;br&gt;INN or Proposed INN: Da</Intervention>
    <Primary_outcome>Main Objective: To document that RO0503821 administered for prolonged periods is efficacious, safe and well tolerated in patients treated for  chronic renal anemia;Secondary Objective: N/A;Primary end point(s): Analysis of Efficacy&lt;br&gt;No formal efficacy assessment will be performed. Efficacy parameters such as hemoglobin will be reported descriptively using means, standard deviations and percentiles.&lt;br&gt;&lt;br&gt;Analysis of Safety &lt;br&gt;All patients who have received at least one dose of RO0503821 or of reference medication and a safety follow-up, whether withdrawn prematurely or not, will be included in the safety analysis. The safety parameters will be vital signs, AEs and the safety laboratory parameters. &lt;br&gt;All safety parameters will be summarized descriptively. Vital signs and laboratory data will be assessed for clinically relevant abnormalities.&lt;br&gt;Frequencies and incidence rates of AEs will be tabulated.  The goal of the statistical evaluation of AE data is a standardized tabulation of the frequencies and incidence rates of all observed AEs. These will be calculated on a per-patient basis rather than on an event basis. &lt;br&gt;Brief narratives will describe each death, each drug related SAE, premature withdrawals arising from AEs, and other significant AEs that are judged to be of special interest because of clinical importance. &lt;br&gt;All safety parameters will be summarized descriptively. Vital signs and laboratory data will be assessed for clinically relevant abnormalities.</Primary_outcome>
    <Secondary_ID>BH 18387</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2453504</Internal_Number>
    <TrialID>EUCTR2004-002310-10-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Study to Investigate Cinacalcet Treatment in Haemodialysis Patients with Secondary Hyperparathyroidism - SENSOR</Public_title>
    <Scientific_title>Study to Investigate Cinacalcet Treatment in Haemodialysis Patients with Secondary Hyperparathyroidism - SENSOR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Amgen Development Europe</Primary_sponsor>
    <Date_registration3>20041110</Date_registration3>
    <Date_registration>10/11/2004</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002310-10                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>17/11/2004</Date_enrollement>
    <Target_size>800</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- CKD patients requiring dialysis (HD, HDF, HF) for at least 1 month before enrolment&lt;br&gt;- Males or females = 18 years of age at the time of informed consent. &lt;br&gt;- Men and women participating in this study must agree to use, in the opinion of the principal investigator, highly effective contraceptive measures throughout the study.  Females must have a negative serum pregnancy test (or definitive evidence to demonstrate lack of pregnancy) within 30 days before randomisation, unless there is a definite history of amenorrhoea.&lt;br&gt;- An iPTH determination within 14 days before randomisation must be = 300 pg/mL (biPTH = 150 pg/mL).  &lt;br&gt;- A serum calcium determination (corrected for calcium) within 14 days before randomisation must be = 8.4 mg/dL [2.1 mmol/L].  &lt;br&gt;- Signed the Independent Ethics Committee (IEC) approved Informed Consent document, before any study specific procedures are initiated &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Have an unstable medical condition, defined as having been hospitalised, other than for dialysis vascular access revision, within 30 days before day 1, or otherwise unstable in the judgment of the investigator.&lt;br&gt;- Are currently breast-feeding.&lt;br&gt;- Are performing peritoneal dialysis&lt;br&gt;- Have had a parathyroidectomy in the 3 months before day 1.&lt;br&gt;- Are currently enrolled in, or have not yet completed at least 30 days before day 1 other invasive investigational device or investigational drug trials, or are receiving other investigational agents (experimental dialysis machines are acceptable).&lt;br&gt;- Have a gastrointestinal disorder that may be associated with impaired absorption of orally administered medications or an inability to swallow tablets.&lt;br&gt;- Have a disorder that would interfere with understanding and giving informed consent or compliance with protocol requirements&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) on dialysis</Condition>
    <Intervention>&lt;br&gt;Product Name: Cinacalcet&lt;br&gt;Product Code: AMG 073&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Cinacalcet&lt;br&gt;CAS Number: 364782-34-3&lt;br&gt;Current Sponsor code: AMG 073&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 30-&lt;br&gt;&lt;br&gt;Product Name: Cinacalcet&lt;br&gt;Product Code: AMG 073&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Cinacalcet&lt;br&gt;CAS Number: 364782-34-3&lt;br&gt;Current Sponsor code: AMG 073&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 60-&lt;br&gt;&lt;br&gt;Product Name: Cinacalcet&lt;br&gt;Product Code: AMG 073&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Cinacalcet&lt;br&gt;CAS Number: 364782-34-3&lt;br&gt;Current Sponsor code: AMG 073&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 90-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To demonstrate that the efficacy of cinacalcet when co-administered with the first meal after dialysis is comparable (non-inferior) to the efficacy of cinacalcet when administered during the dialysis study visit.;Secondary Objective: To evaluate the safety of cinacalcet when co-administered with the first major meal after dialysis.&lt;br&gt;To evaluate a predefined strategy to manage nausea/vomiting during the study&lt;br&gt;;Primary end point(s): The proportion of subjects with a mean iPTH £ 300 pg/mL at weeks 11 and 13</Primary_outcome>
    <Secondary_ID>20040143</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2453669</Internal_Number>
    <TrialID>EUCTR2004-004488-31-NO</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Does cyclosporine A reduce the insulin secretion from the pancreas?</Public_title>
    <Scientific_title>Does cyclosporine A reduce the insulin secretion from the pancreas?                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Rikshospitalet University Hospital, University of Oslo</Primary_sponsor>
    <Date_registration3>20050201</Date_registration3>
    <Date_registration>01/02/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-004488-31                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement />
    <Target_size>16</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;Other trial design description: Therapy followed by wash out&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Dialysis patients planned to be kidney transplanted and not treated with steroids&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Age above 75 years or below 18 years&lt;br&gt;Pregnancy&lt;br&gt;Lactating mothers&lt;br&gt;Diabetes mellitus&lt;br&gt;Less than 2 months of dilayses&lt;br&gt;Coronary heart disease&lt;br&gt;Ongoing corticosteroid treatment&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Kidney failure / dialysis patients / transplantation</Condition>
    <Intervention>&lt;br&gt;Trade Name: Sandimmun Neoral&lt;br&gt;Product Name: Sandimmun Neoral&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Current Sponsor code: NOVARTIS&lt;br&gt;Other descriptive name: Sandimmun Neoral&lt;br&gt;Concentration unit: µg/l microgram(s)/litre&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 150-200&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Other descriptive name: cyclosporine A&lt;br&gt;Concentration unit: µg/l microgram(s)/litre&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 150-200&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Test the effect of cyclosporine A on insulin release;Secondary Objective: Test the effect of cyclosporine A on insulin action, endothelial function. Test the useage of pretransplant cyclosporine A pharmacokinetics detrminations for dose individualisation at the time of transplantation;Primary end point(s): Change in insulin secretion&lt;br&gt;</Primary_outcome>
    <Secondary_ID>S-02005</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2453918</Internal_Number>
    <TrialID>EUCTR2004-001608-11-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A Multi-centre, Open Label, Randomised, Parallel Group Pilot Study to assess the Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal Disease</Public_title>
    <Scientific_title>A Multi-centre, Open Label, Randomised, Parallel Group Pilot Study to assess the Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal Disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>Shire Pharmaceutical Development Ltd</Primary_sponsor>
    <Date_registration3>20050303</Date_registration3>
    <Date_registration>03/03/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-001608-11                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>18/11/2004</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Male or female patients greater than or equal to 18 years of age receiving haemodialysis for end stage renal disease with a level of serum phosphate&gt;5.9mg/dL (1.9mmol/L) after washout or sub-optimally treated with current phosphate binder. Patients (including those who have undergone renal transplantation in the past) must have received haemodialysis for chronic renal failure three times per week for at least the previous two months. &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Pregnant or lactating women. Patients with screening calcium below 8.8mg/dL (2.2mmol/L) or with significant abnormal laboratory values (excluding markers of pathologies associated with chronic renal failure), which in the opinion of the investigator should exclude the patient from the study. Patients with clinically significant uncontrolled concurrent illness a life threatening malignancy or current multiple myeloma or known to be HIV positive. Patients with any significant bowel obstruction, active inflammatory disease, gastrointestinal (GI) motility disorders, abnormal or irregular bowel motion or a history of major GI surgery within the last 6 mnths. Patients who have been in any other clinical trial within the last 30 days or who have previously taken lanthanum carbonate in the last year. &lt;br&gt;</Exclusion_Criteria>
    <Condition>Hyperphosphataemia in Patients Receiving Haemodialysis for End Stage Renal Disease</Condition>
    <Intervention>&lt;br&gt;Product Name: Lanthanum Carbonate &lt;br&gt;Product Code: SPD 405&lt;br&gt;Pharmaceutical Form: Chewable tablet&lt;br&gt;INN or Proposed INN: Lanthanum (III) carbonate hydrate &lt;br&gt;Current Sponsor code: SPD 405&lt;br&gt;Other descriptive name: Lanthanum carbonate hydrate&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;Product Name: Lanthanum Carbonate &lt;br&gt;Product Code: SPD 405&lt;br&gt;Pharmaceutical Form: Chewable tablet&lt;br&gt;INN or Proposed INN: Lanthanum (III) carbonate hydrate &lt;br&gt;Current Sponsor code: SPD 405&lt;br&gt;Other descriptive name: Lanthanum carbonate hydrate&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;Product Name: Lanthanum Carbonate &lt;br&gt;Product Code: SPD 405&lt;br&gt;Pharmaceutical Form: Chewable tablet&lt;br&gt;INN or Proposed INN: Lanthanum (III) carbonate hydrate &lt;br&gt;Current Sponsor code: SPD 405&lt;br&gt;Other descriptive name: Lanthanum carbonate hydrate&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration number: 750-&lt;br&gt;&lt;br&gt;Product Name: Lanthanum Carbonate &lt;br&gt;Product Code: SPD 405&lt;br&gt;Pharmaceutical Form: Chewable tablet&lt;br&gt;INN or Proposed INN: Lanthanum (III) carbonate hydrate &lt;br&gt;Current Sponsor code: SPD 405&lt;br&gt;Other descriptive name: Lanthanum carbonate hydrate&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration number: 1000-&lt;br&gt;&lt;br&gt;Trade Name: Renagel 800mg Film Coated Tablets &lt;br&gt;Product Name: Renagel &lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Sevelamer &lt;br&gt;Concentration unit: mg/g milligram(s)/gram&lt;br&gt;Concentration number: 800-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To assess phosphate reduction and control (3.5-5.5mg/dL [1.1-1.8mmol/L]) in patients with End Stage Renal Disease (ESRD) following administration of lanthanum carbonate or sevelamer hydrochloride;Secondary Objective: To assess: &lt;br&gt;The effects of lanthanum carbonate and sevelamer hydrochloride on serum calcium and calcium phosphate product levels&lt;br&gt;The percentage of patients achieving a reduction in serum calcium-phosphate product to less than or equal to 4.4 (mmol/L)2 (54.56mg2/dL2) following administration of lanthanum carbonate or sevelamer hydrochloride&lt;br&gt;Average daily pill burden, dose levels and compliance&lt;br&gt;The safety and tolerability of lanthanum carbonate&lt;br&gt;Patient satisfaction with treatment ;Primary end point(s): Serum phosphate reduction and control rate (defined as 3.5-5.5mg/dL [1.1-1.8 mmol/L])</Primary_outcome>
    <Secondary_ID>SPD405-310</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2454519</Internal_Number>
    <TrialID>EUCTR2005-000087-12-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio multicéntrico, aleatorizado, doble ciego, de grupos paralelos, en fase IV, para comparar los efectos renales del medio de contraste no iónico isosmolar, iodixanol 320 mg I/ml (VisipaqueTM), con el medio de contraste no iónico de baja osmolaridad, iopamidol 300 mg I/ml, en sujetos con insuficiencia renal y diabetes mellitus sometidos a TC helicoidal multidetector.</Public_title>
    <Scientific_title>Estudio multicéntrico, aleatorizado, doble ciego, de grupos paralelos, en fase IV, para comparar los efectos renales del medio de contraste no iónico isosmolar, iodixanol 320 mg I/ml (VisipaqueTM), con el medio de contraste no iónico de baja osmolaridad, iopamidol 300 mg I/ml, en sujetos con insuficiencia renal y diabetes mellitus sometidos a TC helicoidal multidetector.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Amersham Health S.A. (parte de GE Healthcare Ltd y sus filiales)</Primary_sponsor>
    <Date_registration3>20050608</Date_registration3>
    <Date_registration>08/06/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-000087-12                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>16/08/2005</Date_enrollement>
    <Target_size>500</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.) The subject is at least 18 years old.&lt;br&gt;2.) The subject has diabetes mellitus (type I or II), treated with insulin or oral antidiabetic agents for at least 1 year.&lt;br&gt;3.) The subject has a pre-study serum creatinine = 1.7 mg/dl (150 µmol/l) if a man, or = 1.5 mg/dl (133 µmol/l) if a woman,&lt;br&gt;or an estimated pre-study glomerular filtration rate (eGFR) = 50 mL/min/1.73m2 according to the Modification of Diet in Renal Disease (MDRD) equation.*&lt;br&gt;The pre-study serum creatinine value must not be older than 3 months and any acute causes of impaired renal function have to be ruled out.&lt;br&gt;* the four-component MDRD equation provides estimates of GFR standardised for body surface, based on the variables serum creatinine concentration (SCr), age, race, and sex:&lt;br&gt;eGFR (mL/min/1.73m2) = 186 x SCr-1.154 x age-0.203 (x 0.742 if female) (x 1.210 if black)&lt;br&gt;Pre-study serum creatinine has to be expressed in milligrams per decilitre, age in years.&lt;br&gt;4.) The subject is referred for a contrast-enhanced MDCT examination, using a standardised CM volume of 1.5 mL per kilogram of body weight and an injection rate of 4 mL/s (in cases with inadequate venous access, a flow of 3 mL/s may be applied). For subjects with a body weight exceeding 100 kilogram, a total CM volume of 150 mL should be administered.&lt;br&gt;5.) The subject is a man, or a woman who is either surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), postmenopausal (with cessation of menses for more than 1 year), or, if of child-bearing potential, the result of a urine or serum ?-HCG pregnancy test conducted at screening must be known to be negative before IMP administration.&lt;br&gt;6.) The subject is able and willing to comply with study procedures.&lt;br&gt;7.) Signed and dated (i.e., date and time) written informed consent is obtained.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.) The subject is pregnant or lactating.&lt;br&gt;2.) The subject was previously included in this study.&lt;br&gt;3.) The subject has received another IMP within 30 days before or is scheduled to receive one within 7 days after IMP administration.&lt;br&gt;4.) The subject has received iodinated contrast medium within 7 days before or will receive one within 7 days after IMP administration.&lt;br&gt;5.) The subject has a history of serious hypersensitivity reaction to iodinated contrast media.&lt;br&gt;6.) The subject has non-compensated heart failure (NYHA III or IV).&lt;br&gt;7.) The subject has manifest thyrotoxicosis.&lt;br&gt;8.) The subject is in acute renal failure or in acute on chronic renal failure.&lt;br&gt;9.) The subject has undergone kidney transplantation.&lt;br&gt;10.) The subject is on haemodialysis or peritoneal dialysis.&lt;br&gt;11.) The subject has liver cirrhosis with ascites.&lt;br&gt;12.) The subject has multiple myeloma.&lt;br&gt;13.) The subject is haemodynamically unstable pre-study.&lt;br&gt;14.) The subject is scheduled for major surgery within 7 days after IMP administration.&lt;br&gt;15.) The subject has received or will receive any of the following potentially nephroprotective drugs from 3 days before until 7 days after IMP administration:&lt;br&gt;n-acetylcysteine, fenoldopam, dopamine, or hydration with sodium bicarbonate. Concurrent medication with other drugs that are potentially nephroprotective, like calcium channel blockers or theophylline, are permitted provided they are used for the subject’s underlying disease (e.g., cardiac disease, arterial hypertension, bronchial asthma).&lt;br&gt;16.) The subject has received nephrotoxic drugs within 7 days before or will receive such drugs within 7 days after IMP administration. Respective nephrotoxic drugs include antibiotics (e.g., aminoglycosides, vancomycin, amphotericin B), antineoplastic agents (e.g., methotrexate, cisplatin), and immunosuppressants (e.g., cyclosporine).&lt;br&gt;17.) The subject has received nonsteroidal anti-inflammatory drugs (NSAID) within 3 days before or will receive such drugs within 7 days after IMP administration, with the exception of low dose aspirin (up to 325 mg per day). However, subjects who are on a stable NSAID regimen may be enrolled.&lt;br&gt;18.) The subject has had or is planned to have the initiation, discontinuation, or change in dose of any of the following from 3 days before until 7 days after IMP administration: trimethoprim, cimetidine, angiotensin converting enzyme inhibitors, or angiotensin receptor blockers.&lt;br&gt;&lt;br&gt;19.) The subject is on metformin treatment at the time of the study procedure: metformin administration has to be discontinued prior to IMP administration, according to local guidelines, withheld for at least 48 hours, and resumed only if renal function / serum creatinine did not worsen compared to the baseline values.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Subjects with a combination of diabetes mellitus (type I or II), and impaired renal function.

 &lt;br&gt;MedDRA version: 7.0
Level: Pt
Classification code 10061835
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Visipaque 320 mgI/ml &lt;br&gt;Product Name: Visipaque 320 mg I/ml&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Iodixanol&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 320 mg I/ml-&lt;br&gt;&lt;br&gt;Trade Name: Iopamiro 300 mg I/ml&lt;br&gt;Product Name: Iopamiro&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Iopamidol&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 300 mg I/ml-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To evaluate and compare the effects of two different contrast media, iodixanol 320 mg I/mL and iopamidol 300 mg I/mL, on renal function;Secondary Objective: To evaluate and compare the safety profile of iodixanol 320 mg I/mL and iopamidol 300 mg I/mL&lt;br&gt;To evaluate and compare the efficacy of iodixanol 320 mg I/mL and iopamidol 300 mg I/mL&lt;br&gt;;Primary end point(s): The primary endpoint will be the incidence rate of contrast-induced nephropathy (CIN), defined as an intra-individual increase in serum creatinine of at least 44.2 µmol/l (0.5 mg/dl) from baseline up to day 3.&lt;br&gt;&lt;br&gt;</Primary_outcome>
    <Secondary_ID>DXV406</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2454536</Internal_Number>
    <TrialID>EUCTR2005-001231-29-SE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A PROSPECTIVE, RANDOMISED, PLACEBO CONTROLLED, MULTI-CENTER STUDY 
OF THE EFFICACY AND SAFETY OF RITUXIMAB AS INDUCTION THERAPY TOGETHER WITH TACROLIMUS, MYCOPHENOLATE MOFETIL AND STEROIDS FOR PATIENTS UNDERGOING RENAL TRANSPLANTATION
</Public_title>
    <Scientific_title>A PROSPECTIVE, RANDOMISED, PLACEBO CONTROLLED, MULTI-CENTER STUDY 
OF THE EFFICACY AND SAFETY OF RITUXIMAB AS INDUCTION THERAPY TOGETHER WITH TACROLIMUS, MYCOPHENOLATE MOFETIL AND STEROIDS FOR PATIENTS UNDERGOING RENAL TRANSPLANTATION
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Dept of Transplantation Surgery B 56, Karolinska University Hospital, Huddinge</Primary_sponsor>
    <Date_registration3>20050705</Date_registration3>
    <Date_registration>05/07/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-001231-29                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>08/09/2005</Date_enrollement>
    <Target_size>140</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients aged 18 years or above&lt;br&gt;Recipients of first or second renal transplant&lt;br&gt;Recipients from living or cadaveric donors&lt;br&gt;Single organ recipients (kidney only)&lt;br&gt;Patients providing written informed consent&lt;br&gt;Patients cooperative and able to complete all the assessment procedures&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;HLA-identical siblings&lt;br&gt;Patients receiving immunosuppressive therapy within the preceding 28 days&lt;br&gt;PRA &gt;50% within 6 months prior to enrolment&lt;br&gt;Previous exposure to murine antibodies&lt;br&gt;History of malignancy (except localised non-melanotic skin cancer) or the presence of any active malignancy at the time of transplant&lt;br&gt;Active infection (HCV, HBV, HIV)&lt;br&gt;Pregnant or lactating females &lt;br&gt;Women of child bearing potential not willing to use reliable form of contraception                                                                                                       &lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Chronic renal failure patients who are receiving a kidney transplant.  Different immunosuppressive protocls are awailable. However, current strategies for the medical management of transplant patients are largely focused on the prevention and treatment of T-cell mediated processes. However, there is an increasing evidence that B cells may significantly contribute to post-transplant morbidity in addition to their role in acute humoral rejection.</Condition>
    <Intervention>&lt;br&gt;Trade Name: MabThera&lt;br&gt;Product Name: Mabthera&lt;br&gt;Product Code: RO 45-2294/V02&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective of the study is to determine the effect of one dose of rituximab as induction therapy together with a conventional tacrolimus, mycophenolate mofetil, prednisolone immunosuppressive protocol on the incidence of treatment failure (biopsy-proven acute rejection, graft loss or death) at 6 months post transplant. &lt;br&gt;&lt;br&gt;;Secondary Objective: To assess the effect of rituximab induction on renal function at 6 months post transplant, measured as creatinine clearance. &lt;br&gt;&lt;br&gt;To assess the incidence and severity of  infections (CMV, BKV, fungal and bacterial) in the two groups. &lt;br&gt;Creatinine clearance determined by the iohexol technique at 6 months &lt;br&gt;Incidence of opportunistic infections (CMV, BK, fungus)&lt;br&gt;Incidence of urinary tract infections and septicemia &lt;br&gt;Incidence of rituximab-related adverse events&lt;br&gt;Incidence of malignancies &lt;br&gt;All adverse events including clinically significant abnormalities and clinical and laboratory parameters&lt;br&gt;&lt;br&gt;Additional parameters to be assessed peroperatively and at 6 months&lt;br&gt;Number of CD19+, CD20+ lymphocytes in blood &lt;br&gt;Immunoglobulin G and M levels&lt;br&gt;Anti-tetanus IgG&lt;br&gt;Anti-CMV IgG&lt;br&gt;Cystatin C &lt;br&gt;Iohexol clearance (at 6 months only)&lt;br&gt;Transplant biopsy&lt;br&gt;&lt;br&gt;&lt;br&gt;;Primary end point(s): The primary endpoint will be a composite endpoint defined as treatment failure,&lt;br&gt;including the occurrence of any of the following: biopsy-proven acute rejection, graft loss or death during the first 6 months following transplantation. &lt;br&gt;</Primary_outcome>
    <Secondary_ID>2005-01-02</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2454693</Internal_Number>
    <TrialID>EUCTR2004-002973-22-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Epidemiological open-label study to evaluate the frequency of helicobacter Pylori infections prior to and after equimolar switch from therapy with MMF to enteric-coated Mycophenolic Acid (MYFORTIC-ERL080) in stable renal transplant patients</Public_title>
    <Scientific_title>Epidemiological open-label study to evaluate the frequency of helicobacter Pylori infections prior to and after equimolar switch from therapy with MMF to enteric-coated Mycophenolic Acid (MYFORTIC-ERL080) in stable renal transplant patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>AZIENDA UNIVERSITARIA OSPEDALE POLICLINICO UMBERTO I</Primary_sponsor>
    <Date_registration3>20050801</Date_registration3>
    <Date_registration>01/08/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002973-22                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>28/04/2004</Date_enrollement>
    <Target_size>250</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;</Exclusion_Criteria>
    <Condition>Profilaxis of rejection in stable renal transplant patients &lt;br&gt;MedDRA version: 6.1
Level: PT
Classification code 10046694
</Condition>
    <Intervention>&lt;br&gt;Product Name: NA&lt;br&gt;Product Code: NA&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Mycophenolic acid&lt;br&gt;CAS Number: 115007-34-6&lt;br&gt;Current Sponsor code: ERL080&lt;br&gt;Other descriptive name: NA&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 180-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: ;Secondary Objective: ;Primary end point(s): </Primary_outcome>
    <Secondary_ID>CERL080AIT03</Secondary_ID>
    <Secondary_Sponsor>AZIENDA POLICLINICO UMBERTO I</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2454739</Internal_Number>
    <TrialID>EUCTR2005-000855-14-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Multicenter, not controlled, prospectic clinical phase IV study: safety and efficacy of an immunosuppressive regimen with Thymoglobuline and Rapamune in patients receiving a renal transplantation from a marginal donor.</Public_title>
    <Scientific_title>Multicenter, not controlled, prospectic clinical phase IV study: safety and efficacy of an immunosuppressive regimen with Thymoglobuline and Rapamune in patients receiving a renal transplantation from a marginal donor.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>AZIENDA OSPEDALIERA DI PADOVA</Primary_sponsor>
    <Date_registration3>20050810</Date_registration3>
    <Date_registration>10/08/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-000855-14                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>18/07/2005</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;</Exclusion_Criteria>
    <Condition>Acute rejection prophylaxis after single-double kidney transplantation from marginal donors making use of a not nephrotoxic immunosuppressive regimen. &lt;br&gt;MedDRA version: 6.1
Level: PT
Classification code 10023439
</Condition>
    <Intervention>&lt;br&gt;Trade Name: RAPAMUNE*1MG 100 CPR&lt;br&gt;Product Name: NA&lt;br&gt;Product Code: NA&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: RAPAMUNE*2MG 30 CPR&lt;br&gt;Product Name: NA&lt;br&gt;Product Code: NA&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2-&lt;br&gt;&lt;br&gt;Trade Name: RAPAMUNE*OS 60 ML 1 MG&lt;br&gt;Product Name: NA&lt;br&gt;Product Code: NA&lt;br&gt;Pharmaceutical Form: Oral solution&lt;br&gt;INN or Proposed INN: Sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: THYMOGLOBULINE*IV 1F 25MG +F&lt;br&gt;Product Name: NA&lt;br&gt;Product Code: NA&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: Antithymocyte immunoglobulin (rabbit)&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: ;Secondary Objective: ;Primary end point(s): </Primary_outcome>
    <Secondary_ID>01-865-2005</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2454772</Internal_Number>
    <TrialID>EUCTR2005-002380-90-DK</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Effekten af intravenøs infusion af n-3 polyumættede fedtsyrer på risikomarkører for pludselig hjertedød hos hæmodialysepatienter</Public_title>
    <Scientific_title>Effekten af intravenøs infusion af n-3 polyumættede fedtsyrer på risikomarkører for pludselig hjertedød hos hæmodialysepatienter                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Nyremedicinsk afdeling, Aalborg Sygehus</Primary_sponsor>
    <Date_registration3>20050824</Date_registration3>
    <Date_registration>24/08/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-002380-90                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>26/09/2005</Date_enrollement>
    <Target_size>70</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: yes&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients with chronic renal failure undergoing haemodialysis treatment three times a week&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Allergy to fish or egg protein. Age &lt; 18 yrs. Body Weight &lt; 50 kg. Chronic supraventricular arrhythmias. Implanted pacemaker. Myocardial infarction or stroke within the past 6 months. Tendency to significant drop in bloodpressure during haemodialysis. Ongoing infection. Other serious illness. Fasting triglycerides &gt; 3 mmol/L. &lt;br&gt;</Exclusion_Criteria>
    <Condition>Chronic renal failure</Condition>
    <Intervention>&lt;br&gt;Trade Name: Omegaven&lt;br&gt;Product Name: Omegaven&lt;br&gt;Pharmaceutical Form: Emulsion for infusion&lt;br&gt;Pharmaceutical form of the placebo: Intravenous infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To investigate the effect of intravenous infusion of an emulsion rich on n-3 polyunsaturated fatty acids on heart rate variability and the occurence of arrhythmias in relation to haemodialysis treatment;Secondary Objective: To determine the content of n-3 polyunsaturated fatty acids in plasma and cell membranes before and after infusion;Primary end point(s): The effect on heart rate variability and arrhythmias</Primary_outcome>
    <Secondary_ID>IVN3DIALYSE;N/A</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2454985</Internal_Number>
    <TrialID>EUCTR2004-005002-68-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio multicéntrico, aleatorizado, doble ciego, paralelo y de fase IV para comparar los efectos en la función renal del medio de contraste no iónico, isosmolar, iodixanol 320 mgI/ml (VisipaqueTM) con el medio de contraste no iónico, de baja osmolalidad, iopamidol 370 mgI/ml, en sujetos con función renal disminuida y diabetes mellitus sometidos a una angiografía coronaria con o sin intervención coronaria percutánea (ICP).</Public_title>
    <Scientific_title>Estudio multicéntrico, aleatorizado, doble ciego, paralelo y de fase IV para comparar los efectos en la función renal del medio de contraste no iónico, isosmolar, iodixanol 320 mgI/ml (VisipaqueTM) con el medio de contraste no iónico, de baja osmolalidad, iopamidol 370 mgI/ml, en sujetos con función renal disminuida y diabetes mellitus sometidos a una angiografía coronaria con o sin intervención coronaria percutánea (ICP).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Amersham Health SA (Parte de GE Healthcare Ltd. y sus filiales)</Primary_sponsor>
    <Date_registration3>20050922</Date_registration3>
    <Date_registration>22/09/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-005002-68                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>03/11/2005</Date_enrollement>
    <Target_size>450</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;(1) The subject is over 18 years of age. &lt;br&gt;(2) The subject is referred for coronary angiography with or without PCI.&lt;br&gt;(3) The subject has diabetes mellitus I or II, treated with insulin or oral antiglycemics for at least 1 year.&lt;br&gt;(4) The subject has renal impairment of non-acute aetiology:&lt;br&gt;SCr measurement not older than 6 months ?150 µmol/L (1.7 mg/dL) for men and  ?133 µmol/L (1.5 mg/dL) for women or a creatinine clearance = 50 mL/min calculated according to Cockcroft-Gault formula. &lt;br&gt;(5) The subject is able and willing to comply with study procedures including hydration protocol and signed and dated (i.e. date and time) informed consent is obtained.&lt;br&gt;(6) The subject is male, or a female who is either surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), postmenopausal (cessation of menses for more than 1 year), or non-lactating, or if of childbearing potential the results of a serum or urine human chorionic gonadotropin pregnancy test, performed at screening, with the result known before IMP administration, must be negative.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;(1) The subject was previously included in this study. &lt;br&gt;(2) The subject has participated in any IMP study within 30 days prior to study enrolment.&lt;br&gt;(3) The subject received iodinated contrast medium within 7 days before IMP administration or is scheduled to receive one within the study period.&lt;br&gt;(4) The subject is planned to undergo major surgery (CABG, CEA, vascular bypass) within 3 days after the IMP administration.&lt;br&gt;(5) The subject is planned to undergo selective renal angiography.&lt;br&gt;(6) The subject has a history of serious hypersensitivity reaction to iodinated contrast media.&lt;br&gt;(7) The subject has severe liver or haematologic disease, multiple myeloma or manifest thyrotoxicosis.&lt;br&gt;(8) The subject has severe heart failure requiring intravenous therapy with diuretics, inotropes, and/or vasodilators.&lt;br&gt;(9) The subject is planned to receive an intravenous diuretic or intravenous mannitol in connection to the IMP administration.&lt;br&gt;(10) The subject is haemodynamically unstable pre-study (i.e., inability to sustain systolic blood pressure above 90 mmHg within 48 hours before IMP-administration without pressor or balloon support).&lt;br&gt;(11) The subject is on haemodialysis or peritoneal dialysis, and/or is in acute renal failure. &lt;br&gt;(12) The subject has undergone kidney transplantation. &lt;br&gt;(13) The subject has received or will receive any of the following potentially nephroprotective drugs within 3 days before or 3 days after IMP administration; n-acetylcysteine, fenoldopam, dopamine or hydration with sodium bicarbonate (NaHCO3).  Potentially nephroprotective drugs such as Ca-channel blockers, theophylline etc, are allowed provided they are used for treatment of the subject’s chronic underlying disease. &lt;br&gt;(14) The subject has received or is planned to receive any of the following nephrotoxic drugs within 7 days before or 3 days after IMP administration; aminoglycosides, vancomycin, amphotericin B, cyclosporin, methotrexate, cisplatin.  &lt;br&gt;(15) The subject has received or is planned to receive nonsteroidal anti-inflammatory drugs (NSAID) within 3 days before or 3 days after IMP administration, with the exception of low dose acetyl salicylic acid (up to 325 mg per day, and at a single occasion in connection with PCI up to 500 mg).  However, subjects who are on a stable NSAID regimen may be enrolled.&lt;br&gt;(16) The subject has had or is planned to have the initiation, discontinuation, or change in dose within 3 days before or 3 days after IMP administration of any of the following: trimethoprim, cimetidine, angiotensin converting enzyme inhibitors (ACEI), or angiotensin receptor blockers (ARB).&lt;br&gt;(17) The subject is on metformin (e.g., Glucophage?) at the time of coronary angiography/intervention.  Metformin must be discontinued according to local guidelines, and stopped no later than the time of IMP administration, withheld for at least 48 hours, until the subject’s SCr has been evaluated and it is deemed safe to resume metformin.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Subjects with impaired renal function and diabetes mellitus undergoing coronary angiography.
 &lt;br&gt;MedDRA version: 8.0
Level: Pt
Classification code 10061835
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Visipaque 320 mg I/ml&lt;br&gt;Product Name: Visipaque&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Iodixanol&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 320 mg I/ml-&lt;br&gt;&lt;br&gt;Trade Name: Iopamiro 370 mg I/ml&lt;br&gt;Product Name: Iopamiro&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Iopamidol&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 370 mg I/ml-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To evaluate and compare the effects of two different contrast media, the iso-osmolar contrast medium (IOCM), iodixanol 320 mgI/mL, and the low-osmolar contrast medium (LOCM) iopamidol 370 mgI/mL, on renal function.;Secondary Objective: - To evaluate and compare the safety profile of iodixanol 320 mgI/mL and iopamidol 370 mgI/mL.&lt;br&gt;- To evaluate and compare the efficacy of iodixanol 320 mgI/mL and iopamidol 370 mgI/mL.&lt;br&gt;;Primary end point(s): - The peak increase in SCr from baseline up to day 3.&lt;br&gt;- The incidence of CIN, defined as number of subjects with an increase in SCr of at least 44.2 µmol/L (0.5 mg/dL) from baseline up to day 3.&lt;br&gt;</Primary_outcome>
    <Secondary_ID>DXV405</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455044</Internal_Number>
    <TrialID>EUCTR2005-002372-16-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Multicenter, open-label, single-arm, safety, tolerability, efficacy and pharmacokinetic study of RAD001 in pediatric de novo renal transplant patients

Estudio multicéntrico, abierto, con un grupo de tratamiento, para evaluar la eficacia, la tolerabilidad, la seguridad y la farmacocinética de RAD001, en pacientes pediátricos receptores de un trasplante renal de novo - RAD351</Public_title>
    <Scientific_title>Multicenter, open-label, single-arm, safety, tolerability, efficacy and pharmacokinetic study of RAD001 in pediatric de novo renal transplant patients

Estudio multicéntrico, abierto, con un grupo de tratamiento, para evaluar la eficacia, la tolerabilidad, la seguridad y la farmacocinética de RAD001, en pacientes pediátricos receptores de un trasplante renal de novo - RAD351                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Novartis Farmaceútica S.A</Primary_sponsor>
    <Date_registration3>20050906</Date_registration3>
    <Date_registration>06/09/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-002372-16                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>11/10/2005</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;a.Male and female patients ? 16 years of age.&lt;br&gt;b.Patients receiving a primary cadaveric or non-HLA identical living donor (related or unrelated) renal transplant.&lt;br&gt;c.The graft must be functional within 48 hours post transplantation. A functional graft is defined at the investigator’s determination by a 50 % fall of serum creatinine from the pre-transplant value. In the event of dialysis immediately preceding transplantation, the pre-dialysis serum creatinine value may be used.&lt;br&gt;d.Females capable of becoming pregnant must have a negative pregnancy test (qualitative dip stick test on urine) immediately prior to study entry. Females of child bearing potential must practice an approved method of birth control for the one year duration of the study and for a period of three months following discontinuation of study medication.&lt;br&gt;e.Patients who are willing and able to participate in the whole course of the study and for whom written informed consent has been obtained from the parent(s) or legal guardian.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? yes&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) no&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;a.Cold ischemia time &gt; 40 hours.&lt;br&gt;b.Patients who are recipients of multiple solid organ transplants, including dual and en bloc kidneys, or who have previously received transplanted organs.&lt;br&gt;c.Patients with non-diarrhea associated hemolytic-uremic syndrome.&lt;br&gt;d.Recipients of donor specific transfusions.&lt;br&gt;e.Patients with panel reactive T cell antibodies of 50 % or higher at the last assessment before transplantation.&lt;br&gt;f.Patients unable to undergo renal biopsies post-transplant. &lt;br&gt;g.Induction therapy with ALG, ATG and OKT3.&lt;br&gt;h.Use of anti-fungal azoles such as ketoconazole, itraconazole and fluconazole.&lt;br&gt;i.Patients requiring treatments with rifampin, carbamazepine, phenobarbital, phenytoin at the time of entry in the study.&lt;br&gt;j.The use of any investigational drug within 4 weeks prior to administration of the initial dose of study medication.&lt;br&gt;k.Patients who have received an investigational immunosuppressive agent within 4 months prior to administration of the initial dose of study medication.&lt;br&gt;l.Presence of any severe allergy (within 4 weeks prior to administration of the initial dose of study medication) requiring acute or chronic treatment; or hypersensitivity to drugs similar to RAD001 (e.g., erythromycin or other macrolide antibiotics) or to any component of the formulation.&lt;br&gt;m.Patients with any known contraindication to CsA.&lt;br&gt;n.Patients with severe or unstable medical conditions likely to affect patient safety or the objectives of this study. Other social circumstances that prevent full compliance with the protocol.&lt;br&gt;o.Patients with a history of alcohol or drug abuse, or signs of alcohol-induced organ damage, mental dysfunction or other factors limiting their ability to cooperate fully with the study.&lt;br&gt;p.Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug. The investigator should be guided by evidence of any of the following:&lt;br&gt;presence of inflammatory bowel syndrome, or gastrointestinal bleeding;&lt;br&gt;history of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection (bladder augmentations and feeding tubes are acceptable).&lt;br&gt;q.Patients who are Hepatitis C positive, HIV positive, or Hepatitis B surface antigen positive. Laboratory results obtained within 6 months prior to administration of the initial dose of study medication are acceptable. Recipients of organs from donors who test positive for Hepatitis B surface antigen, Hepatitis C or HIV.&lt;br&gt;r.Evidence of liver injury as indicated by abnormal liver tests (AST or ALT &gt; 3 times ULN, total bilirubin &gt; 2 mg/dL).&lt;br&gt;s.Presence of uncontrolled hypercholesterolemia ( =350 mg/dL, = 9.1 mmol/L) or hypertriglyceridemia (= 500 mg/dL, = 5.6 mmol/L).&lt;br&gt;t.White blood cell count = 4500/mm3 or platelet count = 100,000/mm3.&lt;br&gt;u.Patients with severe systemic infections.&lt;br&gt;v.Patients with any past or present malignancy (other than excised basal cell carcinoma).&lt;br&gt;w.History of splenectomy.&lt;br&gt;x.Patients with any history of significant coagulopathy or medical condition requiring long term systemic anticoagulation after transplantation which would interfere with obtaining biopsies. Low dose aspirin is allowed.&lt;br&gt;y.Abnormal physical or laboratory findings of clinical significance which would interfere with the objectives of the study.&lt;br&gt;z.Females who are breast feeding.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>pediatric de novo renal trasplant &lt;br&gt;MedDRA version: 7.0
Level: LLT
Classification code 10050432
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Certican 0.1mg fast-dispersable tablets&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001B&lt;br&gt;Pharmaceutical Form: Dispersible tablet&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 1.5mg/day-&lt;br&gt;&lt;br&gt;Trade Name: Certican 0.25mg fast-dispersable tablets&lt;br&gt;Product Name: certican&lt;br&gt;Product Code: RAD001B&lt;br&gt;Pharmaceutical Form: Dispersible tablet&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 1.5mg/day-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: 1. To evaluate the safety and tolerability of RAD001 administered b.i.d. in combination with Neoral® and corticosteroids in pediatric de novo renal transplant recipients, and to provide additional safety data (quantitative protein/creatinine ratio in urine).;Primary end point(s): To evaluate the safety and tolerability of RAD001 administered b.i.d. in combination with Neoral® and corticosteroids in pediatric de novo renal transplant recipients;Secondary Objective: 1.To evaluate the efficacy of RAD001 administered b.i.d. in combination with Neoral® and corticosteroids as measured by the incidence of biopsy proven acute allograft rejection episodes, graft loss or death at 6 and 12 months after initial dose of study medication.&lt;br&gt;2.To characterize the multiple dose pharmacokinetics of RAD001 administered b.i.d.&lt;br&gt;3.To evaluate the efficacy of RAD001 administered b.i.d. in combination with Neoral® and corticosteroids in the prevention of chronic allograft rejection (chronic graft dysfunction) at 12 months post-transplantation.&lt;br&gt;</Primary_outcome>
    <Secondary_ID>CRAD001B351</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455172</Internal_Number>
    <TrialID>EUCTR2005-001854-25-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio comparativo de tacrolimus y rapamicina para evaluar la función renal en pacientes mayores de 50 años, receptores de un riñón de donante mayor de 55 años, en un régimen inmunosupresor de daclizumab y micofenolato mofetil. - ALHAMBRA</Public_title>
    <Scientific_title>Estudio comparativo de tacrolimus y rapamicina para evaluar la función renal en pacientes mayores de 50 años, receptores de un riñón de donante mayor de 55 años, en un régimen inmunosupresor de daclizumab y micofenolato mofetil. - ALHAMBRA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Sociedad Andaluza de Trasplante de Órganos y Tejidos</Primary_sponsor>
    <Date_registration3>20051010</Date_registration3>
    <Date_registration>10/10/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-001854-25                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>05/12/2005</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Pacientes de ambos sexos cuya edad sea mayor o igual a 50 años, y que sean receptores primarios de aloinjerto renal proveniente de donante mayor o igual a 55 años.&lt;br&gt;2. Pacientes que hayan otorgado su consentimiento de manera previa a su participación en el estudio.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Pacientes receptores de trasplante multiorgánico.&lt;br&gt;2. Pacientes que reciben trasplante de donante cadáver con un tiempo de isquemia fría mayos de 30 horas.&lt;br&gt;3. Pacientes con un PRA mayor del 20% en los 6 meses anteriores a la inclusión.&lt;br&gt;4. Mujeres en periodo de lactancia, embarazadas o en edad fértil, que no usen un método anticonceptivo fiable antes de comenzar la terapia con el fármaco en estudio, durante la terapia, y durante los 4 meses siguientes a la última dosis de los fármacos administrados dentro de este estudio clínico.&lt;br&gt;5. Pacientes con recuento leucocitario menor de 2,5 x 109/L, recuento de plaquetas menor de 100 x 109/L, o hemoglobina inferior a 6 g/dL en el momento de ser incluido en el estudio,&lt;br&gt;6. Pacientes con evidencia de enfermedad hepática activa.&lt;br&gt;7. Pacientes con úlcera péptica activa.&lt;br&gt;8. Pacientes con diarrea grave o cualquier otro trastorno intestinal que pudiera interferir en la capacidad de absorción de medicación oral, incluyendo pacientes diabéticos con gastroenteropatía diabética diagnosticada previamente,&lt;br&gt;9. Pacientes con evidencia de infección sistémica activa que requiera el uso continuado de antibióticos, o evidencia de infección por VIH, o presencia de hepatitis B (HBs-Ag positiva) o C crónica activa,&lt;br&gt;10. Pacientes con historia de malignidad (excepto cáncer de piel no melanocítico localizado, tratado satisfactoriamente y carcinoma “in situ” de cervix),&lt;br&gt;11. Pacientes con una historia de enfermedad, o afección psicológica, que interfiera en la capacidad del paciente para comprender los requisitos del estudio,&lt;br&gt;12. Pacientes en quienes el investigador considera necesario un tratamiento con la siguiente medicación: &lt;br&gt;a.	-Azatioprina,&lt;br&gt;b.	Metotrexato,&lt;br&gt;c.	Ciclofosfamida&lt;br&gt;d.	-Anticuerpos antilinfocitos policlonales y monoclonales (por ejemplo, OKT3, ATG), usados para la inducción en pacientes de alto riesgo inmunológico,&lt;br&gt;e.	Basiliximab,&lt;br&gt;f.	Otros fármacos en investigación,&lt;br&gt;&lt;br&gt;13. Hipersensibilidad conocida o contraindicación absoluta de cualquiera de las medicaciones administradas en el contexto del estudio, o cualquier otra sustancia presente en las medicaciones del  estudio.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Trasplante renal en pacientes mayores de 50 años, receptores de un riñón de donante mayor de 55 años.</Condition>
    <Intervention>&lt;br&gt;Trade Name: PROGRAF&lt;br&gt;Product Name: tacrolimus&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: tacrolimus&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: RAPAMUNE&lt;br&gt;Product Name: SIROLIMUS&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Comparar la función renal (creatinina sérica a los 6 meses) en la entrada tardía del tratamiento con tacrolimus o rapamicina basados en regímenes con daclizumab, micofenolato mofetil y esteroides en pacientes mayores de 50 receptores de un injerto de donante mayor de 55 años.;Secondary Objective: 1. Eficacia:&lt;br&gt;Comparar los datos relativos al retraso en la función del injerto.&lt;br&gt;Comparar los datos relativos al rechazo.&lt;br&gt;Comparar la supervivencia del paciente y del injerto tras 6 meses de tratamiento.&lt;br&gt;Comparar los datos relativos al fallo de tratamiento a los 6 meses.&lt;br&gt;2. Seguridad:&lt;br&gt;Describir la incidencia de acontecimientos adversos entre ambos brazos a lo largo de 6 meses de tratamiento.;Primary end point(s): creatinina sérica a los 6 meses</Primary_outcome>
    <Secondary_ID>SATOT42005</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455280</Internal_Number>
    <TrialID>EUCTR2004-000520-32-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A MULTICENTRE, RANDOMISED, OPEN CLINICAL STUDY TO COMPARE THE EFFICACY AND SAFETY OF A COMBINATION OF TACROLIMUS AND MYCOPHENOLATE MOFETIL BASED REGIMEN WITH OR WITHOUT INDUCTION IN ELDERLY RECIPIENTS UNDERGOING KIDNEY TRANSPLANTATION
 - SENIOR (Safety and Efficacy with kNown Immunosuppression in Older Recipients)</Public_title>
    <Scientific_title>A MULTICENTRE, RANDOMISED, OPEN CLINICAL STUDY TO COMPARE THE EFFICACY AND SAFETY OF A COMBINATION OF TACROLIMUS AND MYCOPHENOLATE MOFETIL BASED REGIMEN WITH OR WITHOUT INDUCTION IN ELDERLY RECIPIENTS UNDERGOING KIDNEY TRANSPLANTATION
 - SENIOR (Safety and Efficacy with kNown Immunosuppression in Older Recipients)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Fujisawa GmbH</Primary_sponsor>
    <Date_registration3>20051102</Date_registration3>
    <Date_registration>02/11/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000520-32                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>26/01/2005</Date_enrollement>
    <Target_size>230</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: different drug combination regimen&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1 Male or female patients minimum 60 years of age&lt;br&gt;2 Patient has end stage kidney disease and is a suitable candidate for primary renal transplantation or retransplantation&lt;br&gt;3. Patient is receiving a kidney transplant, from a cadaveric or living donor (not HLA identical) with compatible ABO blood type&lt;br&gt;4. Patient has been fully informed and has given written informed consent according to ICH-GCP. Patient unable to write and/or read but who fully understands the oral information given by the investigator (or nominated representative) has given oral informed consent witnessed by an independent person&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Patient has an immunological high risk, defined as a PRA grade &gt;50% &lt;br&gt;2. Cold ischemia time of the donor kidney greater than 30 hours&lt;br&gt;3. Patient has significant liver disease, defined as having during the past 30 days continuously elevated ASAT (SGOT) and/or ALAT (SGPT) levels greater than 2 times the upper value of the normal range of the investigational site or is receiving a graft from a hepatitis C or B positive donor&lt;br&gt;4. Patient is allergic or intolerant to corticosteroids, macrolide antibiotics, mycophenolate mofetil, mycophenolic acid, tacrolimus, basiliximab or to the excipients of the study medication&lt;br&gt;5. Patient requires ongoing dosing with corticosteroids &lt;br&gt;6. Patient requires initial sequential or parallel therapy with immunosuppressive antibody preparation(s) or prohibited medication (see section 7.4 of protocol)&lt;br&gt;7. Patient or donor is known to be HIV positive&lt;br&gt;8. Patient with malignancy or history of malignancy, except non-metastatic basal or squamous cell carcinoma of the skin that has been treated successfully&lt;br&gt;9. Patient has significant, uncontrolled concomitant infections and/or severe diarrhoea, vomiting, active upper gastro-intestinal tract malabsorption or active peptic ulcer&lt;br&gt;10. Patient is participating or has participated in another clinical trial and/or is taking or has been taking an investigational drug in the past 30 days&lt;br&gt;11. Patient has previously received or is receiving an organ transplant other than kidney&lt;br&gt;12. Patient has been previously enrolled in this study&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients with end stage kidney disease who will undergo primary renal transplantion or retransplantation &lt;br&gt;MedDRA version: 7.0
Level: LLT
Classification code 10014646
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Prograf&lt;br&gt;Product Name: Prograf&lt;br&gt;Product Code: FK506&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Tacrolimus&lt;br&gt;CAS Number: 109581-93-3&lt;br&gt;Current Sponsor code: FK506&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;&lt;br&gt;Trade Name: Prograf&lt;br&gt;Product Name: Prograf&lt;br&gt;Product Code: FK506&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Tacrolimus&lt;br&gt;CAS Number: 109581-93-3&lt;br&gt;Current Sponsor code: FK506&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1.0-&lt;br&gt;&lt;br&gt;Trade Name: Prograf&lt;br&gt;Product Name: Prograf&lt;br&gt;Product Code: FK506&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Tacrolimus&lt;br&gt;CAS Number: 109581-93-3&lt;br&gt;Current Sponsor code: FK506&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5.0-&lt;br&gt;&lt;br&gt;Trade Name: CellCept&lt;br&gt;Product Name: CellCept&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: Mycophenolate mofetil&lt;br&gt;CAS Number: 116680-01-4&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;Trade Name: Simulect&lt;br&gt;&lt;br&gt;Product Name: Simulect&lt;br&gt;Pharmaceutical Form: Powder for solution for injection&lt;br&gt;INN or Proposed INN: Basiliximab  &lt;br&gt;CAS Number: 179045-86-4&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20.00-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To compare renal function as well as incidence of renal dysfunction, patient death, graft loss or first biopsy proven acute rejection within the first 6 months after transplantation for the two therapy regimens (Arm 1: Delayed Tacrolimus + MMF+ Basiliximab + Corticosteroids (1 week), Arm 2: Tacrolimus + MMF + Corticosteroids (3 months)). The aim is to demonstrate that Arm 1 is non-inferior to Arm 2 with regard to the primary endpoint.;Secondary Objective: To compare the efficacy and safety profiles of the two therapy regimens (Arm 1: Delayed Tacrolimus + MMF+ Basiliximab + Corticosteroids (1 week), Arm 2: Tacrolimus + MMF + Corticosteroids (3 months)). &lt;br&gt;;Primary end point(s): A two step testing strategy will be applied for the two primary endpoints. The first primary efficacy endpoint of this study will be the renal function measured by calculated creatinine clearance at month 6, determined from the serum creatine using the Cockcroft formula.&lt;br&gt;&lt;br&gt;If the result of the test for the first primary endpoint is statistically significant, then the composite endpoint can also be tested in a confirmatory way.&lt;br&gt;&lt;br&gt;The composite endpoint is the incidence of death, graft loss or acute rejection within the first 6 months after transplantation and incidence of renal dysfunction defined as a calculated creatinine clearance value of =40 ml/min/1.73 m2 at month 6. &lt;br&gt;</Primary_outcome>
    <Secondary_ID>FG-506-02-42</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455320</Internal_Number>
    <TrialID>EUCTR2004-001270-77-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio piloto para evaluar la eficacia y seguridad de Valsartán para el control de la progresión de la insuficiencia renal y la morbimortalidad cardiovascular en pacientes con trasplante renal funcionante con proteinuria e insuficiencia renal leve o moderada.</Public_title>
    <Scientific_title>Estudio piloto para evaluar la eficacia y seguridad de Valsartán para el control de la progresión de la insuficiencia renal y la morbimortalidad cardiovascular en pacientes con trasplante renal funcionante con proteinuria e insuficiencia renal leve o moderada.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>Equipo de doctores: Dr. Amado Andrés y Dr. Manuel Praga</Primary_sponsor>
    <Date_registration3>20051103</Date_registration3>
    <Date_registration>03/11/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-001270-77                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>01/03/2005</Date_enrollement>
    <Target_size>178</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Hombres y mujeres con edad entre 18 y 70 años de edad, con un trasplante renal funcionante de más de 1 año, sea cual sea la causa de la insuficiencia renal terminal que lo haya motivado (nefropatía diabética o no diabética)&lt;br&gt;2.	Insuficiencia renal leve o moderada, definida como una creatinina sérica &gt; 1,3 mg/dl en las mujeres y &gt; 1,5 mg/dl en los  varones y &lt; 3 mg/dl en ambos casos. &lt;br&gt;3.	Proteinuria &gt; 0,5 g/24 h en al menos 3 determinaciones previas al inicio del estudio y &lt; 3, 5 g /24 h.&lt;br&gt;4.	En el momento de la aleatorización y durante las 6 semanas previas a la misma, los pacientes no estarán tomando IECA o ARAII como tratamiento antihipertensivo.&lt;br&gt;5.	Se incluirá a los pacientes con estos criterios independientemente de su presión arterial, es decir, podrán ser incluidos tanto pacientes normotensos como hipertensos. No obstante, la presencia de una hipertensión de difícil control constituirá un criterio de  exclusión.&lt;br&gt;6.	No será requisito necesario la realización de biopsia renal antes del inicio del estudio. Si se hubiera realizado, los pacientes podrán ser incluidos independientemente del diagnóstico establecido (rechazo crónico, glomerulonefritis de novo o de recidiva...) siempre que cumplan los criterios de inclusión/exclusión.&lt;br&gt;&lt;br&gt;&lt;br&gt;7.	La inmunosupresión empleada en estos pacientes estará basada en Ciclosporina A y los pacientes no deben estar incluidos en ningún otro protocolo de estudio en el momento de su reclutamiento.&lt;br&gt;8.	Las mujeres potencialmente fértiles deberán presentar una prueba de embarazo negativa antes de la aleatorización y deberán practicar un método anticonceptivo probado médicamente durante todo el ensayo. &lt;br&gt;9.	El paciente ha de otorgar su consentimiento informado por escrito para participar en el estudio.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	Diagnóstico de más de 2 episodios de rechazo agudo hasta el inicio del estudio.&lt;br&gt;2.	Presencia de uropatía obstructiva no resuelta.&lt;br&gt;3.	Presencia de estenosis de arteria renal del injerto no resuelta&lt;br&gt;4.	Hepatopatía severa&lt;br&gt;5.	Enfermedad sistémica o deterioro general que haga previsible la imposibilidad de su seguimiento regular.&lt;br&gt;6.	Embarazo o lactancia&lt;br&gt;7.	Alteraciones psiquiátricas&lt;br&gt;8.	Hipersensibilidad conocida a los antagonistas de receptores de angiotensina (ARAII)&lt;br&gt;9.	Potasio sérico superior a 5.5 mEq/l en ausencia de fármacos que lo justifiquen.  &lt;br&gt;10.	Creatinina sérica &gt; 3.0 mg/dl o proteinuria &gt; 3,5 g/24h.&lt;br&gt;11.	Pacientes que hayan utilizado cualquier fármaco en investigación en las 6 semanas previas.&lt;br&gt;12.	Antecedentes de abuso de alcohol o de drogas no resuelto.&lt;br&gt;13.	Pacientes receptores de trasplantes de múltiples órganos sólidos o trasplantados previamente con cualquier otro órgano.&lt;br&gt;14.	Pacientes con alguna enfermedad maligna durante los últimos 5 años, excepto carcinoma de células basales o escamosas extirpado o carcinoma de cérvix in situ tratado adecuadamente.&lt;br&gt;15.	Estar participando en el momento de inclusión en otros protocolos de estudio.&lt;br&gt;16.	Hipertensión arterial de difícil control.&lt;br&gt;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Pacientes varones y mujeres de 18 a 70 años con trasplantes renales funcionantes de más de 1 año de evolución y una insuficiencia renal leve o moderada (creatinina sérica &gt; 1,3 mg/dl en mujeres y &gt; 1,5 mg/dl en varones y &lt; 3 mg/dl en ambos casos) y proteinuria (&gt;0,5 g/24 h y &lt; 3,5 g/24 h).</Condition>
    <Intervention>&lt;br&gt;Trade Name: DIOVAN&lt;br&gt;Product Name: Diovan&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: VALSARTÁN&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 80-160&lt;br&gt;&lt;br&gt;Product Name: HIPOTENSORES&lt;br&gt;Product Code: C02&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Product Name: DIURETICOS&lt;br&gt;Product Code: C03&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Product Name: VASODILATADORES PERIFÉRICOS&lt;br&gt;Product Code: C04&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Product Name: BETABLOQUEANTES&lt;br&gt;Product Code: C07&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Product Name: CALCIO ANTAGONISTAS&lt;br&gt;Product Code: C08&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Evaluar la eficacia de Valsartán en comparación con el tratamiento estándar para el control de la progresión de la insuficiencia renal, definida como un incremento de la creatinina sérica igual o superior al 50% del valor basal, en pacientes con trasplantes renales funcionantes con proteinuria e insuficiencia renal leve o moderada.;Secondary Objective: 1.	La reducción de la proteinuria&lt;br&gt;2.	Tolerabilidad de valsartán, evaluada mediante la frecuencia, tipo y gravedad de los acontecimientos adversos observados durante el estudio.  Se valorará la seguridad mediante exploraciones físicas, parámetros de laboratorio hematológicos y bioquímicos (incluyendo la determinación de creatinina y potasio) y medición de las constantes vitales.&lt;br&gt;3.	La morbimortalidad cardiovascular, evaluada mediante la incidencia global y específica de cada uno de los siguientes parámetros:&lt;br&gt;-	infarto agudo de miocardio o angina de pecho&lt;br&gt;-	necesidad de revascularización coronaria&lt;br&gt;-	episodios de insuficiencia cardiaca&lt;br&gt;-	accidente vascular cerebral&lt;br&gt;-	amputación y/o revascularización de extremidades inferiores&lt;br&gt;-	muerte de causa cardiovascular&lt;br&gt;;Primary end point(s): Porcentaje de pacientes con progresión de la insuficiencia renal, definida como un incremento de la creatinina sérica igual o superior al 50% del valor basal.	&lt;br&gt;</Primary_outcome>
    <Secondary_ID>TRASVAL</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455462</Internal_Number>
    <TrialID>EUCTR2004-000655-41-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A one-year, multicenter, open-label, feasibility study to evaluate the safety and the efficacy of FTY720 5mg introduction and CNI elimination in adult maintenance renal transplant reicpients maintained on a triple immunosuppressive regimen with either MPA or mTOR inhibitor</Public_title>
    <Scientific_title>A one-year, multicenter, open-label, feasibility study to evaluate the safety and the efficacy of FTY720 5mg introduction and CNI elimination in adult maintenance renal transplant reicpients maintained on a triple immunosuppressive regimen with either MPA or mTOR inhibitor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Novartis Farmacéutica S.A</Primary_sponsor>
    <Date_registration3>20051201</Date_registration3>
    <Date_registration>01/12/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000655-41                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>10/02/2005</Date_enrollement>
    <Target_size>88</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;male and female adults between 6 and 60 months post renal transplantation, maintained for the last 6 months on the same triple immunussupressive regimen : CNI + MPA + corticosteroids or CNI + mTOR + corticosteroids&lt;br&gt;stable renal function and no history of rejection&lt;br&gt;PRA &lt;10% pre-transplantation&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;patient at high immunological risk of rejection&lt;br&gt;pulse rate &lt; 50bpm at screening&lt;br&gt;presence or history of second or third degree AV block&lt;br&gt;history of cardiac arrest&lt;br&gt;history of malignancy&lt;br&gt;systemic infection within 2 weeks prior to start study medication&lt;br&gt;HIV or hepatitis B surface Ag positive&lt;br&gt;</Exclusion_Criteria>
    <Condition>prevention of acute rejection in maintenance renal transplant recipients &lt;br&gt;MedDRA version: 7.0
Level: LLT
Classification code 10023439
</Condition>
    <Intervention>&lt;br&gt;Product Name: FTY720&lt;br&gt;Product Code: FTY720&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: Not applicable&lt;br&gt;Current Sponsor code: FTY720&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 2.5-5&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Evaluate whether FTY720 can be safely introduced in a maintenance renal transplant population and can allow for CNI elimination resulting in an improvement of the renal function ;Secondary Objective: Validate discharge criteria following the first administration of FTY720;Primary end point(s): improvement of the renal function 12 months after FTY720 introduction, measured by the change in estimated glomerular filtration rate (Cockroft-Gault formula)</Primary_outcome>
    <Secondary_ID>CFTY720A2308</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455483</Internal_Number>
    <TrialID>EUCTR2005-004299-19-CZ</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>New Possibilities of TDM of Cyclosporine A and its metabolites after kidney transplantation</Public_title>
    <Scientific_title>New Possibilities of TDM of Cyclosporine A and its metabolites after kidney transplantation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>University Hospital Ostrava</Primary_sponsor>
    <Date_registration3>20051007</Date_registration3>
    <Date_registration>07/10/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-004299-19                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>26/10/2005</Date_enrollement>
    <Target_size>375</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;renal transplant patients on standart therapy with cyclosporine A&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;end of treatment with cyclosporine A, disagreement of patients&lt;br&gt;</Exclusion_Criteria>
    <Condition>patient on standart immunusupresive therapy with cyclosporine A after renal transplantation</Condition>
    <Intervention>&lt;br&gt;Trade Name: not fixed in the protocol&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: CICLOSPORINUM&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The target of this project is to clarify the importance of TDM of CsA and its principal metabolites by LC-MS in lymphocytes when compared with currently used methods C through, AUC, and C2. ;Secondary Objective: We further wish for detection the role of the lipofile metabolite AM4N in imunosupresion and toxicity, and alternatively other metabolites analyzed by LC-MS.;Primary end point(s): to clarify the importance of TDM of CsA and its principal metabolites by LC-MS in lymphocytes when compared with currently used methods C through, AUC, and C2. We further wish for detection the role of the lipofile metabolite AM4N in imunosupresion and toxicity, and alternatively other metabolites analyzed by LC-MS.&lt;br&gt;to find the therapeutic range for safety and effective therapy with CsA</Primary_outcome>
    <Secondary_ID>1A/8655-5</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455503</Internal_Number>
    <TrialID>EUCTR2005-003383-39-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A randomized, open-label, multi-center study comparing a steroid sparing regimen versus standard steroid regimen in combination with daclizumab, mycophenolate mofetil and sirolimus in the prevention of acute renal allograft rejection.Estudio abierto, aleatorizado, multicéntrico, nacional, comparando un régimen libre de esteroides frente a un régimen de esteroides estándar, en combinación con Daclizumab, Micofenolato Mofetil y Sirolimus, en la prevención del rechazo agudo en trasplante renal.</Public_title>
    <Scientific_title>A randomized, open-label, multi-center study comparing a steroid sparing regimen versus standard steroid regimen in combination with daclizumab, mycophenolate mofetil and sirolimus in the prevention of acute renal allograft rejection.Estudio abierto, aleatorizado, multicéntrico, nacional, comparando un régimen libre de esteroides frente a un régimen de esteroides estándar, en combinación con Daclizumab, Micofenolato Mofetil y Sirolimus, en la prevención del rechazo agudo en trasplante renal.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Roche Farma S.A.</Primary_sponsor>
    <Date_registration3>20051111</Date_registration3>
    <Date_registration>11/11/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-003383-39                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>29/12/2005</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;–	Patients who are males or non-pregnant females &gt; 18 years old.&lt;br&gt;–	Patients who are recipients of primary kidney allografts.&lt;br&gt;–	Patients who are single-organ recipients (kidney only).&lt;br&gt;–	Patients with PRA &lt;20%&lt;br&gt;–	If patients are women of childbearing potential, they must have a negative pregnancy test, and use a reliable form of contraception&lt;br&gt;–	Patients and their guardians must be capable of understanding the purpose and risks of the study.&lt;br&gt;–	Patients who are willing to give written informed consent.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;–	Patients previously treated with Daclizumab, MMF or SRL.&lt;br&gt;–	Patients who require in addition to the study immunosuppresive regimen anti-lymphocyte preparations for induction therapy.&lt;br&gt;–	Women lactating, pregnant or of childbearing potential not using a reliable contraceptive method during the study.&lt;br&gt;–		Patients with severe gastrointestinal disorders that interfere with  &lt;br&gt;Their ability to receive or absorb oral medication and patients with severe diarrhoea.&lt;br&gt;–	Patients who are expected than to require oral corticosteroids post-transplant (i.e. patients suffering autoinmune diseases).&lt;br&gt;–	Patients with active peptic ulcer disease.&lt;br&gt;–	Patients receiving bile-acid sequestrants.&lt;br&gt;–	Patients with severe anemia (Hb&lt;6 g/dl), leucopenia (WBC&lt;2500/mm3) or thrombocytopenia (Tc&lt;100’000/mm3)&lt;br&gt;–	Patients with a history of a psychological illness or condition such as to interfere with the patient's ability to understand the requirements of the study.&lt;br&gt;–	HIV positive donor or patient&lt;br&gt;–	Patients with history of malignancy within the last 5 years, except localised and treated non melanoma skin cancer, treated and without recidive evidence.	&lt;br&gt;–	Patients for whom the investigator considers a treatment with the following medications necessary:&lt;br&gt;?	Azathioprine,&lt;br&gt;?	methotrexate&lt;br&gt;?	cyclophosphamide,&lt;br&gt;?	Cyclosporine&lt;br&gt;?	Tacrolimus&lt;br&gt;?	Everolimus&lt;br&gt;?	Mycophenolate sodium&lt;br&gt;?	polyclonal and monoclonal anti-lymphocyte antibodies other than daclizumab (e.g. OKT3, ATG, basiliximab) &lt;br&gt;–	Known hypersensitivity or absolute contraindications to any of the medications administered in the context of the study or any other substances present in the study medications&lt;br&gt;–		Patients who require concomitant treatment with other investigational or prohibited drugs.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal Transplant</Condition>
    <Intervention>&lt;br&gt;Trade Name: Rapamune&lt;br&gt;Product Name: Rapamune&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: Rapamune&lt;br&gt;Product Name: Rapamune&lt;br&gt;Pharmaceutical Form: Oral solution&lt;br&gt;INN or Proposed INN: sirolimus&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: ZENAPAX&lt;br&gt;Product Name: Daclizumab&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: Daclizumab&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To compare the efficacy of a steroid free regimen against normal doses of corticosteroids for prevention of acute rejection, when given in conjunction with daclizumab, mycophenolate mofetil (MMF) and sirolimus as maintenance therapy in the management of renal allograft recipients.;Secondary Objective: To assess clinical efficacy and safety of  the two treatment regimens&lt;br&gt;;Primary end point(s): Proportion of patients experiencing a biopsy proven acute rejection episode 6 months post-randomization</Primary_outcome>
    <Secondary_ID>ML18690</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455613</Internal_Number>
    <TrialID>EUCTR2005-004431-21-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio abierto, multicéntrico, aleatorio, con el objetivo de evaluar la eficacia y la seguridad de la inmunosupresión tras un primer trasplante renal cadavérico a corazón latiente basado la utilización de suero anti-linfocitos T de conejo, tacrolimus y micofenolato, libre de corticoesteroides concomitantes desde el inicio. - IBERICA</Public_title>
    <Scientific_title>Estudio abierto, multicéntrico, aleatorio, con el objetivo de evaluar la eficacia y la seguridad de la inmunosupresión tras un primer trasplante renal cadavérico a corazón latiente basado la utilización de suero anti-linfocitos T de conejo, tacrolimus y micofenolato, libre de corticoesteroides concomitantes desde el inicio. - IBERICA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Fresenius Biotech GmbH</Primary_sponsor>
    <Date_registration3>20051219</Date_registration3>
    <Date_registration>19/12/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-004431-21                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>17/02/2006</Date_enrollement>
    <Target_size>160</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Triple terapia Tacro/MMF/Corticosteroides&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Varón o mujer adulto, candidato para un primer transplante cadavérico, hasta los 70 años.&lt;br&gt;Las mujeres que se encuentren en edad fértil deberán utilizar métodos anticonceptivos seguros a lo largo de todo el estudio.&lt;br&gt;Donante a corazón latiente hasta los 65 años de edad, con de isquemia fría &lt;36 horas.&lt;br&gt;El paciente que haya recibido la información relativa al estudio y prestado su consentimiento informado por escrito.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Embarazo actual o en período de lactancia. &lt;br&gt;Mujeres que hayan tenido más de 3 embarazos (incluidos abortos). &lt;br&gt;Paciente con riesgo inmunológico considerado alto, definido por la presencia de un porcentaje de anticuerpos anti-HLA (PRA) ³25 %.&lt;br&gt;Hipersensibilidad a las proteínas del conejo (¿test cutáneo?) o alergias conocidas a cualquier componente de la inmunosupresión prevista. &lt;br&gt;Paciente/Donante HCV+, HBV+, HIV+&lt;br&gt;Paciente en tratamiento inmunosupresor pretransplante.&lt;br&gt;Paciente con neoplasia maligna actual o con antecedentes de neoplasia maligna, a excepción de cánceres basocelulares o espinocelulares en remisión. &lt;br&gt;Paciente sometido algún tipo de trasplante previo o candidato a trasplante múltiple (p.ej SKP).&lt;br&gt;Leucocitos &lt;2000/mm3 y/o plaquetas &lt;50 000/mm3 antes de iniciar el trasplante&lt;br&gt;</Exclusion_Criteria>
    <Condition>Trasplante renal de donante cadavérico</Condition>
    <Intervention>&lt;br&gt;Trade Name: ATeGe Fresenius&lt;br&gt;Product Name: ATeGe-Fresenius&lt;br&gt;Product Code: ATG&lt;br&gt;Pharmaceutical Form: Concentrate for solution for injection&lt;br&gt;INN or Proposed INN: Inmunoglobulina de conejo anti-linfocitos T humanos&lt;br&gt;Other descriptive name: ATG Fresenius&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Incidencia de rechazo subclínico y rechazo agudo (demostrados por biopsia).&lt;br&gt;   incidencia y lapso de tiempo hasta su manifestación&lt;br&gt;   gravedad histológica (BANFF)&lt;br&gt;   incidencia de resistencia a los corticoesteroides;Secondary Objective: Incidencia y duración de retraso inicial función injerto.&lt;br&gt;Función renal a los 1, 3, 6, 12 meses.&lt;br&gt;Porcentaje de pacientes proteinúricos y cantidad de proteína secretada&lt;br&gt;Porcentaje de pacientes con hipertensión arterial y en tratamiento hipotensor.&lt;br&gt;Porcentaje de pacientes hiperlipidémicos y en tratamiento hipolipemiante&lt;br&gt;Porcentaje de diabetes mellitas post-trasplante&lt;br&gt;Fallo de tratamiento y porcentaje de pacientes libres de esteroides al año.&lt;br&gt;Incidencia de complicaciones infecciosas bacterianas, víricas, fúngicas o parasitarias al año.  &lt;br&gt;Incidencia de neoplasias y enfermedad linfoproliferativa post-trasplante al año&lt;br&gt;Incidencia de cataratas&lt;br&gt;Incidencia de fracturas y osteoporosis diagnosticada densitometría osea al año&lt;br&gt;Incidencia de complicaciones cardiovasculares al año&lt;br&gt;Supervivencia total de pacientes al año&lt;br&gt;Supervivencia del injerto al año&lt;br&gt;Histología renal al año ;Primary end point(s): Evaluación de eficacia: La eficacia será valorada por la observación de eventos de rechazo agudo y rechazo agudo subclínico.&lt;br&gt;Evaluación de seguridad/tolerancia:La seguridad y tolerancia será determinada por la observación de graves efectos adversos. La evaluación incluirá pruebas clínicas y de laboratorio (exploración física, constantes vitales, hematología, bioquímica  y análisis de orina).</Primary_outcome>
    <Secondary_ID>IBERICA</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455627</Internal_Number>
    <TrialID>EUCTR2005-005664-88-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Prospective Study of Mycobacterium Tuberculosis Specific Cellular immune Responses in Iatrogenically Immunosuppressed Patients: those undergoing TNF-alpha blockade or Awaiting Renal Trasnplants: A Potential New Method For Accurate Diagnosis of Latent Tuberculosis Infection in Clinical Practice - Diagnosis of Latent TB Infection in Anti-TNF alpha or Dialysis</Public_title>
    <Scientific_title>Prospective Study of Mycobacterium Tuberculosis Specific Cellular immune Responses in Iatrogenically Immunosuppressed Patients: those undergoing TNF-alpha blockade or Awaiting Renal Trasnplants: A Potential New Method For Accurate Diagnosis of Latent Tuberculosis Infection in Clinical Practice - Diagnosis of Latent TB Infection in Anti-TNF alpha or Dialysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>University of Oxford</Primary_sponsor>
    <Date_registration3>20051215</Date_registration3>
    <Date_registration>15/12/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005664-88                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>08/12/2006</Date_enrollement>
    <Target_size>520</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: The RD1 based ex vivo enzyme linked immunospot assay&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients in chronic renal failure who are potential transplant recipients &lt;br&gt;OR &lt;br&gt;Patients with a rheumatological condition who are potential recipients of Tumour Necrosis Factor alpha blockade&lt;br&gt;&lt;br&gt;AND &lt;br&gt;adult (over 18)&lt;br&gt;AND&lt;br&gt;able to give written informed consent&lt;br&gt;AND &lt;br&gt;with risk factors for tuberculosis:&lt;br&gt;-[renal arm] from collaborating units in high prevalence areas of the UK&lt;br&gt;-[anti TNF alpha arm] patients who would be considered for tuberculin skin testing under current anti-TNFalpha treatment guidelines, including past history of exposure or disease, immigrant from high prevalence area, CXR changes suggestive of prior TB, grade 2 heaf test or above&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Children&lt;br&gt;Current active tuberculosis&lt;br&gt;Unable to give written informed consent&lt;br&gt;Hypersensitivity to tuberculin&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal failure and iatrogenic immunosuppression associated with solid organ transplantation or TNF alpha blockade in rheumatoid arthritis
ICD 10 codes included: N18 Z94.0 M05 M06 M07 M45</Condition>
    <Intervention>&lt;br&gt;Trade Name: Tuberculin PPD RT 23 SSI for mantoux testing&lt;br&gt;Product Name: Tuberculin PPD RT 23 SSI for mantoux testing&lt;br&gt;Product Code: 1&lt;br&gt;Pharmaceutical Form: Injection*&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To validate the use of the RD1 based Exvivo IFNy ELISpot in the immunodiagnosis of tuberculosis in iatrogenically immunosuppressed populations by calculation of positive and negative predictive values for the assay and for a comparator: the tuberculin based mantoux test;Secondary Objective: To investigate potential immune correlates of latency and active disease in tuberculosis and identify potential markers of prognosis and disease progression in tuberculosis.;Primary end point(s): Development of active tuberculosis</Primary_outcome>
    <Secondary_ID>HB996</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455632</Internal_Number>
    <TrialID>EUCTR2005-001714-41-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio multicéntrico, abierto, randomizado,  de doce meses de duración,  sobre la seguridad, tolerabilidad y eficacia de Certican®, administrado junto a un antagonista del receptor IL-2, corticoesteroides y dos niveles de exposición diferentes de tacrolimus, en pacientes con trasplante renal de novo

</Public_title>
    <Scientific_title>Estudio multicéntrico, abierto, randomizado,  de doce meses de duración,  sobre la seguridad, tolerabilidad y eficacia de Certican®, administrado junto a un antagonista del receptor IL-2, corticoesteroides y dos niveles de exposición diferentes de tacrolimus, en pacientes con trasplante renal de novo

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Novartis Farmacéutica, S.A.</Primary_sponsor>
    <Date_registration3>20051205</Date_registration3>
    <Date_registration>05/12/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-001714-41                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>24/05/2006</Date_enrollement>
    <Target_size>230</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;El investigador debe asegurarse de que cada paciente cumple todos los criterios de inclusión al momento de ingresar en el estudio (basal), inmediatamente antes de la aleatorización: &lt;br&gt;- Hombre o mujeres entre 18 y 65 años de edad.&lt;br&gt;- Paciente que haya recibido un primer trasplante de riñón de un donante cadavérico, de un donante vivo no emparentado o de un donante vivo emparentado con HLA no idéntico.&lt;br&gt;- Receptor de un riñón con un tiempo de isquemia fría (TIF) &lt; 30 horas.&lt;br&gt;- Receptor de un riñón procedente de un donante que tiene entre 10 y 65 años de edad.&lt;br&gt;- Paciente capaz de recibir la primera dosis de tacrolimus dentro de las 24 horas de efectuada la reperfusión del injerto.&lt;br&gt;- Mujeres con capacidad de procrear deben tener una prueba de embarazo negativa, y es necesario que utilicen un método anticonceptivo médicamente probado durante el estudio y por un periodo de tres meses tras la discontinuación del fármaco en investigación.&lt;br&gt;- Paciente dispuesto y capaz de dar consentimiento informado escrito para participar en el estudio y capaz de participar en el estudio durante 12 meses.&lt;br&gt;&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;El paciente que cumpla con alguno de los siguientes criterios al momento de ingresar al estudio (basal) justo antes de la aleatorización no podrá participar en el estudio:&lt;br&gt;- Paciente que anteriormente haya recibido un trasplante de órgano.&lt;br&gt;- Receptor de trasplante múltiple de órganos.&lt;br&gt;- Receptor de un trasplante de riñón de un donante a corazón parado .&lt;br&gt;- Receptor con transfusiones específicas del  donante&lt;br&gt;- Receptor de un trasplante A-B-O incompatible o trasplante con cross-match para células T positivo.&lt;br&gt;- Paciente con un nivel actual con Panel de Anticuerpos Reactivos (PRA) = 50%.&lt;br&gt;- Receptor de un riñón de un donante con  antígeno de superficie positivo de la hepatitis B o anticuerpos contra hepatitis C .&lt;br&gt;- Paciente positivo para el virus de inmunodeficiencia humano (HIV).&lt;br&gt;- Paciente con serología positiva para hepatitis C, o que es positivo para el antígeno de superficie de la hepatitis B con evidencia de daño hepático indicado por niveles de AST/ALT = 2.5 veces el LSN. Se aceptan los resultados de serología viral obtenidos dentro de los 6 meses previos a la administración de la primera dosis de Certican®.&lt;br&gt;- Paciente con hipercolesterolemia severa ( = 350 mg/dl, 9.1 mmol/dl) o hipertrigliceridemia severa     ( = 500 mg/dl, 5.6 mmol/l).&lt;br&gt;- Paciente con recuento de glóbulos blancos (WBC) &lt; o = 3.000/mm3 o recuento plaquetario &lt; o =  75,000/mm3&lt;br&gt;- Paciente con alguna alergia severa que requiere tratamiento agudo (dentro de las 4 semanas anteriores al examen basal) o crónico, o que presenta hipersensibilidad a fármacos similares a Certican® (Ej. macrólidos).&lt;br&gt;- Paciente que ha recibido tratamiento con un fármaco inmunosupresor o un fármaco en investigación dentro de las 4 semanas previas a la administración de la primera dosis de Certican®.&lt;br&gt;- Paciente con infección no controlada.&lt;br&gt;- Paciente con alguna condición médica o quirúrgica, distinta del actual trasplante, que a criterio del investigador impida la participación en este ensayo.&lt;br&gt;- Paciente con una neoplasia conocida, o antecedentes de neoplasia en los últimos 5 años, excepto carcinoma cutáneo localizado de células basales o escamosas que haya sido tratado con éxito.&lt;br&gt;- Hallazgos anormales de importancia clínica, ya sea en las evaluaciones físicas o en las pruebas de laboratorio, efectuados en las 2 semanas previas a la administración de la primera dosis de Certican® y que, a juicio del investigador, podrían interferir con los objetivos del estudio.&lt;br&gt;- Mujeres en periodo de lactancia.&lt;br&gt;- Paciente con síntomas de enfermedad somática o mental significativa, o con historia no resuelta de abuso de drogas o alcohol.&lt;br&gt;- Paciente que no coopera ni se comunica con el investigador.&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Transplante renal de novo

de novo kidney transplantation</Condition>
    <Intervention>&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001  &lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.25-&lt;br&gt;&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001&lt;br&gt;Pharmaceutical Form: Dispersible tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0,1-&lt;br&gt;&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001  &lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.50-&lt;br&gt;&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001  &lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001&lt;br&gt;Pharmaceutical Form: Dispersible tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0,25-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: El objetivo primario es determinar si la reducción de la dosis de tacrolimus puede preservar la función renal en pacientes receptores de trasplantes renales de novo que reciben tacrolimus además de Certican®, AR IL-2 y corticosteroides. Este objetivo se valorará comparando la función renal evaluada a los 12 meses de realizado el trasplante a través de una tasa de filtrado glomerular (GFR) calculada (fórmula MDRD) entre dos grupos de pacientes que reciben dos diferentes niveles de exposición al tacrolimus.&lt;br&gt;&lt;br&gt;;Secondary Objective: El objetivo secundario principal es evaluar la eficacia de los dos regímenes. Esto se evaluará con la comparación entre los dos grupos de la incidencia de rechazo agudo confirmado por biopsia (RACB), desde el Mes 4 hasta el Mes 12 después del trasplante. &lt;br&gt;Los otros objetivos secundarios son evaluar la eficacia y la seguridad de los dos regímenes. Esto se evaluará a los 12 meses, efectuando una comparación entre los dos grupos.&lt;br&gt;;Primary end point(s): La función renal se evaluará a los doce meses post-transplante por la creatinina sérica, el aclaramiento de creatinina calculado (fórmula de Cockcroft-Gault), la GFR calculada (fórmula de MDRD y fórmula de Nankivell). También se evaluará la proteinuria cuantitativa. </Primary_outcome>
    <Secondary_ID>CRAD001A2426</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2456453</Internal_Number>
    <TrialID>EUCTR2005-005972-34-DK</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Retrograd intrarenal stenkirurgi. En metode til behandling af den ESWL-resistente nyresten - Retrograde intrarenal Stone Surgery</Public_title>
    <Scientific_title>Retrograd intrarenal stenkirurgi. En metode til behandling af den ESWL-resistente nyresten - Retrograde intrarenal Stone Surgery                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Fredericia Hospital</Primary_sponsor>
    <Date_registration3>20060105</Date_registration3>
    <Date_registration>05/01/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005972-34                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>22/03/2006</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: saline irrigation fluid as usually used in this kind of procedures &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Stone surgery required&lt;br&gt;Age &gt; 18 years&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Previous coronary infarct&lt;br&gt;Use of alpha-blocking or beta-blocking drugs&lt;br&gt;Untreated hypertension&lt;br&gt;Ureteral stone&lt;br&gt;Malignant disase in the upper urinary tract&lt;br&gt;Pregnancy&lt;br&gt;</Exclusion_Criteria>
    <Condition>kidney stone</Condition>
    <Intervention>&lt;br&gt;Trade Name: Isoprenalin&lt;br&gt;Product Name: isoprenalin&lt;br&gt;Product Code: 5115&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;Current Sponsor code: HJ1&lt;br&gt;Other descriptive name: isoprenalin&lt;br&gt;Concentration unit: µg microgram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0,1-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To lower the intrarenal pelvic pressure during retrograde intrarenal stone surgery by adding isoprenalin to the irrigation fluid during the operation.;Secondary Objective: To shorten surgical time in retrograde intrarenal stone surgery whilst optimizing security and quality of the procedure. To spare the kidney parenchyma  from high pressures.;Primary end point(s): Lowering of the renal pelvic pressure.&lt;br&gt;Making the procedure easier for the surgeon (=shorter duration of operation time, fewer complications)</Primary_outcome>
    <Secondary_ID>HJ1</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2456484</Internal_Number>
    <TrialID>EUCTR2006-000753-22-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A phase I/II feasability trial to assess the safety, immunological activity and efficacy of TroVax plus interferon alpha in patients with advanced or metastatic renal cell cancer.</Public_title>
    <Scientific_title>A phase I/II feasability trial to assess the safety, immunological activity and efficacy of TroVax plus interferon alpha in patients with advanced or metastatic renal cell cancer.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Oxford MioMedica UK Ltd.</Primary_sponsor>
    <Date_registration3>20060410</Date_registration3>
    <Date_registration>10/04/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-000753-22                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>04/05/2006</Date_enrollement>
    <Target_size>10</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Locally advanced or metastatic, histologically proven clear cell or papillary cell renal&lt;br&gt;carcinoma.&lt;br&gt;&lt;br&gt;If previously treated at least four weeks from any previous therapy (except Interferon a) for renal cancer includi,ng surgery chemotherapy, immunotherapy, or radiotherapy. (Patients receiving interferon a whose renal cancer is stable may also be included in the study)&lt;br&gt;&lt;br&gt;Newly diagnosed or progressive of stable measurable disease as defined by the&lt;br&gt;RECIST criteria&lt;br&gt;&lt;br&gt;Patients receiving first or second line treatment for locally advanced or metastatic renal cancer.&lt;br&gt;&lt;br&gt;Patients on stable doses of bisphosphonates that show subsequent tumor progression may continue on this medication; however, patients are not allowed to initiate bisphosphonate therapy within one month prior to starting therapy or throughout the study.&lt;br&gt;&lt;br&gt;Patients must be well enough to tolerate first or second line immunotherapy with&lt;br&gt;interferon alpha.&lt;br&gt;&lt;br&gt;Measurable disease.&lt;br&gt;&lt;br&gt;Aged 18 years or more.&lt;br&gt;&lt;br&gt;Patients must comply with 2 out of 3 of the following:&lt;br&gt;a. Karnofsky score greater than or equal to  80%.&lt;br&gt;b. Haemoglobin concentration greater than or equal to  13g/dL (males) or 11.5 g/dL (females)&lt;br&gt;c. Corrected calcium less than or equal to 10 g/dL (2.5 mmols/L).&lt;br&gt;&lt;br&gt;Clinically immunocompetent.&lt;br&gt;&lt;br&gt;Free of clinically apparent autoimmune disease (including no prior confirmed diagnosis or treatment for autoimmune disease including Systemic Lupus Erythematosis, Grave's disease, Hashimoto's thyroiditis, multiple sclerosis, insulin dependant diabetes mellitus or systemic (non-joint) manifestations of rheumatoid disease).&lt;br&gt;&lt;br&gt;Total white cell count greater than or equal to 3 x 10e9/L and lymphocyte count greater than or equal to 1 x 10e9/dL.&lt;br&gt;&lt;br&gt;Serum creatinine up to 1.5 times upper limit of normal.&lt;br&gt;&lt;br&gt;ALT, AST and bilirubin &lt; 2 times the upper limit of normal.&lt;br&gt;&lt;br&gt;Able to give written informed consent and to comply with the protocol.&lt;br&gt;&lt;br&gt;Women must be either post menopausal, or rendered surgically sterile or, if of child&lt;br&gt;bearing potential, must have been practising a reliable form of contraception (oral&lt;br&gt;contraception + a barrier method) for at least three months prior to the first dose of&lt;br&gt;TroVax and must continue while they are being treated with TroVax. Men must&lt;br&gt;practise a reliable form of contraception while they are being treated with TroVax.&lt;br&gt;&lt;br&gt;No acute changes on 12-lead ECG.&lt;br&gt;&lt;br&gt;No clinical suspicion that cardiac ejection fraction is less than 45% (If clinically&lt;br&gt;suspicion exists the ejection fraction should be measured according to local site&lt;br&gt;procedures)&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Serious infections within the 28 days prior to entry to the trial.&lt;br&gt;&lt;br&gt;Prior TroVax&lt;br&gt;&lt;br&gt;Patients that initiate bisphosphonate therapy within one month prior to starting therapy or throughout the study.&lt;br&gt;&lt;br&gt;Already completed prior second line therapy for advanced or metastatic renal cancer.&lt;br&gt;(Note however that patients currently receiving interferon as second line therapy for&lt;br&gt;advanced or metastatic renal cancer who are stable (ie do not demonstrate response or progression by RECIST criteria) may enter the study)&lt;br&gt;&lt;br&gt;Major surgery or radiation therapy completed less than or equal to 4 weeks prior to enrollment.&lt;br&gt;&lt;br&gt;Prior radiopharmaceuticals (strontium, samarium) within 8 weeks prior to enrollment.&lt;br&gt;&lt;br&gt;Participation in any other clinical trial of a licensed or unlicensed drug within the&lt;br&gt;previous 30 days. (except sorafanib or sutnitinib who may enter the study after 7 days discontinuation)&lt;br&gt;&lt;br&gt;Cerebral metastesis on MRI scan&lt;br&gt;&lt;br&gt;"Currently active" second malignancy, other than non-melanoma skin cancer. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are considered by their physician to be at least less than 30% risk of relapse.&lt;br&gt;&lt;br&gt;Serious intercurrent infections or nonmalignant medical illnesses that are uncontrolled.&lt;br&gt;&lt;br&gt;Psychiatric illnesses/social situations that would limit compliance with protocol&lt;br&gt;requirements.&lt;br&gt;&lt;br&gt;Creatinine 21.5 x ULN.&lt;br&gt;&lt;br&gt;Chronic oral corticosteroid use unless prescribed as replacement therapy in the case&lt;br&gt;of adrenal insufficiency.&lt;br&gt;&lt;br&gt;Clinical indication of reduced cardiac function or an ejection fraction of r 40%.&lt;br&gt;&lt;br&gt;Requirement for radiotherapy (this is a sign of disease progression and is classed as a withdrawal criterion).&lt;br&gt;&lt;br&gt;Concurrent chemotherapy, immunotherapy and radiation therapy&lt;br&gt;&lt;br&gt;No investigational or commercial agents or therapies other than those included in protocol treatment may be administered with the intent to create regression of the&lt;br&gt;patient's malignancy.&lt;br&gt;&lt;br&gt;Life threatening illness unrelated to cancer.&lt;br&gt;&lt;br&gt;Cerebral metastases on MRI scan.&lt;br&gt;&lt;br&gt;History of allergic response to previous vaccinia vaccinations.&lt;br&gt;&lt;br&gt;Participation in any other clinical trial of a licensed or unlicensed drug within the&lt;br&gt;previous 30 days or during the course of this trial.&lt;br&gt;&lt;br&gt;Previous malignancies within the last 10 years other than successfully treated&lt;br&gt;squamous carcinoma of the skin or in situ carcinoma of the cervix treated with cone&lt;br&gt;biopsy.&lt;br&gt;&lt;br&gt;Previous history psychosis or of major a psychiatric disorder requiring hospitalization or any current psychiatric disorder that would impede the patient's ability to provide&lt;br&gt;informed consent or to comply with the protocol.&lt;br&gt;&lt;br&gt;Known allergy to egg proteins.&lt;br&gt;&lt;br&gt;Known to test positive for HIV or hepatitis B or C.&lt;br&gt;&lt;br&gt;Pregnancy or lactation.&lt;br&gt;&lt;br&gt;Prior history of organ transplantation.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Advanced or Metastatic Renal Cell Cancer</Condition>
    <Intervention>&lt;br&gt;Product Name: TroVax&lt;br&gt;Product Code: TV&lt;br&gt;Pharmaceutical Form: Suspension for injection&lt;br&gt;Current Sponsor code: TroVax&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 1.58 x 10e8-1.58 x 10e9&lt;br&gt;&lt;br&gt;Trade Name: Roferon-A&lt;br&gt;Product Name: Roferon-A&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Interferon A&lt;br&gt;Concentration unit: IU/ml international unit(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 18 x 10e6-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Secondary Objective: Though this is a phase I/II feasibility study to assess the safety and immunological&lt;br&gt;activity of TroVax combined with IFN-a, tumour response in each patient will also&lt;br&gt;be evaluated using RECIST criteria.;Main Objective: To evaluate whether IFN-a markedly increases the cellular or humoral anti-5T4&lt;br&gt;response to TroVax compared to that observed in previous studies using TroVax&lt;br&gt;alone, in combination with IL-2 or with chemotherapy.;Primary end point(s): Immunology endpoints&lt;br&gt;Antibody response to 5T4 as measured by ELISA&lt;br&gt;Cellular response to 5T4 antigen as measured by lFN gamma Elispot&lt;br&gt;&lt;br&gt;Primary safety endpoints&lt;br&gt;Assessment of the number of adverse events and serious adverse events&lt;br&gt;Assessment of safety by analysis of clinical laboratory variables (complete blood&lt;br&gt;count and chemistry panel).&lt;br&gt;&lt;br&gt;Efficacy endpoint&lt;br&gt;Tumour outcomes will be reported according to RECIST criteria.</Primary_outcome>
    <Secondary_ID>TV2/003/06</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2456489</Internal_Number>
    <TrialID>EUCTR2005-005809-38-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Does prophylactic N acetylcysteine reduce the incidence of contrast nephropathy in patients undergoing peripheral angiography - NAC as a Nehroprotective agent in Peripheral Angiography</Public_title>
    <Scientific_title>Does prophylactic N acetylcysteine reduce the incidence of contrast nephropathy in patients undergoing peripheral angiography - NAC as a Nehroprotective agent in Peripheral Angiography                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Research &amp; Development Department, Addenbrookes Hospital</Primary_sponsor>
    <Date_registration3>20060110</Date_registration3>
    <Date_registration>10/01/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005809-38                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>08/12/2006</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Any patient undergoing peripheral angiography in the Cambridge Vascular Unit, Addenbrooke’s Hospital, Cambridge who consents to participation&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Any patient undergoing peripheral angiography in Cambridge Vascular Unit, &lt;br&gt;Any patient that does not consent to participation in the study.&lt;br&gt;Any patient under the age of 18 years&lt;br&gt;Any patient with established renal failure on renal replacement therapy (dialysis).&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>We will use N acetylcystiene prophylactically in patient undergoing peripheral angiography at the Cambridge Vascular Unit at Addenbrooke's Hospital in order to prevent renal injury. Patients undergoing peripheral angiography have large quanities of contrast medium injected intravenously, contrast medium is a nephrotoxic substance. Thge drug will be administrated prophylactically to aviod acute renal failure.</Condition>
    <Intervention>&lt;br&gt;Trade Name: Fluimucil&lt;br&gt;Pharmaceutical Form: Effervescent tablet&lt;br&gt;INN or Proposed INN: N acetylcysteine&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 600-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To investigate the role of N acetylcysteine as a nephroprotective agent in patients undergoing peripheral angiography at Addenbrooke’s Hospital, Cambridge.&lt;br&gt;&lt;br&gt;Primarily we are looking for a reduction in the elevation of serum creatinine and also of other markers of renal damage in urine (retinol binding protein and albumin)&lt;br&gt;&lt;br&gt;A reduction in the mortality and morbidity related to renal failure that may result from a contrast medium induced nephropathy.&lt;br&gt;;Secondary Objective: ;Primary end point(s): To obtain eveidence that shows prophylactic use of N acetylcysteine is significantly nephroprotective for patients undergoing peripheral angiography</Primary_outcome>
    <Secondary_ID>NACP1</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2456539</Internal_Number>
    <TrialID>EUCTR2004-002852-33-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>a randomised, open clinical trial to study the efficacy of risedronate 35 mg/week in prevention of bone mass loss and vascular calcifications after kidney transplantation
Ensayo aleatorio, abierto para estudiar la eficacia de risedronato 35mg/semanal en la prevención de pérdida de masa ósea y calcificaciones vasculares post-trasplante renal - PREVENOS</Public_title>
    <Scientific_title>a randomised, open clinical trial to study the efficacy of risedronate 35 mg/week in prevention of bone mass loss and vascular calcifications after kidney transplantation
Ensayo aleatorio, abierto para estudiar la eficacia de risedronato 35mg/semanal en la prevención de pérdida de masa ósea y calcificaciones vasculares post-trasplante renal - PREVENOS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Dr. Jose Vicente Torregrosa Prats (fundacio clinic)</Primary_sponsor>
    <Date_registration3>20060124</Date_registration3>
    <Date_registration>24/01/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002852-33                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>13/04/2005</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: same treatment (calcium carbonate and cholecalciferol) without risedronato&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Male and female aged 18-75 years old; chronic renal failure's patients on dialysis that have had a kidney transplant; patients who have been fully informed and have given written informed consent&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Hyperimmunized patients (PRA ›75%); multiorganic transplant; diabetes mellitus patients on insulin treatment at the transplant moment; parathyroidectomised patients with parathyroid hormone values ‹ 50 pg/ml; patients that have received fluorine, biphosphonates or hormone replacement therapy in the previous 6 months, antiepileptic or calcitonin treatment in the previous 3 months, patients with biphosphonate allergy history, dyspepsia or reflux history and pregnant patients or nursing mothers.&lt;br&gt;</Exclusion_Criteria>
    <Condition>bone metabolic pathology associated to kidney transplantation &lt;br&gt;MedDRA version: 7.1
Level: LLT
Classification code 10058972
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Actonel semanal&lt;br&gt;Product Name: Actonel semanal&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: risedronate&lt;br&gt;Other descriptive name: risedronic acid&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 35-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: study the efficacy of risedronate 35 mg/week to reduce the bone mass loss in patients after kidney transplantation;Secondary Objective: study the efficacy of risedronate 35 mg/week in bone fractures prevention and in the vascular calcifications of kidney graft recipients. Safety evaluation;Primary end point(s): bone masses evolutions through bone densitometry tests: basal and after 6 and 12 months</Primary_outcome>
    <Secondary_ID>TOR-RIS-2004-01</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2456630</Internal_Number>
    <TrialID>EUCTR2005-005155-18-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Study on the effectiveness of a treatment with statine in reducing the morbility and cardiovascular mortality in patients with moderate-strict renal insufficiency. - ND</Public_title>
    <Scientific_title>Study on the effectiveness of a treatment with statine in reducing the morbility and cardiovascular mortality in patients with moderate-strict renal insufficiency. - ND                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI</Primary_sponsor>
    <Date_registration3>20060125</Date_registration3>
    <Date_registration>25/01/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005155-18                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>24/02/2004</Date_enrollement>
    <Target_size>350</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: yes&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients of age 18-80 years, with moderated light renal insufficiency, identified from a VFG calculated with formula of Cockcoft and Gault between the 60 and 20 ml/min.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients for which the cardiovascular risk is much elevated  40  .  Patients already in treatment with statine.&lt;br&gt;</Exclusion_Criteria>
    <Condition>patients with moderate-strict renal insufficiency &lt;br&gt;MedDRA version: 6.1
Level: PT
Classification code 10038474
</Condition>
    <Intervention>&lt;br&gt;Trade Name: TORVAST 10 10 CPR 10 MG&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Atorvastatin&lt;br&gt;CAS Number: 134523-03-8&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To verify in a population of patients with moderate-strict IR that an aggressive treatment of cholesterolemia  target   the levels of cholesterol LDL   100 mg/dL  meaningfully reduces the entity of a end point composite, constituted from mortality and cardiovascular morbility.;Secondary Objective: To verify in a population of patients with moderate-strict IR that an aggressive treatment of cholesterolemia  target   the levels of cholesterol LDL   100 mg/dL  meaningfully reduces the entity of a end point composite, constituted from mortality and cardiovascular morbility.;Primary end point(s): A composite of serious cardiovascular events  infarct, ictus, intestinal infarct, thrombosis renal arteries  and cardiovascular mortality.</Primary_outcome>
    <Secondary_ID>61/2003/O</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2456830</Internal_Number>
    <TrialID>EUCTR2005-005770-72-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>RAPSODY - RANDOMIZED, PROSPECTIVE TRIAL OF TWO SCHEDULES OF SORAFENIB 800 mg DAILY AND INTERFERON ALPHA IN METASTATIC RENAL CELL CARCINOMA  MRCC   A GOIRC PHASE II STUDY - RAPSODY</Public_title>
    <Scientific_title>RAPSODY - RANDOMIZED, PROSPECTIVE TRIAL OF TWO SCHEDULES OF SORAFENIB 800 mg DAILY AND INTERFERON ALPHA IN METASTATIC RENAL CELL CARCINOMA  MRCC   A GOIRC PHASE II STUDY - RAPSODY                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>GRUPPO ONCOLOGICO ITALIANO DI RICERCA</Primary_sponsor>
    <Date_registration3>20060217</Date_registration3>
    <Date_registration>17/02/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005770-72                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>13/01/2006</Date_enrollement>
    <Target_size>100</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Sorafenib 800 mg/die   interferone alfa 2a 9MU TIW&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.Signed informed consent  2.Histologically or cytologically documented Clear Cell Renal Carcinoma  RCC . In the case of a mixed histology the presence of a documented component of clear cell histology   61619; 50  is mandatory . Other variants are excluded  3.Prior Nephrectomy for primary site  conservative approaches are allowed   4.In cases with initial diagnosis of RCC of more than 2 years  RFS   2 years  a histological/cytological confirmation of renal cell carcinoma origin of actual metastases is mandatory  5.Metastatic measurable disease  at least one uni-dimensional measurable lesion by CT-scan or MRI  according to RECIST criteria  reported in Appendix   6.ECOG performance status   8804;2  ECOG scale reported in Appendix   7.Age   8805; 18 years  8.Life expectancy   8805; 3 months  9.Prior Surgery and/or Radiation Therapy  to less or equal than 25  of the bone marrow  are allowed. However, at least 4 weeks must have been elapsed since surgery or completion of radiation therapy and the patient must has recovered from side effects  10.ANC   8805;1.5 x 109/L; PLT   8805;100 x 109/L; Hb   8805;10 g/dl  11.Adequate hepatic function  Total bilirubin  1.5 times the UNL ; ALT and AST  2.5 times the UNL   5 UNL in presence of liver metastases   12.Amylase and lipase  1.5 x the UNL  13.Serum creatinine  2.0 x the UNL  14.PT or INR and PTT  1.5 times the UNL  Note  patients who receive anti-coagulation treatment will be allowed to participate provided that no evidence of abnormality in these parameters exists   15.Patients must be accessible for treatment and follow up   UNL   upper normal limit of the institution.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.CNS metastases  2.Previous malignancy except for basal cell skin cancer and cervical carcinoma in situ adequately treated, or any other cancer from which the patient has been disease-free for   61619; 5 years  3.Any of the concomitant illness or medical condition indicated below     Serious respiratory or cardiovascular disease such as  congestive heart failure    NYHA Class II -refer to Appendix- ; previous history  within 6 months  of myocardial infarction, angina pectoris or cardiac arrhythmias requiring anti-arrythmics  excluding beta blockers or digoxin . Active coronary artery disease, uncontrolled hypertension  4.Unstable diabetes mellitus, significant neurological or psychiatric disorders or seizure disorder requiring medication  such as anti-epileptics   5.Active clinically serious bacterial or fungal infections    grade 2 NCI-CTC, Version 3  or active human immunodeficiency virus  HIV  infection or chronic hepatitis B or C  6.Previous treatment  chemotherapy, Immunotherapy or experimental drugs  for advanced disease  adjuvant immnunotherapy could be allowed in the case of a relapse free survival   6 months   7.Prior isotope treatment  e.g. strontium or samarium   8.Participation in clinical trials with other experimental agents within 30 days of study entry or concomitant treatment with other experimental drug  9.Concomitant treatment with bisphosphonates or any other anti-cancer therapy  10.Concomitant treatment with ketoconazole or itraconazole  11.Pregnant or breast-feeding patients.  Women of childbearing potential must have a negative pregnancy test performed within seven days prior to the start of study drug.  Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial  12.History of organ allograft or autologous bone marrow transplant or stem cell rescue within four months of start of study drug   13.Prior use of Raf-kinase inhibitors  RKI , MEK or Farnesyl transferase inhibitors  14.Known or suspected allergy to the investigational agent or any agent given in association with this trial&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients with histologically- or cytologically-confirmed, metastatic, clear cell renal cell cancer  RCC &lt;br&gt;MedDRA version: 6.1
Level: PT
Classification code 10050513
</Condition>
    <Intervention>&lt;br&gt;Product Name: Sorafenib&lt;br&gt;Product Code: BAY 43-9006&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Sorafenib&lt;br&gt;CAS Number: 284461-73&lt;br&gt;Current Sponsor code: BAY 43-9006&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Product Name: Sorafenib&lt;br&gt;Product Code: BAY43-9006&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Sorafenib&lt;br&gt;CAS Number: 284461-73&lt;br&gt;Current Sponsor code: BAY 43-9006&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Aim of this study is to evaluate if the combination of Sorafenib 800 mg daily plus low-dose frequent interferon  total weekly dose 15 MU  has an increased antiangiogenic activity, and  a consequent possible increased activity, than Sorafenib 800 mg daily plus interferon in the classic schedule  total weekly dose 27 MU . Serum surrogate markers will be evaluated to eventually support clinical results of the study.;Secondary Objective: A pharmacoeconomic evaluation of the two treatment  schedules  Sorafenib same schedule and dosage, IFN total weekly dose 27 MU in Arm A vs  15 MU in ArmB  will be performed.;Primary end point(s): Primary end-point of the study is to determine the Progression Free Survival  PFS  rates in the two arms.</Primary_outcome>
    <Secondary_ID>0681</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2456841</Internal_Number>
    <TrialID>EUCTR2005-005695-32-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Ensayo clínico aleatorizado, controlado y abierto, para evaluar la eficacia (biocompatibilidad peritoneal) de la adición de bemiparina a la solución de icodextrina, en pacientes en diálisis peritoneal con trastornos del trasporte peritoneal. - Bemidextrina</Public_title>
    <Scientific_title>Ensayo clínico aleatorizado, controlado y abierto, para evaluar la eficacia (biocompatibilidad peritoneal) de la adición de bemiparina a la solución de icodextrina, en pacientes en diálisis peritoneal con trastornos del trasporte peritoneal. - Bemidextrina                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Fundación Renal Iñigo Álvarez de Toledo</Primary_sponsor>
    <Date_registration3>20060216</Date_registration3>
    <Date_registration>16/02/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005695-32                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>10/03/2006</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Sin tratamiento experimental&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Pacientes mayores de 18 años de ambos sexos, que hayan otorgado su consentimiento informado para participar en el estudio.&lt;br&gt;- Pacientes en tratamiento estable con diálisis peritoneal durante más de 6 semanas que presenten trastorno funcional peritoneal definido por capacidad de ultrafiltración estandarizada (glucosa 3.86% mantenida 4 horas en peritoneo) menor de 600 ml y/o transporte de creatinina elevado (definido por D/P de creatinina mayor de 0.65 a las 4h de permanencia). &lt;br&gt;- Pacientes con tratamiento con solución de icodextrina para diálisis peritoneal durante al menos un mes previo a su inclusión.&lt;br&gt;- Pacientes en los que el resto de líquidos dializantes que emplean en su DP contengan glucosa y PDG (productos de degradación de glucosa).&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Peritonitis en los últimos 2 meses.&lt;br&gt;- Pacientes con hemorragia en el momento de la inclusión, o pacientes con antecedentes de episodios hemorrágicos clínicamente evidentes y/o con incremento del riesgo de sangrado debido a cualquier alteración de la hemostasia que contraindique la terapia anticoagulante, y/o que en los dos últimos meses hayan presentado, al menos, alguna de las siguientes situaciones: hemorragia activa o lesiones orgánicas susceptibles de sangrar (ej.: úlcera péptica activa, accidente cerebrovascular hemorrágico, aneurismas).&lt;br&gt;- Cirugía mayor en el último mes. &lt;br&gt;- Hipersensibilidad conocida a las HBPM, a la heparina o sustancias de origen porcino.&lt;br&gt;- Hipersensibilidad conocida a icodextrina.&lt;br&gt;- Pacientes tratados con anticoagulación sistémica.&lt;br&gt;- Pacientes con diátesis hemorrágica congénita o adquirida. &lt;br&gt;- Daños o intervenciones quirúrgicas en el sistema nervioso central, ojos y oídos dentro de los 6 meses previos. &lt;br&gt;- Endocarditis bacteriana aguda y endocarditis lenta. &lt;br&gt;- Pacientes con historia de trombocitopenia asociada a heparina. &lt;br&gt;- Pacientes con insuficiencia hepática (con valores de AST y/o ALT &gt; 5 veces el valor normal establecido en los rangos de referencia del laboratorio local del hospital).&lt;br&gt;&lt;br&gt;- Hipertensión arterial grave (presión arterial sistólica mayor de 200 mmHg y/o presión arterial diastólica mayor de 120 mmHg).&lt;br&gt;- Pacientes con sospecha o incapacidad para cumplir el tratamiento y/o seguimiento del estudio.&lt;br&gt;- Pacientes que estén participando en otro ensayo clínico o lo hayan hecho en los últimos 30 días. &lt;br&gt;- Pacientes que tengan una esperanza de vida inferior a 6 meses.&lt;br&gt;- Mujeres embarazadas o en edad fértil que no utilicen un método anticonceptivo eficaz o mujeres en periodo de lactancia. &lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Pacientes con insuficiencia renal en tratamiento con diálisis peritoneal y trastornos de la función peritoneal. &lt;br&gt;Classification code 10051055
</Condition>
    <Intervention>&lt;br&gt;Trade Name: HIBOR® 3.500 UI anti Xa&lt;br&gt;Product Name: HIBOR®&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Bemiparina sodica&lt;br&gt;Concentration unit: IU/ml international unit(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 17500-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Evaluar si la adición de bemiparina (3500 Ul/día), una vez al día en la solución de icodextrina para la diálisis peritoneal durante 16 semanas, aumenta la capacidad peritoneal de ultrafiltración y/o disminuye la de transporte de creatinina de pacientes en diálisis peritoneal que presenten trastornos funcionales de tipo déficit de ultrafiltración y/o alto transporte.;Secondary Objective: Evaluar si la adición de bemiparina (3500 Ul/día), una vez al día en la solución de icodextrina para la diálisis peritoneal durante 16 semanas, modifica algunos biomarcadores del efluente peritoneal relacionados con los procesos de regeneración tisular.;Primary end point(s): La función peritoneal definida mediante la capacidad de ultrafiltración estandarizada (glucosa 3,86%, 4 horas de permanencia i.p.) y/o el transporte peritoneal de creatinina estimado por D/P y coeficiente de transferencia de masas o MTC durante el periodo de tratamiento aleatorizado (desde el día 1 al día 112).</Primary_outcome>
    <Secondary_ID>FRIAT-BEM-2005-01</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2456879</Internal_Number>
    <TrialID>EUCTR2006-000607-42-CZ</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Treatment of borderline changesin protocol biopsy 3 months after renal transplantation</Public_title>
    <Scientific_title>Treatment of borderline changesin protocol biopsy 3 months after renal transplantation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>Institute for clinical and experimental Medicine</Primary_sponsor>
    <Date_registration3>20060208</Date_registration3>
    <Date_registration>08/02/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-000607-42                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>20/02/2006</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: no treatment&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;a. 3 months after kidney transplantation&lt;br&gt;b. stabilised graft function with serum creatinine under 300 umol/l&lt;br&gt;c.  borderline changes according to Banff classification in protocol biopsy&lt;br&gt;d. signed  informed consent&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;a. Graft dysfunction due to rejection or to other reasons less than 1 month before biopsy&lt;br&gt;b. reduced graft function with serum creatinine 300 umol/l or higher &lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients with transplanted kidney and stabilised graft function</Condition>
    <Intervention>&lt;br&gt;Trade Name: SOLU-MEDROL inj.&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: methylprednisolon&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Impact of antirejection treatment with Solu-Medrol on graft function development&lt;br&gt;in patients with borderline changes in 3-months protocol graft biopsy.;Secondary Objective: Impact of antirejection treatment with Solu-Medrol on acute rejection prevalence and  graft survival in patients  with borderline changes in 3-months protocol graft biopsy ;Primary end point(s): Graft function assessed by serum creatinine and glomerular filtration rate calculated by Cockroft-Gault formula and MDRD at 1 and 2 years posttransplant</Primary_outcome>
    <Secondary_ID>KN-1/06</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2457059</Internal_Number>
    <TrialID>EUCTR2004-000678-30-CZ</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>An Evaluation of the Efficacy of Epo-Omega in Treatment of Anaemia in ESRD Patients When Administered by Thrice Weekly Intravenous Injection: A Dose Dependency Evaluation. - Epomax (3 x week i.v.) A dose dependency evaluation</Public_title>
    <Scientific_title>An Evaluation of the Efficacy of Epo-Omega in Treatment of Anaemia in ESRD Patients When Administered by Thrice Weekly Intravenous Injection: A Dose Dependency Evaluation. - Epomax (3 x week i.v.) A dose dependency evaluation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Baxter Healthcare S.A.</Primary_sponsor>
    <Date_registration3>20040910</Date_registration3>
    <Date_registration>10/09/2004</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000678-30                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>22/11/2004</Date_enrollement>
    <Target_size>105</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Patients who have provided written informed consent.&lt;br&gt;2. Patients with stable Hb &lt;10.5g/dL (stable = at least two Hb measurements &lt;10.5g/dL, a minimum of 7 days apart, in a 42 day period prior to formal screening for the study.  &lt;br&gt;3. Haemodialysis 3X/W for a minimum of 3 months and with delivered Kt/V =1.20/session (renal clearance to be added to K in case of residual renal function (RRF) [urine volume &gt;100mL] and renal urea clearance &gt;0.5mL/min). In the case that Kt/V determinations are not possible, a urea reduction rate (URR) of &gt; 65% will be accepted.&lt;br&gt;4. Patients 18-75 years of age (inclusive).&lt;br&gt;5. Patients with an adequate iron status defined as serum ferritin =100µg/L and transferrin saturation =20% at the screening visit.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	Patients with uncontrolled hypertension (diastolic BP &gt;100 mm Hg determined during two separate pre-dialysis measurements, preferably the second session of the week).&lt;br&gt;2.	Patients with Vit B12 deficiency (&lt;200 ng/L) or folic acid deficiency (&lt;3.0µg/L).&lt;br&gt;3.	Patients receiving treatment for cancer.&lt;br&gt;4.	Patients with haemolytic anaemia or anaemia due to other diseases.&lt;br&gt;5.	Patients with clinically persistent blood loss (e.g. gastrointestinal).&lt;br&gt;6.	Patients with known epilepsy.&lt;br&gt;7.	Patients with severe hyperparathyroidism and/or indication for parathyroidectomy.&lt;br&gt;8.	Pregnant or lactating patients. &lt;br&gt;N.B. Female patients of childbearing potential must have a negative serum pregnancy test at the time of screening and will be required to use a medically acceptable means of contraception during their participation in this study.&lt;br&gt;9.	Patients who have received Interferon or Ribavirin within 30 days prior to the screening visit.&lt;br&gt;10.	Patients who have received Epoetin (Alpha, Beta) or darbepoetin alfa treatment, androgens or transfusions within the last 90 days prior to screening.&lt;br&gt;11.	Patients with acute infection(s).&lt;br&gt;12.	Patients with inflammatory status (CRP &gt;30mg/L).&lt;br&gt;13.	Patients with HIV.&lt;br&gt;14.	Patients with chronic hepatitis C or chronic hepatitis B (with transaminases &gt;2X upper limit).&lt;br&gt;15.	 Patients who have received cytotoxic agents, immunosuppressives or radiation therapy within 30 days prior to the screening visit.&lt;br&gt;16.	Patients participating in another interventional study.&lt;br&gt;17.	Patients who have received investigational drug within 30 days prior to the screening visit.&lt;br&gt;18.	Patients with known hypersensitivity to Epoetin, mammalian cell line products or human serum albumin.&lt;br&gt;19.	Patients with a history of pure red cell aplasia (any cause).&lt;br&gt;20.	Patients with a serum albumin &lt; 30 g/L.&lt;br&gt;21.	Patients with a life expectancy &lt; 6 months.&lt;br&gt;Patients who have had a renal transplant are allowed to participate in the study, as are those who are on the transplant waiting list.  Those who are scheduled to have a living related donor operation within the next 3 months must be excluded.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Anaemia in End Stage Renal Disease  (ESRD) hemodialyzed Patients
 &lt;br&gt;MedDRA version: 7.0
Level: LLT
Classification code 10009120
</Condition>
    <Intervention>&lt;br&gt;Trade Name: NeoRecormon Multidose 50,000IU Powder and solvent for solution for injection&lt;br&gt;Product Name: NEORECORMON &lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection&lt;br&gt;INN or Proposed INN: epoetin beta&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50000-&lt;br&gt;&lt;br&gt;Product Name: EPOMAX 5000 IU, solution for injection&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: epoetin omega&lt;br&gt;Current Sponsor code: rHu-EPO&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5000-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The objective of this study is to evaluate the dose dependency of the effects of Epoetin-Omega administered by thrice weekly intravenous (i.v.) injection on erythropoiesis in anaemic renal patients on haemodialysis.;Secondary Objective: The trial will also evaluate the dose dependency of possible untoward effects.;Primary end point(s): 1.       Response rate. The Response Rate is the proportion of “responders”, where response to the assigned dose is defined as Packed Red Cell (PRC)   transfusion-independent attainment of Hb levels during the trial that meet one of the  following criteria: a) two consecutive weekly Hb values &gt;1.5 g/dL higher than the baseline Hb (HbB); b) Hb level is &gt;13.0 g/dL at least once, c) reduction in Epoetin dose due to a too rapid increase in Hb (i.e. &gt; 2.5 g/dL/2 weeks).&lt;br&gt;The baseline Hb level is defined as the average value of three Hb concentrations determined at the Screening Visit, in between the  screening visit and visit 0, and at visit 0.&lt;br&gt;2.       The weekly change in Hb until the end of the study. This parameter is defined as the weekly consecutive differences in Hb for each patient  (Hbi - Hbi-1, where i is the visit number and may range from 1 to 12).  For Visit 1, the value Hbi-1 is the baseline Hb value. The duration of  the observed period is from enrolment until one of the following events (whichever occurs first).&lt;br&gt;a)	The Hb level &gt; 13 g/dL.&lt;br&gt;b)	Patient requires an Epoetin dose increase.&lt;br&gt;c)	Patient requires an Epoetin dose decrease.&lt;br&gt;d)	Patient receives a PRC transfusion.&lt;br&gt;e)	Patient drops out of the study and Hb values are no longer available.&lt;br&gt;f)	The planned end of the study (completed 12 weeks).</Primary_outcome>
    <Secondary_ID>PRO-RENAL-REG-056</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2457194</Internal_Number>
    <TrialID>EUCTR2005-004052-12-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio abierto, aleatorizado y controlado sobre las propiedades antiinflamatorias de sevelamer (Renagel®) en pacientes sometidos a hemodiálisis crónica</Public_title>
    <Scientific_title>Estudio abierto, aleatorizado y controlado sobre las propiedades antiinflamatorias de sevelamer (Renagel®) en pacientes sometidos a hemodiálisis crónica                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Asociación Científica para la investigación Nefrológica (ACINEF)</Primary_sponsor>
    <Date_registration3>20060330</Date_registration3>
    <Date_registration>30/03/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-004052-12                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>13/06/2006</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Sujetos de ambos sexos, con edad igual o superior a 18 años; Sujetos sometidos a hemodiálisis durante un período igual o superior a 3 meses;	Sujetos que otorguen su consentimiento informado por escrito.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Sujetos que padezcan algún tipo de enfermedad inflamatoria, infecciosa o tumoral; Sujetos que hayan presentado algún episodio de enfermedad cardiovascular en los 3 meses previos a su inclusión en el estudio; Sujetos con enfermedad gastrointestinal severa (disfagia, gastroparesia activa no tratada, problemas de motilidad gastrointestinal, cirugía intestinal...); Sujetos con antecedentes de alcoholismo o abuso de tóxicos; Sujetos con antecedentes de vasculitis; Sujetos con diabetes mellitus y/o hipertensión mal controlada;	Sujetos que estén tomando fármacos con propiedades antiinflamatorias o inmunosupresores (corticoides, AINEs, inmunosupresores o inmunomoduladores, cualquier principio activo en cuya ficha técnica aparezca reflejado efecto alguno sobre la síntesis y/o liberación de citoquinas)&lt;br&gt;</Exclusion_Criteria>
    <Condition>Enfermedad renal terminal (ESRD)</Condition>
    <Intervention>&lt;br&gt;Trade Name: Renagel 800 mg&lt;br&gt;Product Name: Renagel&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Sevelamer&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 800-&lt;br&gt;&lt;br&gt;Product Name: Acetato cálcico&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Acetato cálcico&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Determinar la influencia del tratamiento con sevelamer en los niveles séricos de citoquinas pro-inflamatorias (TNF-alfa, IL-1beta, IL-6, IL-18), antiinflamatorias (IL-10) y de proteína C reactiva (PCR) en pacientes sometidos a hemodiálisis crónica.;Secondary Objective: Determinar la relación entre el metabolismo fosfocálcico y el estado inflamatorio.;Primary end point(s): Concentraciones séricas de citoquinas pro-inflamatorias (TNF-alfa, IL-1beta, IL-6, IL-18) y anti-inflamatorias (IL-10) en pacientes sometidos a hemodiálisis crónica.</Primary_outcome>
    <Secondary_ID>CAN-NEFRO-2005-01</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2457243</Internal_Number>
    <TrialID>EUCTR2006-000830-11-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A randomised prospective trial of tacrolimus-based steroid avoidance in renal transplantation with either alemtuzumab induction or, basiliximab induction and mycophenolate mofetil maintenance therapy - SALAMI</Public_title>
    <Scientific_title>A randomised prospective trial of tacrolimus-based steroid avoidance in renal transplantation with either alemtuzumab induction or, basiliximab induction and mycophenolate mofetil maintenance therapy - SALAMI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Leeds Teaching Hospitals NHS Trust</Primary_sponsor>
    <Date_registration3>20060403</Date_registration3>
    <Date_registration>03/04/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-000830-11                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>26/07/2006</Date_enrollement>
    <Target_size>120</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•	Male and female patients who must be over age 18 years.&lt;br&gt;•	Patients must be recipients of heart-beating cadaveric, non-heart beating or living donors.&lt;br&gt;•	Patients receiving a 2nd or subsequent grafts must have maintained their primary graft for a minimum of 6 months, except if graft failure was due to technical reasons.&lt;br&gt;•	Written Informed consent&lt;br&gt;•	Women at risk of pregnancy must have a negative pregnancy test before commencing the trial and agree to use a medically acceptable method of contraception throughout the treatment period and for 3 months after discontinuing the trial.  The manufacturer of Alemtuzumab advises effective contraception for 6 months after administration to men or women.  Advice will be given to patients to discuss with the transplant medical staff if a pregnancy is planned. &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•	Regional patients from Hull Royal Infirmary (due to the logistical difficulties in following these patients up from Leeds).&lt;br&gt;•	High Risk Recipients - defined as recipients who have one or more of the following; 2 HLA-DR mismatch, previous immunologically mediated graft loss in less than 6 months, Preoperative donor specific antibodies&lt;br&gt;•	Known hypersensitivity to the IMP including the standard drugs.&lt;br&gt;•	Prohibited prior or concomitant medications&lt;br&gt;•	Pregnant women or nursing mothers. &lt;br&gt;•	WBC count &lt; 3000/mm3 or platelets &lt; 75,000/mm3 at time of study entry&lt;br&gt;•	Any other concurrent cardiovascular, gastrointestinal, pulmonary or haematological conditions that would restrict the administration of study drugs in the opinion of the investigator.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>MabCampath / Alemtuzumab will be used as part of the immunosuppression regime following renal transplant.</Condition>
    <Intervention>&lt;br&gt;Trade Name: MabCampath&lt;br&gt;Product Name: MabCampath&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;&lt;br&gt;Trade Name: Simulect&lt;br&gt;Product Name: Simulect&lt;br&gt;Pharmaceutical Form: Powder for injection*&lt;br&gt;&lt;br&gt;Trade Name: CellCept&lt;br&gt;Product Name: CellCept&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The purpose of this study is to compare the efficacy of two tacrolimus-based steroid avoidance immunosuppressive regimens.&lt;br&gt;The primary objective of this study is to determine whether we can use a regime of immunosuppression that is both as effective as our standard regime and that offers advantages in terms of a lack of some of the specific side effects of our standard regime and one that is simpler and more cost effective.;Secondary Objective: Secondary endpoints can be categorised: 1- contains a number of standard clinical variables anticipated to be similar in both study groups, including rejection rates, patient and graft survival rates and rates of delayed graft function.  2- comprises a number of surrogate markers for cardiovascular outcome which are particularly important in this setting of studying steroid-free patients.  These include 24 hour blood pressure monitoring, pulse wave analysis and metabolic studies including glucose tolerance.  3- various socioeconomic endpoints with quality of life assessment, adherence monitoring and a cost analysis.  4- follows a number of scientific endpoints capitalising on the various expertise available both on and off site&lt;br&gt;;Primary end point(s): 1.	DTPA Isotopic Glomerular Filtration Rate (GFR) at 12 months </Primary_outcome>
    <Secondary_ID>RL05/7239</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2457397</Internal_Number>
    <TrialID>EUCTR2004-002376-42-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>PHASE II TRIAL OF SEQUENTIAL CHEMO-IMMUNOTHERAPY WITH CAPECITABINE PLUS INTERFERON ALPHA2a FOLLOWED BY IL-2 IN PATIENTS WITH METASTATIC KIDNEY CANCER</Public_title>
    <Scientific_title>PHASE II TRIAL OF SEQUENTIAL CHEMO-IMMUNOTHERAPY WITH CAPECITABINE PLUS INTERFERON ALPHA2a FOLLOWED BY IL-2 IN PATIENTS WITH METASTATIC KIDNEY CANCER                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST</Primary_sponsor>
    <Date_registration3>20060421</Date_registration3>
    <Date_registration>21/04/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002376-42                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>12/01/2005</Date_enrollement>
    <Target_size>36</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;</Exclusion_Criteria>
    <Condition>TREATMENT OF METASTATIC KIDNEY CANCER &lt;br&gt;MedDRA version: 6.1
Level: PT
Classification code 10050018
</Condition>
    <Intervention>&lt;br&gt;Trade Name: XELODA 120 CPR RIV. 500MG&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Capecitabine&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: ;Secondary Objective: ;Primary end point(s): </Primary_outcome>
    <Secondary_ID>ASL603LIOM02</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2457519</Internal_Number>
    <TrialID>EUCTR2006-001265-41-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A comparison of Sirolimus versus Tacrolimus as a delayed treatment of recipients of non heart beating donor kidneys after anti-IL2 monoclonal antibody - Sirolimus vs Tacrolimus for NHBD Kidney Recipients after IL-2 mAb</Public_title>
    <Scientific_title>A comparison of Sirolimus versus Tacrolimus as a delayed treatment of recipients of non heart beating donor kidneys after anti-IL2 monoclonal antibody - Sirolimus vs Tacrolimus for NHBD Kidney Recipients after IL-2 mAb                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Newcastle upon Tyne Hospitals NHS Trust</Primary_sponsor>
    <Date_registration3>20060418</Date_registration3>
    <Date_registration>18/04/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-001265-41                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>16/06/2006</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Recipients of kidneys from non heart beating donors&lt;br&gt;&lt;br&gt;Age 18-75&lt;br&gt;&lt;br&gt;Written informed consent obtained from the patient after receiving a comprehensive explanation&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Pregnant women&lt;br&gt;&lt;br&gt;Recipients of multiple transplants (e.g. Both kidneys from one donor transplanted into one recipient or a simultaneous kidney and liver or kidney and pancreas transplant)&lt;br&gt;</Exclusion_Criteria>
    <Condition>Kidney transplantation from non heart beating donors for end-stage renal disease</Condition>
    <Intervention>&lt;br&gt;Trade Name: Sirolimus (Rapamune)&lt;br&gt;Product Name: Sirolimus&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To compare the effects of sirolimus and tacrolimus on kidney function following non heart beating donor kidney transplantation into adult recipients.;Secondary Objective: To determine if the drugs have different effects on patient survival, survival of the transplanted kidney, acute rejection, chronic rejection and complications following surgery.;Primary end point(s): The primary end points are creatinine and calculated GFR (glomerular filtration rate) at monthly intervals from the date of transplant to 12 months.</Primary_outcome>
    <Secondary_ID>200621</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2457646</Internal_Number>
    <TrialID>EUCTR2004-005241-36-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Phase II clinical trial of Cisplatin, Gemcitabine and Trastuzumab (Herceptin®) as first line treatment of advanced irresectable transitional-cell urothelial carcinoma with overexpression of C-erbB-2 - UROTELIALHER2</Public_title>
    <Scientific_title>Phase II clinical trial of Cisplatin, Gemcitabine and Trastuzumab (Herceptin®) as first line treatment of advanced irresectable transitional-cell urothelial carcinoma with overexpression of C-erbB-2 - UROTELIALHER2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>ACROSS Group</Primary_sponsor>
    <Date_registration3>20060508</Date_registration3>
    <Date_registration>08/05/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-005241-36                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>21/06/2005</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Histologically proven diagnosis of urothelial adenocarcinoma of bladder, ureter and renal pelvis with overexpression of C-erbB-2 determined by IHC (+++) or FISH/CISH (in IHC ++) &lt;br&gt;- Non-resectable metastasic or locally advanced disease at the time of inclusion. Any T, any N and M1; T4b, N0, M0 or any T , N1,2 or 3, M0 &lt;br&gt;- Presence of at least one dimensionally measurable target on a CT-scan available for external review, with at least one diameter &gt; or = 2 cm, in a non-irradiated area&lt;br&gt;- Adequate cardiac function (LVEF &gt; or = 50%)&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Prior therapy for advanced disease. Adjuvant or Neoadjuvant therapy or chemo-radiotherapy for primary local disease are permitted if at least 6 months have elapsed&lt;br&gt;- Congestive heart failure (NYHA class II, III, IV) or history of  documented congestive heart failure, unstable angina pectoris, myocardial infarction in the last 6 months, poorly controlled hypertension (systolic &gt;180 mmHg or diastolic &gt;100 mmHg), clinically significant valvular heart disease, or high-risk uncontrolled arrhythmias&lt;br&gt;- Patients with dyspnoea at rest due to malignant or other disease or who require supportive oxygen therapy&lt;br&gt;</Exclusion_Criteria>
    <Condition>Advanced irresectable transitional-cell urothelial carcinoma, that includes cancer of the bladder, ureter and renal pelvis</Condition>
    <Intervention>&lt;br&gt;Trade Name: Trastuzumab (Herceptin)&lt;br&gt;Product Name: Trastuzumab (Herceptin)&lt;br&gt;Product Code: 903674&lt;br&gt;Pharmaceutical Form: Powder for infusion*&lt;br&gt;INN or Proposed INN: TRASTUZUMAB&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 21-&lt;br&gt;&lt;br&gt;Trade Name: Gemcitabine&lt;br&gt;Product Name: Gemcitabine&lt;br&gt;Pharmaceutical Form: Powder for infusion*&lt;br&gt;INN or Proposed INN: GEMZITABINE&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 38-&lt;br&gt;&lt;br&gt;Trade Name: Cisplatin&lt;br&gt;Product Name: Cisplatin&lt;br&gt;Pharmaceutical Form: Powder for infusion*&lt;br&gt;INN or Proposed INN: CISPLATIN&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To determine the efficacy to the combination of Cisplatin, Gemcitabine and Trastuzumab in terms of response rate in patients with advance urothelial carcinoma, that includes the cancer of bladder, of ureter and of renal pelvis with overexpression of C-erbB-2&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;;Secondary Objective: To determine the progression-free interval, the duration of the response, the toxicity profile and the overall survival in patients with advance urothelial carcinoma&lt;br&gt;;Primary end point(s): The principal variable of valoration will be the number of response rates in patientes treated with the combination </Primary_outcome>
  </Trial>
  <Trial>
    <Internal_Number>2457678</Internal_Number>
    <TrialID>EUCTR2005-000380-26-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A 12 month, multicenter, randomized, parallel, open-label study, to evaluate renal function and efficacy of Certican® (everolimus) with Simulect® (basiliximab) and cyclosporine discontinuation at 3 month post-transplant vs minimization, in de novo kidney transplant recipients - CERTES02</Public_title>
    <Scientific_title>A 12 month, multicenter, randomized, parallel, open-label study, to evaluate renal function and efficacy of Certican® (everolimus) with Simulect® (basiliximab) and cyclosporine discontinuation at 3 month post-transplant vs minimization, in de novo kidney transplant recipients - CERTES02                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Novartis Farmacéutica S.A.</Primary_sponsor>
    <Date_registration3>20060509</Date_registration3>
    <Date_registration>09/05/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-000380-26                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>24/05/2005</Date_enrollement>
    <Target_size>168</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: The control arm is the no drug discont of one of the drugs,and the changes of the trial drug dosages&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Each patient must meet all of the following inclusion criteria:&lt;br&gt;1. Male or female patients between 18 and 65 years of age&lt;br&gt;2. Male or female patients who are recipients of a first renal transplant from a primary cadaveric or non-HLA identical living related donor .&lt;br&gt;3. The renal cold ischemic time (CIT) must be &lt; 36 hours&lt;br&gt;4. The age of the donor must be &lt; 65 years&lt;br&gt;5. Females of childbearing potential must have a negative pregnancy test at baseline and are required to practice an approved method of birth control for the duration of the study and for a period of three months following discontinuation of study medication. &lt;br&gt;6. Patients who have given written informed consent to participate in the study&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients meeting any of the following criteria at baseline will be excluded from study participation.&lt;br&gt;1. Patients who are recipients of  multiple organ transplants including any organ other than kidney&lt;br&gt;2. Patients who have been previously transplanted with any organ other than a kidney&lt;br&gt;3. Recipients of non heart-beating donor organs&lt;br&gt;4. Patients with current or past panel reactive T-cell antibodies (PRA) titers of &gt;50%&lt;br&gt;5. Patients that had been treated with any investigational drug 4 weeks before the baseline period&lt;br&gt;6. Presence of any severe allergy requiring acute (within 4 weeks of baseline) or chronic treatment, or hypersensitivity to drugs similar to RAD001 (e.g. macrolides)&lt;br&gt;7. Existence of any surgical or medical condition, other than the current transplant, which in the opinion of the investigator, precludes enrollment in this trial&lt;br&gt;8. Evidence of liver dysfunction as indicated by an abnormal liver profile (AST, ALT, alkaline phosphatase or total bilirubin = 3 times ULN) before transplantation&lt;br&gt;9. Patients who are known to have a positive hepatitis C serology, who are human immunodeficiency virus (HIV) or hepatitis B surface antigen positive.  Laboratory  results obtained within 6 months prior to randomization are acceptable. Recipients of organs from donors who test positive for Hepatitis B surface antigen or Hepatitis C are excluded.&lt;br&gt;10. Patients with symptoms of significant somatic or mental illness. Unresolved history of drug or alcohol abuse&lt;br&gt;11. Presence of revascularized ischemic heart disease or AMI, (or any cardiac disease  considered to be unsafe for the study by the investigator)&lt;br&gt;12. Presence of severe hypercholesterolemia (= 350 mg/dL, 9.1 mmoL/dL) or hypertriglyceridemia (= 500mg/dL, 5.6 mmoL/L). Patients with controlled hyperlipidemia are acceptable&lt;br&gt;13. White blood cell (WBC) count= 3,500/mm3, or platelet count = 100,000/mm3 &lt;br&gt;14.  Patients with severe systemic infections&lt;br&gt;15. Patients with current or past malignancies (except for successfully treated localized basal cell carcinoma of the skin)&lt;br&gt;16. Patients who are recipients of A-B-O incompatible transplants or T-cell cross-match positive transplants &lt;br&gt;17. Patients with coagulopathy or any medical condition requiring long-term anticoagulation after transplantation (low  dose aspirin is allowed)&lt;br&gt;18. Abnormal physical or laboratory findings of clinical significance within 2 weeks prior to baseline visit, which at investigators discretion would interfere with the objectives of the study&lt;br&gt;19. Breast feeding women&lt;br&gt;20. Inability to cooperate or communicate with the investigator &lt;br&gt;21. Patients who have been treated with non-protocol immunosuppressive drug or treatment within 4 weeks prior to baseline visit&lt;br&gt;&lt;br&gt;Exclusion criteria for randomization at the end of month 3 (week 12):&lt;br&gt;&lt;br&gt;1. Any episode of acute rejection grade IIb/III (Banff classification) or a vascular acute rejection in the previous 4 weeks or any episode of acute rejection episode during the month prior to randomization.&lt;br&gt;2. Patients depending on dialysis&lt;br&gt;3. Serum creatinine &gt;3 mg/dL and/or more than 30% elevated during the previous month. &lt;br&gt;4. Patients who do not tolerate any increase in Certican ®  dose.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal Transplant &lt;br&gt;MedDRA version: M15
Classification code 10023438
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Certican®  &lt;br&gt;Product Name: Certican®&lt;br&gt;Product Code: RAD001&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: EVEROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.50-&lt;br&gt;&lt;br&gt;Trade Name: Certican®  &lt;br&gt;Product Name: Certican®&lt;br&gt;Product Code: RAD001&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: EVEROLIMUS&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.75-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective is to compare renal function in the two treatment groups at month 12 post-transplant, as measured by calculated GFR (Nankivell), serum creatinine and calculated creatinine clearance (Cockroft- Gault).&lt;br&gt;Intra-group change in GFR , as determined by Nankivell’s formula, and the GFR’s slope in the period between visits 6 and 12 months will also be determined.&lt;br&gt;;Secondary Objective: The secondary objectives of this study are:&lt;br&gt;•	To evaluate the incidence of biopsy-proven acute rejection (BPAR) episodes, graft loss, death or loss to follow-up after 12 months in both groups.&lt;br&gt;•	To evaluate the incidence of graft loss, death, BPAR episodes, antibody treated acute rejection episodes, clinically confirmed acute rejection episodes, clinically confirmed chronic rejection episodes and biopsy-proven chronic allograft nephropathy after 12 months in both groups.&lt;br&gt;•	To evaluate the safety of Certican® in combination with Simulect® and steroids, with either Neoral® discontinuation at 3 months post-transplant, or  Neoral® minimization.&lt;br&gt;;Primary end point(s): The GFR value is calculated using the Nankivell formula. This is the end point in witch sample size is based. </Primary_outcome>
    <Secondary_ID>CERTES02 (Ce-PoP-RAD001A2419)</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2458046</Internal_Number>
    <TrialID>EUCTR2006-001504-37-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>SUBCUTANEOUS INOCULATION OF ALLOGENEIC GENE-MODIFIED TUMOR CELLS  ACHN-IL2  MIXED TO AUTOLOGOUS TUMOR CELLS  CT-AUT  IN PATIENTS WITH METASTATIC RENAL CARCINOMA. - ND</Public_title>
    <Scientific_title>SUBCUTANEOUS INOCULATION OF ALLOGENEIC GENE-MODIFIED TUMOR CELLS  ACHN-IL2  MIXED TO AUTOLOGOUS TUMOR CELLS  CT-AUT  IN PATIENTS WITH METASTATIC RENAL CARCINOMA. - ND                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI</Primary_sponsor>
    <Date_registration3>20060623</Date_registration3>
    <Date_registration>23/06/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-001504-37                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>18/05/2006</Date_enrollement>
    <Target_size>200</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Terapie standard a base di Interleuchina2 e cellul&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1  documented Diagnosis of metastatic renal carcinoma; 2  Performance status  Karnofsky  80-100  and one prognosis quoad vitam advanced to 4 months;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1  Performance status  Karnofsky   80-100  and one prognosis quoad vitam inferior to 4 months;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Metastatic Kidney Cancer &lt;br&gt;MedDRA version: 6.1
Level: PT
Classification code 10050018
</Condition>
    <Intervention>&lt;br&gt;Product Name: ACHN-IL2&lt;br&gt;Pharmaceutical Form: Suspension for injection&lt;br&gt;Current Sponsor code: ACHN-IL2&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10000000-&lt;br&gt;&lt;br&gt;Product Name: CT-AUT&lt;br&gt;Pharmaceutical Form: Suspension for injection&lt;br&gt;Current Sponsor code: CT-AUT&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5000000-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: appraisal of the survival and quality of the life;Secondary Objective: clinical regression of the lesions;Primary end point(s): appraisal of the survival</Primary_outcome>
    <Secondary_ID>30/2006/O/Sper</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2458152</Internal_Number>
    <TrialID>EUCTR2006-000231-95-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A PHASE II STUDY OF BAY 43-9006 IN COMBINATION WITH WEEKLY GEMCITABINE FOR THE TREATMENT OF METASTATIC RCC EITHER UNSUITABLE FOR OR REFRACTORY TO PRIOR TREATMENT WITH CYTOKINES - TAGUSG6</Public_title>
    <Scientific_title>A PHASE II STUDY OF BAY 43-9006 IN COMBINATION WITH WEEKLY GEMCITABINE FOR THE TREATMENT OF METASTATIC RCC EITHER UNSUITABLE FOR OR REFRACTORY TO PRIOR TREATMENT WITH CYTOKINES - TAGUSG6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>IST - ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO</Primary_sponsor>
    <Date_registration3>20060622</Date_registration3>
    <Date_registration>22/06/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-000231-95                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>13/02/2006</Date_enrollement>
    <Target_size>43</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Written informed consent  - Advanced, histologically confirmed, RCC  - ECOG PS 0-2  - Age 18 years  - UISS 3 cathegory  see appendix  or immunotherapy refractory disease  indipendently of UISS cathegory .  - Presence of measurable disease  - Adequate blood counts  WBC  3.000/ml; HB  10 gr/dl; Ptl  100.000/ml  liver  Transaminases  2N; bilirubin  2N  and kidney  creatinine  2 ng/ml  function tests.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Brain metastasis  - Comorbid conditions which could represent a contraindication to receive the drugs on study or to jeopardize patient compliance  - Unstable diabetes; active coronary disease; active serious infections  - Recent gastrointestinal bleeding&lt;br&gt;</Exclusion_Criteria>
    <Condition>METASTATIC RENAL CANCER CELL &lt;br&gt;MedDRA version: 8.1
Level: PT
Classification code 10050018
Term: Renal cancer metastatic
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Nexavar&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Current Sponsor code: Bay 43-9006&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Gemzar*1g Polv ev 1fl&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: Gemcitabine&lt;br&gt;CAS Number: 122111-03-9&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 800-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: - To evaluate the response  expressed as  clinical benefit   to the combination of Gemcitabine and BAY 43-9006 in women and men with metastatic RCC either unsuitable for or refractory to prior treatment with cytokines.;Secondary Objective: - To evaluate progression-free survival, overall survival, response duration, time to response.  - To evaluate the combined regimen with respect to change in QoL status.  - To evaluate the possible predictive value of baseline phosho ERK  pERK , VEGFr 2 and 3 in tumour cells and of VEGF serum levels in determining tumor response.;Primary end point(s): To evaluate the response  expressed as  clinical benefit   to the combination of Gemcitabine and BAY 43-9006 in women and men with metastatic RCC either unsuitable for or refractory to prior treatment with cytokines.</Primary_outcome>
    <Secondary_ID>TAGUSG6</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2458281</Internal_Number>
    <TrialID>EUCTR2006-001935-23-DE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Real-time contrast-enhanced sonography of renal transplant recipients accurately predicts vascular allograft nephropathy</Public_title>
    <Scientific_title>Real-time contrast-enhanced sonography of renal transplant recipients accurately predicts vascular allograft nephropathy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>University of Heidelberg</Primary_sponsor>
    <Date_registration3>20061024</Date_registration3>
    <Date_registration>24/10/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-001935-23                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>17/10/2006</Date_enrollement>
    <Target_size>200</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients who have had stable renal allograft function for at least three months. &lt;br&gt;Patients with a written informed consent.&lt;br&gt;Patients over 18 years.&lt;br&gt;Patients of the Department of Nephrology; University Heidelberg (D).&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Allograft recipients with lymphocele (&gt;100ml),&lt;br&gt;Patients with significant renal transplant artery stenosis (&gt;70%) &lt;br&gt;Patients with hydronephrosis of grade 2 (dilatation of the renal pelvis and the calyces, with or without a dilatation of the proximal ureter) or more.&lt;br&gt;Patients with a familiar incompatibility against SonoVue TM &lt;br&gt;Patients with pregnancy.&lt;br&gt;Patients are allergic to proteins.&lt;br&gt;Patients with pulmonary hypertension.&lt;br&gt;Patients wirh a thrombotic diathesm&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Vascular allograft nephropathy represents the main cause of renal allograft loss after 1 yr of transplantation. The trial shall find a way for early diagnostics.
</Condition>
    <Intervention>&lt;br&gt;Trade Name: SonoVue 8 Mikroliter/ml Pulver und Lösungsmittel&lt;br&gt;zur Herstellung einer Dispersion&lt;br&gt;zur Injektion&lt;br&gt;&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: SonoVue 8 Mikroliter/ml Pulver und Lösungsmittel&lt;br&gt;CAS Number: 2551-62-4&lt;br&gt;Concentration unit: µl/ml microlitre(s)/millilitre&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Real-time contrast enhanced sonography can assess microvascular tissue perfusion using gas-filled microbubbles. The study shall evaluate the feasibility of RT-CES in detecting vascular allograft nephropathy  in comparison to colour Doppler ultrasonography.;Secondary Objective: ;Primary end point(s): to evaluate the feasibility of RT-CES in detecting vascular allograft nephropathy  in comparison to colour Doppler ultrasonography</Primary_outcome>
    <Secondary_ID>NZHD02</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2458376</Internal_Number>
    <TrialID>EUCTR2006-002851-33-AT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Sorafenib and Bevacizumab as first- line treatment in patients with advanced renal cell carcinoma</Public_title>
    <Scientific_title>Sorafenib and Bevacizumab as first- line treatment in patients with advanced renal cell carcinoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Univ. Prof. Dr. Manuela Schmidinger</Primary_sponsor>
    <Date_registration3>20060816</Date_registration3>
    <Date_registration>16/08/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-002851-33                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>18/08/2006</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•	Age greater or equal to 18 years&lt;br&gt;•	Histologically confirmed renal cell carcinoma (primary tumour or biopsy/surgery of metastases)&lt;br&gt;•	Radiologically confirmed metastatic disease&lt;br&gt;•	Surgically removed primary tumour so feasible (nephrectomy or nephron-sparing surgery as indicated) &lt;br&gt;•	ECOG status of 0 or 1 &lt;br&gt;•	Life expectancy of at least 12 weeks&lt;br&gt;•	Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 14 days prior to treatment start:&lt;br&gt;o	Hemoglobin &gt; 9.0 g/L&lt;br&gt;o	Leucocytes greater than or equal to 3000/µL&lt;br&gt;o	Absolut neutrophil count &gt; or equal 1,500 µL&lt;br&gt;o	Platelet count above &gt; or equal 100,000 /µL&lt;br&gt;o	Total bilirubin &gt; or equal 1.5 x upper limit normal&lt;br&gt;o	Serum creatinine &lt; 2.5 x upper limit normal &lt;br&gt;o	ALT and AST &lt; 2.5 x upper limit normal (&lt; 5 x upper limit normal for patients with liver involvement of their cancer&lt;br&gt;o	PT or INR and PTT&lt; 1.5 x upper limit normal&lt;br&gt;•	Women of childbearing potential and men must agree to use adequate contraception &lt;br&gt;•	Signed informed consent&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•	Prior systemic treatment for advanced renal cell carcinoma&lt;br&gt;•	Previous or concurrent malignancy that is distinct in primary site or histology from the cancer being evaluated in this study except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis and T1) or any cancer curatively treated &gt; 5 years prior to study entry.&lt;br&gt;•	Complete renal shut down requiring hemo-or peritoneal dialysis&lt;br&gt;•	History of cardiac disease: congestive heart failure &gt; NYHA class 2, active cardiovascular disease (MI less than 6 months prior to study entry), cardiac arrhythmia requiring anti-arrhythmic therapy (beta-blockers and digoxins are permitted), uncontrolled hypertension or history of poor compliance with antihypertensive treatment&lt;br&gt;•	Active clinically serious bacterial or fungal infection (&gt; grade 2 NCI-CTCAE, Version 3)&lt;br&gt;•	Known history of human immunodeficiency virus (HIV) infection or chronic hepatitis B/C &lt;br&gt;•	Evidence of spinal cord compression or brain metastases. A CT or MRI of the brain must be performed within 4 weeks prior to enrolment if the presence of metastases at these sites is suspected.&lt;br&gt;•	History or evidence upon physical/neurological examination of CNS disease unrelated to cancer, unless adequately treated with standard medical therapy e.g. uncontrolled seizures.&lt;br&gt;•	Patients with evidence or history of bleeding diathesis, coagulopathy, or thromboembolic event&lt;br&gt;•	Substance abuse, medical, psychological or social conditions that may interfere with the patient’s participation in the study or evaluation of the study results&lt;br&gt;•	Known or suspected allergy to any agent given in association with this trial&lt;br&gt;•	Any condition that is unstable or which could jeopardize the safety of the patient and his compliance in the study (e.g. uncontrolled diabetes mellitus, pancreatitis, acute or chronic liver disease etc).&lt;br&gt;•	Investigational drug therapy outside this trial during or within 4 weeks of the study entry&lt;br&gt;•	Prior use of inhibitors of Ras/Raf-, MEK-, AKT kinase- and mTOR-signaling pathway or of Farnesyl transferase inhibitors&lt;br&gt;•	Prior use investigational or licensed angiogenesis inhibitors&lt;br&gt;•	Concomitant Rifampicin&lt;br&gt;•	Significant surgery within 4 weeks prior to study entry&lt;br&gt;•	Female patients who are pregnant or breast feeding&lt;br&gt;•	Proteinuria defined as a 24-hour urine protein excretion greater than 1000 mg. Urine dipstick proteinuria of 2+ or greater will require a 24 hour urine to determine eligibility for enrollment&lt;br&gt;•	Impairment of the gastrointestinal (GI) function or GI disease that may significantly alter the absorption of Sorafenib&lt;br&gt;•	Therapeutic anticoagulation with coumadin, heparins or heparinoids&lt;br&gt;•	Current or recent (within 10 days of first dose of study treatment) daily use of aspirin (&gt;325 mg/day) or other NSAID &lt;br&gt;•	Thrombic or embolic events within the past 6 months&lt;br&gt;•	Hypertension defined as systolic blood pressure greater than 140 mm/Hg or diastolic pressure greater than 90 mm/Hg despite optimal management&lt;br&gt;•	Serious non-healing wounds, acute or non-healing ulcers, or bone fractures&lt;br&gt;•	Evidence of bleeding diathesis&lt;br&gt;•	History of hemoptysis or high grade varices&lt;br&gt;•	Primary tumor surgically removable&lt;br&gt;•	Solitary, surgically removable metastases&lt;br&gt;•	Patient unwilling or unable to give informed consent&lt;br&gt;•	Pregnancy or breast feeding&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients with advanced renal cell carcinoma</Condition>
    <Intervention>&lt;br&gt;Product Name: Sorafenib&lt;br&gt;Product Code: Bay 43-9006&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Sorafenib&lt;br&gt;CAS Number: 284461-73-0&lt;br&gt;Current Sponsor code: Bay 43-9006&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Product Name: Bevacizumab&lt;br&gt;Product Code: Ro4876646&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: Bevacizumab&lt;br&gt;Current Sponsor code: Ro4876646&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: •	To assess the combination of Sorafenib and Bevacizumab with respect to progression free survival &lt;br&gt;;Secondary Objective: •	To assess the safety of Sorafenib and Bavacizumab when used in combination&lt;br&gt;•	To assess disease control rate (DCR)&lt;br&gt;•	To estimate response rate&lt;br&gt;•	To evaluate time to progression (TTP)&lt;br&gt;•	To evaluate overall survival (OS)&lt;br&gt;•	To evaluate Quality of Life&lt;br&gt;•	To compare VEGF plasma levels before and during the treatment&lt;br&gt;;Primary end point(s): Clinical response measured according to standard criteria&lt;br&gt;•	Progression free survival	&lt;br&gt;•	clinical adverse events&lt;br&gt;•	laboratory parameters</Primary_outcome>
    <Secondary_ID>12197</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2458575</Internal_Number>
    <TrialID>EUCTR2006-003001-49-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Anti-inflammatory effects of rosiglitazone in patients with stage 4 and 5 chronic kidney disease - Hercules</Public_title>
    <Scientific_title>Anti-inflammatory effects of rosiglitazone in patients with stage 4 and 5 chronic kidney disease - Hercules                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Leiden University Medical Center</Primary_sponsor>
    <Date_registration3>20060601</Date_registration3>
    <Date_registration>01/06/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-003001-49                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>07/08/2006</Date_enrollement>
    <Target_size>200</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Willing and able to provide written consent;&lt;br&gt;- Patients must 18 years of age or older;&lt;br&gt;- Well-defined CKD&lt;br&gt;   for stage 4: GFR 15-30 ml/min/1.73m2 according to the abbreviated MDRD formula &lt;br&gt;   for stage 5: haemodialysis or peritoneal dialysis according to the K/DOQI guidelines&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- A diagnosis of diabetes mellitus for which the patient uses insulin;&lt;br&gt;- Significant co-morbidities which, according to the treating nephrologists, makes it unlikely that the patient will be able to complete the foreseen study period;&lt;br&gt;- Significant cardiovascular co-morbidities which are likely to interfere with the objectives of the study (morbid obesity, family history of dyslipidemia, etc.); at the discretion of the treating nephrologists or the principal investigator;&lt;br&gt;- Allergy for PPAR’s;&lt;br&gt;- Cardiac disease with marked limitation of functional capacity (New York Heart Association III or IV clinical status);&lt;br&gt;- Use of immunosuppressant agents;&lt;br&gt;- History of renal transplant;&lt;br&gt;- Hepatic insufficiency (defined as transaminase concentrations above &gt; 2.5 times the upper limit of normal for the laboratories);&lt;br&gt;- A history of alcohol abuse or excessive alcohol use defined as more than 21 consumptions per week;&lt;br&gt;- For female patients: pregnancy, the intention to become pregnant within the study period, or lactating patients.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Chronic kidney disease</Condition>
    <Intervention>&lt;br&gt;Trade Name: Avandia&lt;br&gt;Product Name: Rosiglitazon&lt;br&gt;Product Code: 1360&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objectives of the study are to assess the effect of rosiglitazone in patients with severe renal impairment on the change of carotid artery intima media thickness (IMT) and carotid artery calcifications and to assess the tolerability of rosiglitazone in this patient population.;Secondary Objective: Secondary objectives are to study the effects on (a) inflammation determined by measurement of the serum levels of inflammatory markers, nutrition state, erythropoietin resistance, insulin resistance and peritoneal membrane function in peritoneal dialysis patients and (b) the change of arterial stiffness determined by pulse wave velocity measurements over 48 weeks and (c) the drug safety profile (liver function parameters, weight changes, adverse events, etc.).;Primary end point(s): Intima-media thickness carotid artery</Primary_outcome>
    <Secondary_ID>P05.020</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2458668</Internal_Number>
    <TrialID>EUCTR2006-002913-11-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Randomised controlled, double blinded single centre trial to assess the effects of peri-operative dopexamine on morbidity after major abdominal surgery in patients with low anaerobic threshold. - Peri-operative effects of dopexamine in patients with low AT</Public_title>
    <Scientific_title>Randomised controlled, double blinded single centre trial to assess the effects of peri-operative dopexamine on morbidity after major abdominal surgery in patients with low anaerobic threshold. - Peri-operative effects of dopexamine in patients with low AT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>York Hospitals NHS Trust</Primary_sponsor>
    <Date_registration3>20060930</Date_registration3>
    <Date_registration>30/09/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-002913-11                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>31/07/2006</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients undergoing scheduled resection for carcinoma of the colon, rectum, bladder, pancreas, stomach or kidney, who, after routine CPX testing at the Pre-assessment Clinic, have been found to have an Anaerobic Threshold (AT) less than or equal to 11.0 ml/min/m2 as measured by the V-slope method15, or with an AT of 11.0 -14.0 ml/min/m2 and ischaemic changes on ECG monitoring during testing or with a significant history of ischaemic heart disease (NYHA classification III and IV).&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients less than 60 years of age unless they have significant co morbidities (ASA 3 or greater), patients having emergency or vascular procedures, those who are ASA grade 5, and patients who refuse or are unable to give informed consent&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients undergoing scheduled resection for carcinoma of the colon, rectum, bladder, pancreas, stomach or kidney, who, after routine CPX testing at the Pre-assessment Clinic, have been found to have an Anaerobic Threshold (AT) less than or equal to 11.0 ml/min/m2 as measured by the V-slope method15, or with an AT of 11.0 -14.0 ml/min/m2 and ischaemic changes on ECG monitoring during testing or with a significant history of ischaemic heart disease (NYHA classification III and IV).</Condition>
    <Intervention>&lt;br&gt;Trade Name: Dopacard&lt;br&gt;Product Name: Dopexamine hydrochloride&lt;br&gt;Pharmaceutical Form: Intravenous infusion&lt;br&gt;INN or Proposed INN: DOPEXAMINE HYDROCHLORIDE&lt;br&gt;CAS Number: 86484915&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;Pharmaceutical form of the placebo: Intravenous infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To assess morbidity at 1,3, 5, 8,10, 12 and 15 days using POMS score;Secondary Objective: To identify differences in&lt;br&gt;&lt;br&gt;1.	Length of stay in hospital after surgery&lt;br&gt;2.	Recovery parameters (drinking, eating, mobilising)&lt;br&gt;3.	Incidence of post-operative complications&lt;br&gt;4.	Peri-operative haemodynamic variables (heart rate, blood pressure, CVP)&lt;br&gt;5.	POSSUM score for surgical risk assessment.&lt;br&gt;6.	Oxygen delivery&lt;br&gt;;Primary end point(s): 1.	Morbidity at 1,3,5,8 10,12 and 15 days</Primary_outcome>
    <Secondary_ID>DOP 06;33549216</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2458848</Internal_Number>
    <TrialID>EUCTR2006-003746-42-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Immunotherapy vs immuno-chemotherapy in patients with metastatic kidney carcinoma - ND</Public_title>
    <Scientific_title>Immunotherapy vs immuno-chemotherapy in patients with metastatic kidney carcinoma - ND                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>OSPEDALE ONCOLOGICO DI BARI</Primary_sponsor>
    <Date_registration3>20061003</Date_registration3>
    <Date_registration>03/10/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-003746-42                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>11/02/2003</Date_enrollement>
    <Target_size>210</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: immunoterapia chemioterapia vs immunoterapia&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Histologic diagnosis of kidney carcinoma  2. Presence of metastases and/or  locally advanced primary tumour  3. Age   18 years old&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Severe infections  2. Previous treatment with IL-2  3. Brain metastasis  4. Pregnancy&lt;br&gt;</Exclusion_Criteria>
    <Condition>metastatic kidney carcinoma &lt;br&gt;MedDRA version: 6.1
Level: HLT
Classification code 10038408
</Condition>
    <Intervention>&lt;br&gt;Trade Name: PROLEUKIN*EV 1FL 18MUI 5ML &lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: Aldesleukin&lt;br&gt;CAS Number: 110942-02-4&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 18000000-&lt;br&gt;&lt;br&gt;Trade Name: GEMZAR*INFUS 1FL 1G POLV &lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: Gemcitabine&lt;br&gt;CAS Number: 122111-03-9&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1000-&lt;br&gt;&lt;br&gt;Trade Name: NAVELBINE 50*IV 50MG 5ML &lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: Vinorelbine&lt;br&gt;CAS Number: 122111-03-9&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To estimate if the addition of Gemcitabine and Navelbine leads to  increase of activity and therapeutic efficacy with respect to immunotherapy alone;Secondary Objective: 1. To estimate the toxicity of the two treatments  2. To estimate the treatment impact on the patient s life quality  3. To find the meaning of some predictive factors  VES, PCR, LDH, total lymphocytes ;Primary end point(s): To estimate if immunotherapy with IL-2, Gemcitabina e Navelbine is more effective with respect to immunotherapy alone in patients with kidney carcinoma</Primary_outcome>
    <Secondary_ID>om 145</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2459275</Internal_Number>
    <TrialID>EUCTR2006-005294-22-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Performance de l’équation MDRD corrigée par la cimétidine chez le patient transplanté rénal</Public_title>
    <Scientific_title>Performance de l’équation MDRD corrigée par la cimétidine chez le patient transplanté rénal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>CHU Saint-Etienne</Primary_sponsor>
    <Date_registration3>20061207</Date_registration3>
    <Date_registration>07/12/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-005294-22                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>29/12/2006</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- &gt; 18 years&lt;br&gt;- Kidney transplantation &gt; 1 year &lt;br&gt;- Patient with immunosuppressant treatment of TACROLIMUS (PROGRAF?)&lt;br&gt;- Creatinine clearance &gt; 30 ml/min/1,73m2 within 3 months before inclusion&lt;br&gt;- Written informed consent&lt;br&gt;- Patient affiliated to social insurance&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Unstable renal fonction defined by serum creatinine (J0) &gt; 25% serum creatinine realised in 3 mois&lt;br&gt;- Treatment: Bactrim®, Fansidar®, Cimetidine arrow® withing the week before inclusion&lt;br&gt;- Contraindication listed in in the labeling of Cimetidine arrow® (absolue, relative et médicaments nécessitant des précautions d’emploi cf ficheVidal en annexe 3)&lt;br&gt;- Last residual rate of Tacrolimus &gt; 12 ng/ml.&lt;br&gt;- Treatment : carvedilol, phenytoïne (intercation with cimetidine)&lt;br&gt;- Serious hepatic insuffisancy&lt;br&gt;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Estimating glomerular filtration rate in kidney transplantation: a comparison between inulin clearance and MDRD equation with cimetidin (block of secretion renal tubule) &lt;br&gt;MedDRA version: 8.1
Level: PT
Classification code 10018355
Term: Glomerular filtration rate
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Cimetidine arrow&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: compare performance of inulin clearance and MDRD with or no block of secretion renal tubule with cimetidin,  in kidney transplantation;Secondary Objective: ? Performance of different prediction equations for estimating renal function in kidney transplantation with or no block of secretion renal tubule with cimetidin : &lt;br&gt;- Walser equation&lt;br&gt;- Nankivell equation &lt;br&gt;- Cockcroft and Gault equation&lt;br&gt;&lt;br&gt;? comparison between inulin clearance and cystatin C ;Primary end point(s): Performance of different prediction equation : accuracy -30%, ie defined by proportion of patients with a estimation of glomerular filtration glomerular is include in - 30 % et + 30 % of  inulin clearance value. &lt;br&gt;&lt;br&gt;</Primary_outcome>
    <Secondary_ID>060890</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2459410</Internal_Number>
    <TrialID>EUCTR2006-006491-38-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Sunitinib  prior to nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ</Public_title>
    <Scientific_title>Sunitinib  prior to nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>NKI-AVL</Primary_sponsor>
    <Date_registration3>20061222</Date_registration3>
    <Date_registration>22/12/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006491-38                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>16/04/2007</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Histologically confirmed metastatic renal cell cancer of clear-cell subtype with a resectable  asymptomatic primary in situ. Asymptomatic primary  is defined as the absence of symptoms which can be exclusively assigned to the primary tumor such as flank pain and/or gross hematuria necessitating blood transfusion. As paraneoplastic symptoms cannot be assigned to the primary tumor alone in metastatic disease, they are not included in this definition. Unless the diagnosis of a clear-cell subtype has been established after histological examination of a resected metastatic lesion, all patients need to undergo a transcutaneous tru-cut needle biopsy of the primary tumor.&lt;br&gt;2.	Extensive metastatic disease which is defined as 3 or more non-resectable metastases in case of 1 metastatic site, using the RECIST criteria,  or 2 or more metastatic sites.&lt;br&gt;3.	Age: 18 to 65 years&lt;br&gt;4.	Life expectancy &gt; 3 months&lt;br&gt;5.	WHO performance status 0 or 1&lt;br&gt;6.	Written informed consent obtained from the patient after having been informed about the objectives of the study and the medication used.&lt;br&gt;7.	Blood counts: Leucocytes &gt; 3.0 x 109/l, platelets &gt; 100 x 109/l, hemoglobin &gt; 6.0 mmol/l.&lt;br&gt;8.	Serum bilirubin, ASAT, ALAT and creatinin within 1.5 times of upper limit of reference values of laboratory.&lt;br&gt;9.	No prior systemic treatment with biological response modifiers, tyrosine-kinase inhibitors, monoclonal antibodies or chemotherapy. Patients who receive local radiotherapy for bone lesions can be included. &lt;br&gt;10.	An intermediate MSKCC risk profile&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	Symptomatic primary necessitating nephrectomy. For definition see Inclusion criteria.&lt;br&gt;2.	Irresectable primary tumor&lt;br&gt;3.	Patients in whom complete surgical remission can be achieved by removing metastatic sites at nephrectomy or by delayed surgery.&lt;br&gt;4.	Previous nephrectomy&lt;br&gt;5.	Low metastatic burden (2 or less non-resectable metastases at 1 metastatic site) &lt;br&gt;6.	Metastatic RCC to the bone only. Bone metastases are considered truly non measurable.&lt;br&gt;7.	Current cardiovascular disease, hematopoetic, pulmonary, hepatic or renal dysfunction or WHO performance status &gt; 1.&lt;br&gt;8.	Previous immunotherapy, therapy with tyrosine-kinase inhibitors, monoclonal antibodies or chemotherapy.&lt;br&gt;9.	Presence of autoimmune disease, HIV and hepatitis.&lt;br&gt;10.	Corticosteroid and/ or other immunosuppressive therapies.&lt;br&gt;11.	Prior malignancies. In case of NED the period should be &gt; 5 years.&lt;br&gt;12.	Central nervous system metastases.&lt;br&gt;13.	non-clear cell subtype.&lt;br&gt;14.	Poor or good prognosis according to MSKCC risk assessment&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>metastatic renal cell carcinoma and the primary tumor in situ

</Condition>
    <Intervention>&lt;br&gt;Trade Name: Sutent&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: sunitinib&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To investigate the response rate of the primary tumor following pretreatment with sunitinib;Secondary Objective: Cancer specific survival and morbidity, overall response at metastatic sites and duration of metastatic response will be assessed. (Duration of overall survival; duration of hospital stay; percentage of withdrawal from nephrectomy due to sunitinib-related reduction of performance; response at metastatic sites; progression to irresectability of the primary tumor during initial treatment). &lt;br&gt;Immunomonitoring in the peripheral blood at different time intervals and the primary tumor after nephrectomy.&lt;br&gt;Imaging with CT and dynamic MRI scan prior to treatment with sunitinib and prior to nephrectomy to identify potential response criteria other than RECIST in association with histopathology.&lt;br&gt;;Primary end point(s): The main end point of this study is any objective response in the primary tumor according to RECIST criteria .</Primary_outcome>
    <Secondary_ID>N06SUN</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2459416</Internal_Number>
    <TrialID>EUCTR2005-004024-39-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Título completo del ensayo: Estudio multicéntrico, aleatorizado, abierto, de 12 semanas de duración, para determinar el efecto del  tratamiento con Myfortic® (micofenolato sódico) en términos de calidad de vida en pacientes con síntomas gastrointestinales (GI) en tratamiento con MMF (micofenolato mofetilo) después de un trasplante renal. - MYVIDA2</Public_title>
    <Scientific_title>Título completo del ensayo: Estudio multicéntrico, aleatorizado, abierto, de 12 semanas de duración, para determinar el efecto del  tratamiento con Myfortic® (micofenolato sódico) en términos de calidad de vida en pacientes con síntomas gastrointestinales (GI) en tratamiento con MMF (micofenolato mofetilo) después de un trasplante renal. - MYVIDA2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>Novartis Farmacéutica, S.A.</Primary_sponsor>
    <Date_registration3>20060306</Date_registration3>
    <Date_registration>06/03/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-004024-39                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>25/04/2006</Date_enrollement>
    <Target_size>250</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•Pacientes que hayan sido sometidos a un trasplante renal.&lt;br&gt;•Que estén recibiendo un régimen inmunosupresor que incluya MMF antes de la inclusión en el estudio. &lt;br&gt;•Que sufran efectos secundarios GI relacionados con la dosis estandar de MMF, o bien pacientes en tratamiento con una dosis reducida de MMF para controlar dichos efectos secundarios GI.&lt;br&gt;•Con edad = 18 años.&lt;br&gt;•Capaces de entender la información sobre el estudio y de otorgar su consentimiento informado por escrito.&lt;br&gt;•Que puedan cumplir todos los requisitos del estudio incluyendo la realización de los cuestionarios, y la asistencia a las 3 visitas del estudio.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•Que se conozca o se asuma que los síntomas GI no están causados por el tratamiento con ácido micofenólico (MPA, principio activo de Cellcept®) (por ejemplo, diarrea infecciosa inducida por bisfosfonatos orales).&lt;br&gt;•Rechazo agudo &lt; 1 semana antes de la inclusión en el estudio.&lt;br&gt;•Mujeres físicamente fértiles que tengan previsto quedarse embarazadas, estén embarazadas y/o en periodo de lactancia, o bien que no deseen utilizar un método anticonceptivo eficaz.&lt;br&gt;•Presencia de enfermedad psiquiátrica (como esquizofrenia, depresión mayor) que, a juicio del investigador, pudiese interferir con los requerimientos del estudio.&lt;br&gt;•Que estén siendo sometidos a intervención médica por patología aguda o que estén hospitalizados.&lt;br&gt;•Cualquier otra condición médica que, a juicio del investigador basándose en el recuerdo o en la revisión de historiales clínicos, pudiese afectar a la finalización del estudio, incluyendo, pero no limitado a problemas visuales o deterioro cognitivo.&lt;br&gt;•Que estén recibiendo cualquier fármaco en investigación o lo hayan recibido durante los 30 días previos a la inclusión en el estudio.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Trasplante renal</Condition>
    <Intervention>&lt;br&gt;Trade Name: Myfortic ®&lt;br&gt;Product Name: Myfortic®&lt;br&gt;Product Code: ERL080&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Trade Name: CellCept ®&lt;br&gt;Product Name: CellCept®&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Determinar el efecto del uso de la formulación de comprimidos gastrorresistentes con película de MPA (Myfortic®) en la calidad de vida de los pacientes que requieran una disminución de la dosis de MMF debido a los síntomas gastrointestinales provocados por dicha medicación. ;Secondary Objective: El objetivo secundario será determinar si la formulación de comprimidos gastrorresistentes con película de MPA (Myfortic®) permite la administración con buena tolerancia de dosis más altas de MPA, comparado con el tratamiento estándar de MMF, en pacientes con susceptibilidad demostrada a efectos secundarios gastrointestinales.;Primary end point(s): La variable principal de valoración será la puntuación total de la escala GIQLI. Se hará una estadística descriptiva para la puntuación total de la escala GIQLI en las tres visitas del estudio. El análisis primario determinará los cambios en la puntuación total para dicha escala entre los dos grupos de tratamiento.</Primary_outcome>
    <Secondary_ID>CERL080AES06</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2460281</Internal_Number>
    <TrialID>EUCTR2006-002338-39-DE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Pharmakokinetik von Linezolid bei Dialyse
(pharmacokinetics of linezolid under dialysis) - LINUS</Public_title>
    <Scientific_title>Pharmakokinetik von Linezolid bei Dialyse
(pharmacokinetics of linezolid under dialysis) - LINUS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Universitätsklinikum Heidelberg</Primary_sponsor>
    <Date_registration3>20060817</Date_registration3>
    <Date_registration>17/08/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-002338-39                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>22/12/2006</Date_enrollement>
    <Target_size>15</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: dialysis and not dialysis&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- The receipt of linezolid in the normal treatment of care&lt;br&gt;- acute renale failure with a dialysis-therapy or sepsis without acute renale failure&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- hypersensivity against linezolid&lt;br&gt;- newborn, children, adolescent, pregnant women, nursing women, pre-menopausal women&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>acute renal failure and infection or sepsis without acute renal failure</Condition>
    <Intervention>&lt;br&gt;Trade Name: Zyvoxid (R) 2mg/ml Infusionslösung&lt;br&gt;Product Name: Zyvoxid (R)2 mg/ml Infusionslösung&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: pharmacokinetic of Linezolid under dialysis;Secondary Objective: influence of sepsis alone without dialysis;Primary end point(s): no end points because it is only an accompanying pharmocokinetic-study</Primary_outcome>
  </Trial>
  <Trial>
    <Internal_Number>2460365</Internal_Number>
    <TrialID>EUCTR2007-005401-22-NL</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Effect of Aliskiren on Muscle Sympathetic Nerve Activity in hypertensive patients with chronic kidney disease - Aliskiren and sympathetic activity</Public_title>
    <Scientific_title>Effect of Aliskiren on Muscle Sympathetic Nerve Activity in hypertensive patients with chronic kidney disease - Aliskiren and sympathetic activity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>University Medical Center Utrecht</Primary_sponsor>
    <Date_registration3>20071019</Date_registration3>
    <Date_registration>19/10/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-005401-22                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>20/02/2009</Date_enrollement>
    <Target_size>20</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: no treatment&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients with stable CKD and hypertension: i.e. using antihypertensive drugs and/or blood pressure &gt;145/90mmHg when off medication. &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;-	Patients on renal replacement therapy&lt;br&gt;-	Diabetes mellitus &lt;br&gt;-	Pregnancy&lt;br&gt;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Hypertension and chronic kidney disease</Condition>
    <Intervention>&lt;br&gt;Product Name: Aliskiren (Rasilez)&lt;br&gt;Product Code: ATC-code: C09XA02&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective is to investigate the effect on MSNA by Aliskiren in hypertensive patients with CKD. We hypothesize that there will be a (substantial) decrease in MSNA as result of chronic treatment (6 weeks) of Aliskiren. ;Secondary Objective: Secondary objective is to assess whether MSNA normalizes after chronic treatment (6 weeks) of Aliskiren in hypertensive patients with CKD. &lt;br&gt;Furthermore, we will study the effect of Aliskiren on blood pressure, heart rate, kidney function and PRA in hypertensive patients with CKD.&lt;br&gt;;Primary end point(s): Primary endpoint: the effect of Aliskiren on MSNA&lt;br&gt;&lt;br&gt;Secondary parameters: Effect of aliskiren on blood pressure, heart rate, PRA and kidney function &lt;br&gt;- Comparison of the effect on MSNA after treatment with aliskiren with the effects on ACEi and ARB  as comared to the previous studies and assessment whether normalization of MSNA is obtained after treatment with aliskiren &lt;br&gt;</Primary_outcome>
    <Secondary_ID>24092007</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2460545</Internal_Number>
    <TrialID>EUCTR2006-004857-86-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A multi-centre, open-label, phase II study of the safety, efficacy and pharmacokinetic (PK) profile of CAP-232 administered through continuous intravenous infusion in patients with metastatic kidney cancer</Public_title>
    <Scientific_title>A multi-centre, open-label, phase II study of the safety, efficacy and pharmacokinetic (PK) profile of CAP-232 administered through continuous intravenous infusion in patients with metastatic kidney cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>Caprion Pharmaceuticals Inc.</Primary_sponsor>
    <Date_registration3>20061128</Date_registration3>
    <Date_registration>28/11/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-004857-86                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>19/01/2007</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1) Patients must have histologically confirmed stage IV kidney clear cell carcinoma.  &lt;br&gt;&lt;br&gt;2) Patients must have progressive disease after receiving a previous systemic therapy. &lt;br&gt;&lt;br&gt;3) Patient must have progressive disease confirmed by 2 CT Scans or MRI performed within 6 months. &lt;br&gt;&lt;br&gt;4) Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as &gt;20 mm with conventional techniques or as &gt;10 mm with spiral CT scan.  &lt;br&gt;&lt;br&gt;5) Patients must have an age &gt;18 years.  &lt;br&gt;&lt;br&gt;6) Patients must have life expectancy of greater than 3 months.&lt;br&gt;&lt;br&gt;7) Patient must be at least 5 years free of any other cancer(s). Basal cell carcinoma, provided that is neither infiltrating nor sclerosing and carcinoma in situ of the cervix, is acceptable.&lt;br&gt;&lt;br&gt;8) Patients must have ECOG performance status ? ?2 (Karnofsky 60%).&lt;br&gt;&lt;br&gt;9) Patients must have normal organ and marrow function as defined below:&lt;br&gt;•	Leukocytes &gt;3,000/mm3&lt;br&gt;•	Absolute neutrophil count &gt;1,500/mm3&lt;br&gt;•	Platelets &gt;100,000/ mm3&lt;br&gt;•	Total bilirubin within normal institutional limits&lt;br&gt;•	AST(SGOT)/ALT(SGPT) ?2.5 X institutional upper limit of normal &lt;br&gt;•	Calculated creatinine clearance &gt;30 mL/min/1.73 m2 &lt;br&gt;&lt;br&gt;10) Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.  Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.&lt;br&gt;&lt;br&gt;11) Patients or the patient’s legal guardian must be able to understand and have the willingness to sign a written informed consent document.&lt;br&gt;&lt;br&gt;12) Patients must have the ability to receive central vein access catheter and manage an infusion pump.&lt;br&gt;&lt;br&gt;13) Women of child bearing potential must have a negative serum pregnancy test. &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;11) Patients who have received any known medical treatment targeting cancer within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.&lt;br&gt;&lt;br&gt;2) Patients may not be receiving any other investigational agents at least 30 days prior to enrollment in the study or/and participate in another clinical trial.&lt;br&gt;&lt;br&gt;3) Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.&lt;br&gt;&lt;br&gt;4) Patients with a history of allergic reactions attributed to compounds of similar composition to CAP-232.  CAP-232 consists of a heptapeptide (active ingredient) in an acetate buffered saline solution with mannitol (0.2 M sodium acetate, 0.2 M acetic acid, 3% mannitol). &lt;br&gt; &lt;br&gt;5) Patient with past or current cancer other than kidney cancer, except for:&lt;br&gt;•	Curatively treated non-melanoma skin cancer&lt;br&gt;•	In situ carcinoma of the cervix&lt;br&gt;•	Other cancer curatively treated and with no evidence of disease for at least 10 years&lt;br&gt;&lt;br&gt;6) Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.&lt;br&gt;&lt;br&gt;7) Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with CAP-232, breastfeeding should be discontinued if the mother is treated with CAP-232.&lt;br&gt;&lt;br&gt;8) Patients that have previously been enrolled into this study and subsequently withdrawn must also be excluded.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>metastatic kidney cancer &lt;br&gt;MedDRA version: 8.1
Level: LLT
Classification code 10023405
Term: Kidney cancer stage IV
</Condition>
    <Intervention>&lt;br&gt;Product Name: CAP 232&lt;br&gt;Product Code: CAP 232&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: synthetic peptide CAP-232 acetate&lt;br&gt;Other descriptive name: formerly known as TT-232&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective of this study is to evaluate the efficacy of CAP-232 as a monotherapy (each 28-day cycle consists of 21 days continuous IV infusion of CAP-232 at 0.5 mg/kg/day followed by a 7-day rest period) in patients with metastatic kidney cancer.  The primary efficacy parameter will be the response rate based on RECIST criteria.;Secondary Objective: Secondary objectives include:&lt;br&gt;&lt;br&gt;•	Safety (through clinical and biological evaluations)&lt;br&gt;•	Other efficacy parameters (progression-free survival rate, time to progression and overall survival)&lt;br&gt;•	Pharmacokinetic (PK) characteristics of the first 15 recruited patients&lt;br&gt;•	Quality of life&lt;br&gt;•	Biological modulation (through potential blood and/or urine biomarkers including M2PK)&lt;br&gt;&lt;br&gt;;Primary end point(s): The primary safety endpoints will include the occurrence of AEs, clinical laboratory parameters, vital signs, ECGs and physical examination variables. &lt;br&gt;&lt;br&gt;The primary efficacy endpoints will: &lt;br&gt;- determine the M2PK plasma levels during the course of treatment&lt;br&gt;- determine disease state using RECIST criteria at the end of 2 cycles&lt;br&gt;- determine progression-free survival rate&lt;br&gt;- determine time to progression and overall survival&lt;br&gt;&lt;br&gt;Other endpoints will:&lt;br&gt;- evaluate the quality of life during each cycle&lt;br&gt;- determine the pharmacokinetic (PK) characteristics of CAP-232&lt;br&gt;- determine potential blood and/or urine biomarkers for predicting efficacy&lt;br&gt;&lt;br&gt;&lt;br&gt;</Primary_outcome>
    <Secondary_ID>CTP_CAP001</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2460676</Internal_Number>
    <TrialID>EUCTR2006-003364-64-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A phase IV, open-label, multi-centre trial evaluating the conversion from standard phosphate binder therapy to Fosrenol in chronic kidney disease stage 5 patients on haemodialysis</Public_title>
    <Scientific_title>A phase IV, open-label, multi-centre trial evaluating the conversion from standard phosphate binder therapy to Fosrenol in chronic kidney disease stage 5 patients on haemodialysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Shire Development Inc</Primary_sponsor>
    <Date_registration3>20070105</Date_registration3>
    <Date_registration>05/01/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-003364-64                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>08/05/2007</Date_enrollement>
    <Target_size>760</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Aged 18 or over and receiving stable regimen of haemodialysis (three times a week) for CKD (stage 5) for at least 2 months prior to screening.&lt;br&gt;&lt;br&gt;Females must be non-pregnant and non-lactating.&lt;br&gt;&lt;br&gt;On a stable phosphate binder dose (no change in medication or dose for one month) with screening serum phosphorus levels of between 5.6 and 7.5 mg/dL inclusive.  &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Subjects with a corrected serum calcium level &lt;2.2mmol/L (8.8mg/dL).&lt;br&gt;&lt;br&gt;Subjects with an intact parapthyroid hormone level &gt;500pg/ml or a history of parathyroidectomy within 12 months of screening.&lt;br&gt;&lt;br&gt;Any significant GI disorders (including bowel obstruction, active, inflammatory bowel disease, GI motility disorders, abnormal or irregular bowel motion, major GI surgery in last 6 months.&lt;br&gt;&lt;br&gt;Subjects receiving aluminium, magnesium, or combination therapy other than sevelamer HCl and calcium as a phosphate binder.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Hyperphosphataemia in patients with end-stage renal disease receiving haemodialysis &lt;br&gt;MedDRA version: 8.1
Level: LLT
Classification code 10020712
Term: Hyperphosphatemia
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Fosrenol 750mg Chewable Tablets&lt;br&gt;Product Name: Lanthanum Carbonate&lt;br&gt;Product Code: SPD405&lt;br&gt;Pharmaceutical Form: Chewable tablet&lt;br&gt;INN or Proposed INN: Lanthanum (III) carbonate hydrate&lt;br&gt;CAS Number: 54451-24-0&lt;br&gt;Current Sponsor code: SPD405&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 750-&lt;br&gt;&lt;br&gt;Trade Name: Fosrenol 1000mg Chewable Tablets&lt;br&gt;Product Name: Lanthanum Carbonate&lt;br&gt;Product Code: SPD405&lt;br&gt;Pharmaceutical Form: Chewable tablet&lt;br&gt;INN or Proposed INN: Lanthanum (III) carbonate hydrate&lt;br&gt;CAS Number: 54451-24-0&lt;br&gt;Current Sponsor code: SPD405&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1000-&lt;br&gt;&lt;br&gt;Trade Name: Fosrenol 500mg Chewable Tablets&lt;br&gt;Product Name: Lanthanum Carbonate&lt;br&gt;Product Code: SPD405&lt;br&gt;Pharmaceutical Form: Chewable tablet&lt;br&gt;INN or Proposed INN: Lanthanum (III) carbonate hydrate&lt;br&gt;CAS Number: 54451-24-0&lt;br&gt;Current Sponsor code: SPD405&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To assess the percentage of subjects who have serum phosphorus levels controlled to &lt;or= 1.78mmol/L (&lt;or=5.5mg/dl) following treatment with Fosrenol compared to their previous phosphate binder;Primary end point(s): The percentage of subjects acheiving serum phosphorus levels of less than or equal to 1.78mmol/L following treatment with Fosrenol at week 12 compared to treatment with their previous phosphate binder therapy.;Secondary Objective: To assess the following:&lt;br&gt;&lt;br&gt;If Fosrenol can maintain serum phosphorus levels in subjects converting to Fosrenol from their previous phosphate binder therapy.&lt;br&gt;&lt;br&gt;If Fosrenol can reduce serum phosphorus levels in subjects converting to Fosrenol from their previous phosphate binder therapy.&lt;br&gt;&lt;br&gt;To assess the control of serum calcium-phosphorus product.&lt;br&gt;&lt;br&gt;To assess the average dose of Fosrenol.&lt;br&gt;&lt;br&gt;To assess the safety and tolerability of Fosrenol</Primary_outcome>
    <Secondary_ID>SPD405-403</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2460686</Internal_Number>
    <TrialID>EUCTR2006-005604-14-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A randomized, prospective, multicenter trial to compare the effect on chronic allograft nephropathy prevention of  mycophenolate mofetil versus azathioprine as the sole immunosuppressive therapy for kidney transplant recipients - MAMMOUTH</Public_title>
    <Scientific_title>A randomized, prospective, multicenter trial to compare the effect on chronic allograft nephropathy prevention of  mycophenolate mofetil versus azathioprine as the sole immunosuppressive therapy for kidney transplant recipients - MAMMOUTH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </Scientific_title>
    <Primary_sponsor>IST. DI RICERCHE FARMACOLOG. M. NEGRI</Primary_sponsor>
    <Date_registration3>20070105</Date_registration3>
    <Date_registration>05/01/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-005604-14                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>19/12/2006</Date_enrollement>
    <Target_size>224</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Males and females aged 18-60 years;  - First single kidney transplant from living or deceased donors;  - Written informed consent.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Specific contraindications to RATG therapy such as severe leucopenia  WBC 2000/mm3 ;  - High immunological risk   such as second transplant recipients or those who have a panel reactivity   10 ;  - history of malignancy  except non metastatic basal or squamous cell carcinoma of the skin that has been treated successfully;  - Evidence of active hepatitis C virus, hepatitis B virus or human acquired immunodeficiency virus infection;  - Any chronic clinical conditions that may affect completion of the trial or confound data interpretation;  - Pregnancy or lactating;  - Women of childbearing potential without following a scientifically accepted form of contraception;  - Legal incapacity and/or other circumstances rendering the patient unable to understand the nature, scope and possible consequence of the trial;  - Evidence of an uncooperative attitude;  - Any evidence that patient will not be able to complete the trial follow-up.&lt;br&gt;</Exclusion_Criteria>
    <Condition>kidney transplant &lt;br&gt;MedDRA version: 6.1
Level: PT
Classification code 10023439
</Condition>
    <Intervention>&lt;br&gt;Trade Name: CELLCEPT*50CPR 500MG&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;Trade Name: AZATIOPRINA WELL*50CPR RIV50MG &lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To compare the incidence of CAN in kidney transplant patients receiving induction therapy with basiliximab and low-dose RATG and maintenance immunosuppression with low-dose MMF or AZA monotherapy.;Secondary Objective: - To evaluate whether MMF may exert an higher activity against acute allograft rejection as  compared to AZA when used as the sole immunosuppressive agent.   - To evaluate the relationships between acute rejection episodes and subsequent  occurrence of CAN, and long-term graft function/survival. Should the study demonstrate the superiority of any of the two drugs in preventing CAN, patients will be put on the more effective immunosuppressive treatment. This will allow assessing whether the lesions of CAN may recover in those patients who are shifted from the less to the more effective treatment. The extension phase of the study will be aimed at assessing the long-term patient and graft survival.;Primary end point(s): Incidence of biopsy-proven CAN at 3 years follow-up  end phase B .</Primary_outcome>
    <Secondary_ID>AIFA TX</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2460833</Internal_Number>
    <TrialID>EUCTR2006-004959-38-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A prospective multicenter, open-label, randomised, cross-over study to compare the efficacy and safety of Fosrenol and Sevelemer Hydrochloride in patients receiving hemodialysis for end stage renal disease</Public_title>
    <Scientific_title>A prospective multicenter, open-label, randomised, cross-over study to compare the efficacy and safety of Fosrenol and Sevelemer Hydrochloride in patients receiving hemodialysis for end stage renal disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   </Scientific_title>
    <Primary_sponsor>Shire Development Inc</Primary_sponsor>
    <Date_registration3>20070101</Date_registration3>
    <Date_registration>01/01/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-004959-38                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>17/05/2007</Date_enrollement>
    <Target_size>214</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: yes&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Aged 18 or over&lt;br&gt;Females must be non-pregnant&lt;br&gt;Must have ESRD and have been receiving haemodialysis three times a week for at least 2 months&lt;br&gt;Being treated with a monotherapy calcium based phosphate binder or a combination therapy not containing Fosrenol or sevelamer hydrochloride and is sub-optimally controlled with screening serum phosphorus levels of greater or equal 5.6 to less than or equal 7.5 mg/dL.  Treatment naiive patients are permitted to enter study providing serum phosphorus levels are greater or equal 6.0 mg/dL (1.92 mmol/L)&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients who require treatment with cinacalcet hydrochloride, or with compounds containing phosphorus, magnesium, aluminium or  calcium (except as indicated in section 6.4.1 of the protocol) that are used as a phosphate binder.&lt;br&gt;&lt;br&gt;Any significant GI surgery or GI disorders (including active, uncontrolled peptic ulcer, Crohns disease, GI bleed in last 6 months, past or present GI malignancy&lt;br&gt;&lt;br&gt;Cirrhosis or other clinically relevant liver disease&lt;br&gt;&lt;br&gt;Intact PTH &gt;500 pg/ml&lt;br&gt;&lt;br&gt;Serum calcium &lt;8.8 mg/dL&lt;br&gt;&lt;br&gt;Life threatening malignancy or current multiple myeloma&lt;br&gt;&lt;br&gt;HIV positive&lt;br&gt;&lt;br&gt;Hypersensitivity to investigational products&lt;br&gt;&lt;br&gt;Alcohol or substance abuse 1 year prior to screening&lt;br&gt;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Hyperphosphataemia in patients with end-stage renal disease receiving haemodialysis &lt;br&gt;MedDRA version: 8.1
Level: LLT
Classification code 10020712
Term: Hyperphosphatemia
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Fosrenol 750mg Chewable Tablets&lt;br&gt;Product Name: Lanthanum Carbonate&lt;br&gt;Product Code: SPD405&lt;br&gt;Pharmaceutical Form: Chewable tablet&lt;br&gt;INN or Proposed INN: Lanthanum (III) carbonate hydrate&lt;br&gt;CAS Number: 54451-24-0&lt;br&gt;Current Sponsor code: SPD405&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 750-&lt;br&gt;&lt;br&gt;Trade Name: Fosrenol 1000mg Chewable Tablets&lt;br&gt;Product Name: Lanthanum Carbonate&lt;br&gt;Product Code: SPD405&lt;br&gt;Pharmaceutical Form: Chewable tablet&lt;br&gt;INN or Proposed INN: Lanthanum (III) carbonate hydrate&lt;br&gt;CAS Number: 54451-24-0&lt;br&gt;Current Sponsor code: SPD405&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1000-&lt;br&gt;&lt;br&gt;Trade Name: Renagel 800mg film-coated tablets&lt;br&gt;Product Name: sevelamer hydrochloride &lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: SEVELAMER HYDROCHLORIDE&lt;br&gt;CAS Number: 182683007&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 800-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To compare the efficacy of Fosrenol and sevelamer hydrochloride in the reduction of serum phosphorus levels from baseline;Secondary Objective: To assess the following:&lt;br&gt;&lt;br&gt;the percentage of patients acheiving KDOQI target for serum phosphorus (3.5-5.5mg/dL) following treatment with Fosrenol and sevelamer hydrochloride&lt;br&gt;&lt;br&gt;the percentage of responders, defined as &gt; or = 25% decrease in serum phosphorus from baseline following treatment with Fosrenol and sevelamer hydrochloride&lt;br&gt;&lt;br&gt;the effects of Fosrenol and sevelamer hydrochloride on calcium-phosphate product and parathyroid hormone (PTH)&lt;br&gt;&lt;br&gt;compliance&lt;br&gt;&lt;br&gt;safety and tolerability of Fosrenol and sevelamer hydrochloride;Primary end point(s): The change from baseline in serum phosphorus levels</Primary_outcome>
    <Secondary_ID>SPD405-319</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2460943</Internal_Number>
    <TrialID>EUCTR2006-004606-97-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A MULTICENTER, SINGLE-ARM, OPEN, CONVERSION STUDY FROM A CYCLOSPORINE (CyA) BASED IMMUNOSUPPRESSIVE REGIMEN TO A TACROLIMUS MODFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRANSPLANT SUBJECTS - CONCERTO</Public_title>
    <Scientific_title>A MULTICENTER, SINGLE-ARM, OPEN, CONVERSION STUDY FROM A CYCLOSPORINE (CyA) BASED IMMUNOSUPPRESSIVE REGIMEN TO A TACROLIMUS MODFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRANSPLANT SUBJECTS - CONCERTO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Astellas Pharma GmbH</Primary_sponsor>
    <Date_registration3>20070125</Date_registration3>
    <Date_registration>25/01/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-004606-97                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>22/02/2007</Date_enrollement>
    <Target_size>380</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: yes&lt;br&gt;Other trial design description: 1-way conversion&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Age = 18 years.&lt;br&gt;2. Kidney transplant at least 12 months prior to enrollment.&lt;br&gt;3. Received a CyA-based immunosuppressive regimen since last transplantation. The dose of CyA has remained unchanged during the last four weeks prior to enrollment.&lt;br&gt;4. Immunosuppressive regimen (combination of medications) remained unchanged for a minimum of four weeks prior to enrollment.&lt;br&gt;5. Experienced at least one of the following CyA-related adverse events at enrollment:&lt;br&gt;a) Gingival hyperplasia where, in the opinion of the investigator, therapeutical intervention is required.&lt;br&gt;b) Hypertrichosis/hirsutism where, in the opinion of the investigator, therapeutical intervention is required.&lt;br&gt;c) Arterial hypertension (with the exception of known pre-transplant malignant nephrosclerosis) stages I-III (systolic blood pressure &gt; 140 mmHg and/or diastolic blood pressure &gt; 90mmHg) despite treatment with at least one anti-hypertensive medication. The anti-hypertensive medication(s) has been prescribed at least 4 weeks prior to enrollment.&lt;br&gt;d) Hyperlipidemia defined as total cholesterol higher than 220 mg/dl despite treatment with lipid-lowering medication(s) requires therapeutical intervention. The lipid-lowering medication(s) has been prescribed at least four weeks prior to enrollment.&lt;br&gt;6. Serum creatinine &lt; 200 µmol/l (&lt; 2.3 mg/dl) at enrollment.&lt;br&gt;7. Female subject of childbearing potential must have a negative serum pregnancy test at enrollment and must agree to maintain effective birth control during the study.&lt;br&gt;8. Capable of understanding the purpose and risks of the study, has been fully informed and has given written informed consent (signed Informed Consent has been obtained).&lt;br&gt;9. Clinically stable in the opinion of the investigator.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Previously received an organ transplant other than a kidney.&lt;br&gt;2. Acute rejection episode within 12 weeks prior to enrollment, or an acute rejection episode within the 24 weeks prior to enrollment that required anti-lymphocyte antibody therapy.&lt;br&gt;3. Diagnosis of new-onset malignancy after transplantation, with the exception of basocellular or squamous cell carcinoma of the skin which had been treated successfully.&lt;br&gt;4. Known to have FSGS or MPGN Type II as an underlying disease.&lt;br&gt;5. Proteinuria &gt; 2 g / 24 hrs.&lt;br&gt;6. “Creeping creatinine” (defined as an increase of 20% within the 6 months prior to enrollment and at Baseline).&lt;br&gt;7. Elevated SGPT/ALT and/or SGOT/AST and/or Total Bilirubin levels = 2 times the upper value of the normal range of the investigational site.&lt;br&gt;8. Liver cirrhosis.&lt;br&gt;9. Pregnant woman or breast-feeding mother.&lt;br&gt;10. HIV positive.&lt;br&gt;11. Known allergy or intolerance to tacrolimus, macrolide antibiotics, steroids, additional concomitant immunosuppressive medication or to the excipients of the study medication.&lt;br&gt;12. Any unstable medical condition that could interfere with the study objectives in the opinion of the investigator.&lt;br&gt;13. Receiving prohibited concomitant therapy, or received prohibited concomitant therapy within 28 days prior to enrollment.&lt;br&gt;14. Currently participating in another clinical trial, and/or has taken an investigational drug within 28 days prior to enrollment.&lt;br&gt;15. Any form of substance abuse, psychiatric disorder or condition which, in the opinion of the investigator, may complicate communication with the investigator.&lt;br&gt;16. Unlikely to comply with the visits scheduled in the protocol.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Stable, adult kidney transplant recipients (at least 12 months post transplant) who are currently treated with cyclosporine and who meet the Inclusion and Exclusion Criteria will be enrolled. &lt;br&gt;MedDRA version: 8.1
Level: LLT
Classification code 10023438
Term: Kidney transplant
</Condition>
    <Intervention>&lt;br&gt;Product Name: FK506E (MR4)&lt;br&gt;Product Code: FK506E (MR4)&lt;br&gt;Pharmaceutical Form: Prolonged-release capsule, hard&lt;br&gt;INN or Proposed INN: tacrolimus&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Current Sponsor code: FK506&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;&lt;br&gt;Product Name: FK506E (MR4)&lt;br&gt;Product Code: FK506E (MR4)&lt;br&gt;Pharmaceutical Form: Prolonged-release capsule, hard&lt;br&gt;INN or Proposed INN: tacrolimus&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Current Sponsor code: FK506&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Product Name: FK506E (MR4)&lt;br&gt;Product Code: FK506E (MR4)&lt;br&gt;Pharmaceutical Form: Prolonged-release capsule, hard&lt;br&gt;INN or Proposed INN: tacrolimus&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Current Sponsor code: FK506&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Primary objective is to assess the changes in kidney function in kidney transplant subjects converted from a CyA-based immunosuppressive regimen to a tacrolimus modified release, FK506E (MR4), based immunosuppressive regimen.;Secondary Objective: The secondary objective is to assess the safety and the efficacy of a MR4-based immunosuppressive regimen in kidney transplant subjects converted from a CyA-based immunosuppressive regimen experiencing CyA-related side effects.;Primary end point(s): Change in creatinine clearance, calculated according to Cockcroft and Gault formula, between Baseline (Day 1) and week 24 (End of Study) for each specific CyA-related side-effect group (hypertrichosis/hirsutism, gingival hyperplasia, hyperlipidemia, arterial hypertension).</Primary_outcome>
    <Secondary_ID>PMR-EC-1209</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2461728</Internal_Number>
    <TrialID>EUCTR2007-001048-32-FR</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Prospective, multicentre, open-label study evaluating Fondaparinux (1,5 mg/day) in venous thromboembolic events prevention in patients with renal impairment defined by a creatinin clearance between 20 and 50 ml/min and undergoing a major orthopaedic surgery (hip fracture, total hip replacement and total knee replacement)</Public_title>
    <Scientific_title>Prospective, multicentre, open-label study evaluating Fondaparinux (1,5 mg/day) in venous thromboembolic events prevention in patients with renal impairment defined by a creatinin clearance between 20 and 50 ml/min and undergoing a major orthopaedic surgery (hip fracture, total hip replacement and total knee replacement)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>CHU SAINT-ETIENNE</Primary_sponsor>
    <Date_registration3>20070329</Date_registration3>
    <Date_registration>29/03/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001048-32                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>15/09/2008</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patient affiliated with or a beneficiary of a social security category:&lt;br&gt;•	age &gt; 18 years old,&lt;br&gt;•	requiring a major orthopaedic surgery (THR, TKR, HF) whatever procedure techniques are used, 1st indication or resumption,&lt;br&gt;•	requiring an antithrombotic prophylaxis,&lt;br&gt;•	presenting a renal impairment defined by a creatinin clearance (CrCl) between 20 and 50 ml/min calculated by Cockcroft and Gault’s formula, &lt;br&gt;•	having signed the inform consent form.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•	contra-indications to fondaparinux,&lt;br&gt;•	history of heparin inducted thrombopenia (HIT), &lt;br&gt;•	history of venous thromboembolic event,&lt;br&gt;•	Haemorrhagic diathesis, &lt;br&gt;•	PT &lt; 50 %, aPTT &gt; 1,5 of control value, platelets &lt; 100 G/l.&lt;br&gt;                incapacity to understand protocol&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients with renal impairment defined by a creatinin clearance between 20 and 50 ml/min and undergoing a major orthopaedic surgery (hip fracture, total hip replacement and total knee replacement) &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10038474
Term: Renal insufficiency
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10020100
Term: Hip fracture
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10023476
Term: Knee osteoarthritis
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10049909
Term: Venous thromboembolism prophylaxis
 &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10020108
Term: Hips osteoarthritis
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Arixtra 1,5 mg/0,3 ml&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Fondaparinux&lt;br&gt;CAS Number: 114870-03-0&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: to evaluate between D5 and D10, the incidence of major bleedings after a daily subcutaneous injection of fondaparinux 1,5 mg during at least 5 days for prevention of venous thromboembolic events after major orthopaedic surgery (TKR, THR and HF) in patients with a CrCl between 20 and 50 ml/min (estimated by Cockcroft and Gault formula). ;Secondary Objective: to evaluate: &lt;br&gt;•	The incidence of major bleedings at 1 month ± 5 days&lt;br&gt;•	The incidence of clinically significative bleedings between D5 and D10 and at 1 month ± 5 days&lt;br&gt;•	The incidence of symptomatic venous thromboembolic events (DVT and PE) between D5 and D10 and at 1 month ± 5 days&lt;br&gt;•	Pharmacodynamic parameters based on Xa activity (absorption half-life and elimination clearance of distribution volume and their variability) of fondaparinux based on a non-linear model at mixed effect and to compare the observed real clinical data with those simulated and described in MA file.&lt;br&gt;•	Estimation of haemorrhagic and thromboembolic risk factors.&lt;br&gt;•	Estimation of inter-laboratories variability in the measure of anti-Xa activity with fondaparinux;Primary end point(s): •	Major bleeding (occuring between D5 and D10) is defined by: &lt;br&gt;-	an exteriorised bleeding with a bleeding index &gt; 2 (g/dl of haemoglobin decrease + number of units transfused)&lt;br&gt;-	a bleeding needing a resumption surgery&lt;br&gt;-	a bleeding affecting a critical organ (ocular, retroperitoneal, pericardial, intra-cranial, intra-medullary, intramuscular with compression)&lt;br&gt;-	a fatal bleeding&lt;br&gt;</Primary_outcome>
    <Secondary_ID>0701017</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2461957</Internal_Number>
    <TrialID>EUCTR2006-007021-32-DE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Multi-center, open-label, prospective, randomized, parallel group, long-term study investigating a standard regimen in de novo kidney transplant patients versus a CNI-free regimen and a CNI-low dose regimen - HERAKLES</Public_title>
    <Scientific_title>Multi-center, open-label, prospective, randomized, parallel group, long-term study investigating a standard regimen in de novo kidney transplant patients versus a CNI-free regimen and a CNI-low dose regimen - HERAKLES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Novartis Pharma GmbH</Primary_sponsor>
    <Date_registration3>20070417</Date_registration3>
    <Date_registration>17/04/2007</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-007021-32                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>29/05/2007</Date_enrollement>
    <Target_size>450</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: different treatment regimen&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Males or females, aged 18 – 70 years&lt;br&gt;2.	Recipients of de novo cadaveric, living unrelated or living related kidney transplants&lt;br&gt;3.	Females capable of becoming pregnant must have a negative serum pregnancy test within 7 days prior to or at Baseline visit 1, and are required to practice an approved method of birth control for the duration of the study and for a period of 6 weeks following discontinuation of study medication, even where there has been a history of infertility&lt;br&gt;4.	Patients who are willing and able to participate in the study and from whom written informed consent has been obtained&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	More than one previous renal transplantation&lt;br&gt;2.	Multi-organ recipients (e.g., kidney and pancreas) or previous transplant with any other organ, different from kidney&lt;br&gt;3.	Patients receiving a kidney from a non-heart beating donor&lt;br&gt;4.	Donor age: &lt; 5 years or &gt; 70 years &lt;br&gt;5.	Graft loss due to immunological reasons in the first year after transplantation (in case of secondary transplantation) &lt;br&gt;6.	Patients who are recipients of A-B-O incompatible transplants&lt;br&gt;7.	Patients with a historical or current peak PRA of &gt; 25% (current = 3 months)&lt;br&gt;8.	Patients with already existing antibodies against the HLA-type of the receiving transplant&lt;br&gt;9.	Patients with any known hypersensitivity to Simulect®, Certican®, mycophenolic acid, cyclosporine A, other drugs similar to Certican® (e.g., macrolides), or other components of the formulations (e.g. lactose)&lt;br&gt;10.	Patients who have received an investigational immunosuppressive drug within four weeks prior to study entry (Baseline visit 1)&lt;br&gt;11.	Patients with thrombocytopenia (platelets &lt; 75,000/mm³), with an absolute neutrophil count of &lt; 1,500/mm³ or leucopenia (leucocytes &lt; 2,500/mm³), or hemoglobin &lt; 6 g/dL&lt;br&gt;12.	Patients with symptoms of significant somatic or mental illness. Inability to cooperate or communicate with the investigator, who are unlikely to comply with the study requirements, or who are unable to give informed consent&lt;br&gt;13.	Patients with a history of malignancy during the last five years, except squamous or basal cell carcinoma of the skin&lt;br&gt;14.	Patients who are HIV, HCV, or Hepatitis B surface antigen positive &lt;br&gt;15.	Evidence of severe liver disease (incl. abnormal liver enzyme profile, i.e. AST, ALT or total bilirubin &gt; 3 times UNL)&lt;br&gt;16.	Females of childbearing potential who are planning to become pregnant, who are pregnant and/or lactating, who are unwilling to use effective means of contraception&lt;br&gt;17.	Presence of a clinically significant infection requiring continued therapy, severe diarrhea, active peptic ulcer disease, or uncontrolled diabetes mellitus that in the opinion of the investigator would interfere with the appropriate conduct of the study&lt;br&gt;18.	Evidence of drug or alcohol abuse&lt;br&gt;19.	Patients receiving drugs known to strongly interact with CsA and/or everolimus according to the list provided in Appendix 3 to this protocol should be excluded, if in the opinion of the investigator this drug interaction interferes with the objectives of the study, namely a clinical meaningful potentiation of renal dysfunction and/or maintenance of adequate immunosuppressive drug levels&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>de novo kidney transplant patients &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10023439
Term: Kidney transplant rejection
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Certican Tabletten&lt;br&gt;Product Name: Certican&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;CAS Number: 159351-69-6&lt;br&gt;Current Sponsor code: RAD001&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;&lt;br&gt;Trade Name: Certican Tabletten&lt;br&gt;Product Name: Certican&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;CAS Number: 159351-69-6&lt;br&gt;Current Sponsor code: RAD001&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.75-&lt;br&gt;&lt;br&gt;Trade Name: Simulect 20 mg&lt;br&gt;Product Name: Simulect 20 mg&lt;br&gt;Pharmaceutical Form: Intravenous infusion&lt;br&gt;INN or Proposed INN: Basiliximab&lt;br&gt;CAS Number: 179045-86-4&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;Trade Name: Myfortic 180 mg/ -360 mg Filmtabletten&lt;br&gt;Product Name: Myfortic 180 mg/- 360 mg Filmtabletten&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Mycophenolate sodium&lt;br&gt;CAS Number: 24280-93-1&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 180-&lt;br&gt;&lt;br&gt;Trade Name: Myfortic 180 mg/ -360 mg Filmtabletten&lt;br&gt;Product Name: Myfortic 180 mg/- 360 mg Filmtabletten&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Mycophenolate sodium&lt;br&gt;CAS Number: 24280-93-1&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 360-&lt;br&gt;&lt;br&gt;Trade Name: Sandimmun Optoral&lt;br&gt;10 mg, 25 mg, 50 mg, 100 mg Kapseln&lt;br&gt;Product Name: Sandimmun Optoral&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: Ciclosporin&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;Trade Name: Sandimmun Optoral&lt;br&gt;10 mg, 25 mg, 50 mg, 100 mg Kapseln&lt;br&gt;Product Name: Sandimmun Optoral&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: Ciclosporin&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;Trade Name: Sandimmun Optoral&lt;br&gt;10 mg, 25 mg, 50 mg, 100 mg Kapseln&lt;br&gt;Product Name: Sandimmun Optora</Intervention>
    <Primary_outcome>Main Objective: The primary objective of this trial is to demonstrate superiority of a CNI-free regimen respect to the renal function at Month 12 post Tx assessed by glomerular filtration rate – Nankivell method – as compared to the standard regimen in de novo kidney transplant patients.;Secondary Objective: •	to assess renal function by glomerular filtration rate at Month 12 post Tx of the CNI-low dose regimen compared to the standard regimen&lt;br&gt;•	to assess renal function by glomerular filtration rate at Month 12 post Tx&lt;br&gt;•	to assess renal function by serum creatinine at month 12 post Tx&lt;br&gt;•	to assess efficacy at Month 6 and 12&lt;br&gt;•	to asses occurrence of treatment failures up to or at Month 12&lt;br&gt;•	to assess evolution of renal function between Month 3 and 12 &lt;br&gt;•	to assess safety and tolerability at Month 12:	&lt;br&gt;- AE/SAE	&lt;br&gt;- incidence of infections (with special emphasis on CMV) 	&lt;br&gt;- tumor incidence	&lt;br&gt;- cardiovascular risk (changes in Framingham score)	&lt;br&gt;- occurrence of proteinuria&lt;br&gt;•	to assess efficacy, safety and tolerability at Follow-up visits at month 18, 24, 36, 48, and 60&lt;br&gt;;Primary end point(s): The primary aim of this study is to demonstrate superior renal function under the CNI-free regimen as compared to the Standard regimen.&lt;br&gt;The primary variable for assessment of renal function is the glomerular filtration rate (GFR) at Month 12, as assessed by the Nankivell method.</Primary_outcome>
    <Secondary_ID>CRAD001ADE13</Secondary_ID>
  </Trial>
</Trials_downloaded_from_ICTRP>